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ABSTRACT 
ABSTRACT 
The design of responsive optical cellular probes remains a key challenge for biology 
and medicine. Luminescent lanthanide complexes are well suited for this purpose, with 
their information-rich emission profiles, and long luminescence lifetimes which allow 
gating out of interfering background signals. In order to design complexes for in cellulo 
applications, it is important to gain a greater understanding of the cellular behaviour of 
such complexes. This thesis describes work performed to this end. 
The studies described herein utilise a broad range of complexes synthesised in Durham. 
These complexes comprise a Eu^ "^  or Tb^ "^  ion encapsulated in a cyclen macrocycle to 
which is attached a sensitising chromophore and two or three amide- or carboxylate-
based pendant arms. The synthesis and characterisation of one set of such complexes is 
described. Modification of the pendant arm was shown to result in considerable 
variation of the complex helicity and structure, but with no alteration in the cellular 
behaviour. 
This thesis also describes work which was performed to explore various aspects of 
cellular behaviour. The range of observed sub-cellular localisations are described, 
structure-localisation relationships presented and the observation of nucleolar 
localisation in some cases investigated. Studies of uptake mechanisms indicated that all 
complexes are transported across the cell membrane by a common pathway of 
macropinocytosis. Examples of various sub-cellular speciation states are presented, with 
detailed investigation of one case of reversible protein binding which induces a helicity 
change in the complex in an enantioselective fashion. Finally, the effect of the 
complexes on the cellular homeostasis is discussed, with the finding that complexes do 
not generally perturb the normal function of the cell. 
This work therefore demonstrates that most luminescent lanthanide complexes do 
exhibit behaviour which makes them suitable for use as cellular probes. They are 
generally non-toxic, readily internalised and localise to specific organelles, and have 
demonstrated utility in reporting on the sub-cellular environment. 
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CHAPTER ONE: INTRODUCTION 
1.1 Overview 
Much current research focuses on the development of more sophisticated systems to 
report on sub-cellular conditions. This chapter reviews the various molecular imaging 
techniques, with particular focus on luminescence imaging. The challenges of optical 
probe design are discussed, in addition to an overview of the diverse range of 
luminescent probes which are currently available. Luminescent lanthanide complexes 
are presented as a class which possess attractive properties for use as cellular probes. 
Particular attention is given to the current understanding of the interaction of these 
complexes with biological systems. 
1.2 Molecular imaging 
The study of biological processes in living cells requires techniques which allow for the 
observation of changes in cellulo and in real time. This can be achieved by the use of 
molecular imaging, which is the in vivo characterisation and measurement of processes 
at the cellular and molecular level.' ' Advances in the field of molecular imaging 
require simultaneous improvements of imaging technologies and probe design. There 
are a number of widely-used molecular imaging techniques, which span the 
electromagnetic spectrum from long wave to X-ray frequencies (Figure 1.1). 
t(f 10™' 
1 1 1 
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liO"' to'* 10* 
1 1 1 
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1 1 
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Wavelength 
Figure 1.1: Imaging techniques according to their position in the electromagnetic spectrum. 
The efficacy of a molecular imaging system is measured in terms of its sensitivity and 
resolution. The sensitivity is the minimum signal that can be distinguished from 
background noise, and is usually manifested in the minimum concentration required for 
detection. The terms spatial and temporal resolution refer to the precision of the 
measurement with respect to location and time, respectively. In addition to high 
1 
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resolution and sensitivity, effective whole body imaging requires good tissue 
penetration to allow study of all tissue and organs. 
Magnetic resonance imaging (MRI) detects molecules according to their nuclear spin.'' 
While the technique allows for good temporal (ms) and spatial (|im) resolution, as well 
as good depth penetration (>10 cm), it is limited by its low sensitivity (mM 
concentrations).^ This can be alleviated, in part, by the use of contrast agents. X-ray 
imaging measures the decay of an administered radioactive isotope. This technique 
allows for extremely high sensitivity (10"'^  M) but at the expense of spatial resolution 
(5-10 mm).'' Optical imaging is based on the detection of transmitted light, and allows 
for very high spatial resolution (sub-/im) and good sensitivity.^ It is this imaging system 
which will be explored in this thesis. 
The advantage of optical imaging over other systems lies in its intermediate location on 
the electromagnetic spectrum, which allows for a maximisation of both sensitivity and 
resolution. The intermediate wavelengths and energies also require the simplest 
equipment, which is generally the most cost-efficient. The most basic optical imaging 
device is the light microscope, enhanced by the development of many new technologies 
such as flow cytometry and confocal microscopy. Recent technological advances in 
fibre optics, lasers and computer systems have led to great improvements in optical 
imaging techniques.** 
The principal disadvantage of optical imaging results from its poor depth penetration. 
This is limited to a few mm, but can be as high as 10 cm in the near-infrared spectral 
region.^  As a result of this limitation, optical imaging has found greatest utility in tissue 
culture studies, but has also found valuable clinical applications in retinal angiography, 
cardiovascular surgery and gastrointestinal endoscopy.'" 
There are a number of different forms of optical imaging. These include diffuse optical 
tomography in the near infra-red, optical projection tomography - in which a fixed 
sample is rotated 360° and stepwise images are collected, bioluminescence imaging -
utilising a chemiluminescent enzyme-substrate reaction - and luminescence imaging 
The latter technique will be discussed here. 
4 
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1.2.1 Luminescence imaging 
Luminescence is the emission of light from an electronically excited state of a 
substance." It can be divided into two classes, fluorescence and phosphorescence, 
according to the nature of the excited state. Fluorescence arises from the relaxation of 
an electron from an excited singlet state to the ground state. This is a rapid, spin-
allowed process, and fluorescence lifetimes are therefore very short, typically 
nanoseconds. Phosphorescence is the emission of light from a triplet excited state. As 
such transitions are forbidden, phosphorescence lifetimes are of the order of 
milliseconds to seconds. 
Luminescence imaging is an optical imaging technique in which information is derived 
from the emission output of luminescent molecules within the cell. Some luminescent 
molecules, such as chlorophyll, reduced nicotinamide adenine dinucleotide (NADH) 
and oxidised flavin adenine dinucleotide (FAD) are intrinsic, occurring naturally within 
the cell. The relative lack of naturally occurring fluorescent molecules, however, 
requires the use of extrinsic luminophores, which are added to the cell in order to derive 
information about the system. Such species are generally referred to as luminescent 
probes. 
By selecting luminescent probes that are sensitive to their microenvironment, 
information can be gained about the local chemical environment, such as the pH or ion 
concentration,'^ and about aspects of the local physical environment including polarity, 
fluidity and distance.'^ The challenge is therefore to design luminescent probes that can 
provide useful information about their environment. The next sections outline types of 
luminescence signalling which may be utilised, and the criteria for luminescence 
probes. The subsequent section briefly presents existing classes of luminescent cellular 
probes. 
1.2.2 Classes of Imninescence signalling 
The most rudimentary class of signalling molecules comprises cellular stains. These are 
luminescent molecules which localise to particular organelles or sub-cellular locations. 
The luminescent output of these stains can therefore give information about the physical 
lay-out of the cell.''' While such stains have found wide commercial use as organelle 
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markers,'^ their emission is not sensitive to cellular conditions. To better understand 
biological systems, it is important to use probes which can report on their environment. 
In order for a molecule to act as an informative probe, the presence of a species or a 
biochemical event must be signalled by some form of luminescence change. Such a 
signal can take one of a number of forms (Figure 1.2). Each signalling behaviour will be 
discussed below. 
Intensity (b) Intensity Ratio (c) Anisotropy (d) Lifetime 
/ 
Wavelength Wavelength Wavelength 
[Analyte] [Analyte] [Analyte] 
[Analyte] 
Figure 1.2: Types of luminescence signals which can be employed for probing applications: (a) intensity, 
(b) intensity ratio, (c) anisotropy and (d) lifetime. The lower curve of each pair describes the relationship 
between the measured signal and the analyte concentration. Adapted from Lakowicz." 
The most common mode of luminescence modulation is the increase or decrease in 
emission intensity on analyte binding (Figure 1.2a). By fitting the emission intensity at 
known analyte concentrations to a curve, the concentration of unknown solutions can be 
determined. Changes in emission intensity can be the result of a variety of mechanisms, 
such as dynamic quenching, the enhancement or inhibition of photoinduced electron 
transfer (PeT) and changes in the microenvironment, such as the polarity.'^ 
The principal drawback of a sensor which relies on the luminescence intensity change at 
a single wavelength is the heavy dependence of emission intensity on factors such as 
pH, concentration, light scattering and photobleaching. As a result, much luminescent 
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probe technology utilises complementary responses at different wavelengths (Figure 
1.2b). The ratio of intensities at these two wavelengths (A/B) can be calibrated to 
provide information about the analyte, independent of external factors.'^ Ratiometric 
information can also be obtained from systems in which ligand binding or dissociation 
results in excimer formation.'^ 
The third luminescence signal which can be utilised is that of luminescence polarisation, 
or anisotropy (Figure 1.2c). The technique is based on the principle that the anisotropy 
of a molecule is a function of its tumbling speed, which in turn relies on the molecular 
size and shape. For a bound probe in equilibrium with its free form, therefore, the 
anisotropy will be a weighted average of anisotropies of the free and bound forms." A 
calibration curve can be constructed in which the polarisation change is plotted against 
analyte concentration. As with the ratiometric method, anisotropy is independent of the 
concentration of the probe. 
The final approach, which is also independent of probe concentration, involves 
monitoring of the luminescence lifetime (Figure 1.2d). In many cases, interaction with 
an analyte will resuh in a change to the lifetime of a luminophore."" While this method 
requires more sophisticated technology, it affords the added advantage of reduced 
interference from other molecules. 
This survey has shown that there is a wide variety of methods by which a probe can 
signal a biochemical event or the presence of a sub-cellular species. For a cellular probe, 
it is impractical to determine the concentration of the probe at every sub-cellular 
location or to derive calibration curves for all possible cellular conditions. Therefore, a 
luminescence signal which is independent of these factors is desirable. This precludes 
the use of a simple change in emission intensity, and requires the development of probes 
which signal analyte binding by changes in luminescence lifetime, anisotropy, or the 
ratio of emission peaks. It is the latter class of probes which will be primarily explored 
in this work. 
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1.2,3 The challenge of designing luminescent cellular probes 
In order to design efficient luminescent cellular probes, it is important to consider a 
number of criteria. These required properties can be divided into two main groupings: 
probe suitability and cellular behaviour. 
1.2.3.1 Probe suitability 
The first class of criteria concern the suitability of the probe to report on the .specific 
conditions for which it is designed. These criteria relate to the sensitivity, selectivity and 
stability of the probe, and its luminescence spectral properties, which will influence the 
detectability of the probe and the ease with which information can be derived from the 
emission output. 
Ideally, probes wil l report on a single biochemical species or event at concentrations or 
frequencies which are biologically relevant. A probe must therefore have sufficient 
sensitivity, which is the ability to detect the analyte at appropriate concentrations. In 
addition, the probe must exhibit selectivity for the analyte over other molecules, to 
minimise interference.^" It is also desirable for the probe to possess sufficient chemical 
stability to ensure that it wi l l not be broken down under cellular conditions. Another 
important aspect of stability is minimal susceptibility to photobleaching, in which the 
excited fluorophore is irreversibly destroyed under irradiation (Figure 1.3).^'"'' 
0 I 
0 10 20 30 40 50 
Time / sec 
60 
A ) H,N" 
COOH 
COOH 
Figure 1.3: Luminescence intensity at various times following sample irradiation, showing the relative 
photostability of Alexa Fluor 488 (A; • ) compared to that of fluorescein (B; • ) . Data obtained from 
Invitrogen." 
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As discussed above, luminescence is an attractive method for probing living cells as it is 
non-invasive and allows high resolution. The spectroscopic properties of the probe, 
however, must be optimised to give greatest possible detectability. This requires 
consideration of a number of factors, and is also influenced by the sensitivity of the 
detection instrument - usually a microscope. The molar absorption coefficient and 
luminescence quantum yield must be high enough that the fluorescence output of the 
probe wil l be sufficient to allow detection of the target under normal cellular conditions 
and concentrations, when excited by wavelengths of minimal energy. While absorption 
coefficients are not usually significantly affected by environment, quantum yields are 
sensitive to the solvent, and are hmited by quenching processes involving cellular 
species, so it is important to maximise the quantum yield under cellular conditions. To 
this end, it is desirable to design probes that minimise the quenching by endogenous 
species, such as protein and DNA. 
The properties of the detection instrument must be considered when selecting the 
excitation wavelength. The absorption maximum of the probe should be closely 
matched to the available excitation sources, such as lasers. Higher excitation 
wavelengths are also desirable as they result in less interference from background 
autofluorescence,^^ decreased photochemical damage to the cell "^^ and greater 
penetration into samples due to less light scattering. In addition, probes with a large 
Stokes shift allow greater resolution of incident from emitted light (Figure 1.4). Finally, 
the excited state lifetime of the probe must be matched to its use: for flow cytometry, a 
short lifetime is desired due to the short timescale of the experiment whereas in 
microscopy, longer lifetimes allow removal of background autofluorescence by 
time-gating 26 
1.4 
1.2 
1.0 
0.8 
0.6 
0 4 
0.2 
0.0 
400 500 550 600 
Wavelength / nm 
650 700 
3 0 0 H 
Figure 1.4: Excitation (—) and emission (—) spectra demonstrating the small Stokes shift of fluorescein 
(A; red)'"*^  compared to that of a porphyrin derivative (B; blue).^^ 
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The final criterion of a luminescent probe is that interaction with the target must be 
signalled by a luminescence response, as discussed in Section 1.2.2 above. For organelle 
stains, this response may take the form of the distribution of luminescence in the cell, 
but for probes of sub-cellular species and events, a luminescence change following 
binding is required. Ideally, this change would be independent of probe concentration. 
An additional luminescence response that can be utilised is Fdrster resonance energy 
transfer (FRET), in which emission of one fluorophore is coupled to the excitation of 
another in a distance-dependent manner." 
1.2.3.2 Cellular behaviour 
The development of cellular probes requires certain key cellular behaviour. It is 
important, therefore to ensure efficient delivery, targeting to the region of interest, and 
minimal perturbation of cellular homeostasis. '^^ ' Each wil l be discussed in turn below. 
The principal requirement for a cellular probe is that it is able to enter the cells on which 
it is to report. Ideally, the probe would be cell-permeating, so that introducing a stock 
solution to the extracellular medium would result in cellular uptake, by an active or 
passive mechanism. In some cases, however, it is necessary to induce uptake by bulk 
loading methods such as electroporation^^ or ATP-induced permeabilisation.''° Another 
commonly-used technique is the conversion of the probe to its acetate or acetoxymethyl 
ester form, which is membrane-permeating. The added group is subsequently 
hydrolysed in cellulo to give the desired probe.'" In order for probes to have widespread 
applicability, it is also important that they be readily introduced into a wide variety of 
tissues and organisms. 
In order to use a probe to study the structure and function of a cell, it is necessary to 
ensure that the probe encounters the molecular species about which it will report. Thus, 
the probe must have affinity for the relevant target. In addition, a probe that is designed 
to report on the conditions within a particular region of the cell, such as an organelle, 
must be trafficked to that region. In some cases, this may be achieved by incorporating a 
targeting group into the probe or by attaching a transducer protein that carries the probe 
to a specific location. A wide range of sub-cellular localisations are possible (Figure 
1.5). 
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Figure 1.5: Multichannel fluorescence image showing localisation of commercially-available dyes. 
Peroxisomes (green) are labelled with a primary antibody -Alexa Fluor 488 conjugate, mitochondria (red) 
are labelled with MitoTracker Red CMXRos, and the nucleus (blue) is stained with DAPI.15 
The impetus for the development of cellular probes is the need for methods to study the 
structure and function of cells. Probes must therefore report on the cell's physiology 
without interfering with cellular processes. It is an important design consideration that 
the probe should not alter the homeostasis of the cell. The primary manifestation of this 
is that the probe, whether in its natural state, or in its photoactive state, does not have 
toxic effects on the cell (Figure 1.6). In addition, the probe should not interfere with 
cellular function and structure. For example, i f part of the probe lodged in the cell 
membrane, it could alter the membrane properties, while a protein-binding probe could 
inhibit enzyme activity. 
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Figure 1.6: Cytotoxicity of naphthopyranone-based dyes as a function of dye concentration showing the 
relative non-toxicity of A ( • ) compared to the toxicity of B ( • ) . " 
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Many different classes of compound have been developed for use as cellular probes. 
Each class will be discussed briefly, with particular attention to the criteria outlined 
above. The subsequent discussion will then focus on the class of luminescent lanthanide 
complexes, which is the topic of this thesis. 
1.3 Luminescent cellular probes 
1.3.1 Fluorescent organic dyes 
The first widely studied fluorescent organic molecule was the natural product quinine. 
Its visible emission in aqueous solution was reported by Herschel in 1845." Quinine 
was also one of the first molecules used as a fluorescent probe; during the Second 
World War, the composition of anti-malarial cocktails was determined by measuring 
quinine fluorescence.^'' Since that time, the library of fluorescent organic dyes has 
expanded and developed. There are now a wide range of dyes available, which span the 
UV-visible spectrum, and offer various chemical and photophysical properties. 35 
While the synthesis of new classes of efficient dyes remains a challenge, the structures 
of common dyes such as fluorescein can be modified slightly to generate vastly 
different fluorescence p rope r t i e s . " The most common classes of fluorescent dyes are 
derivatives of fluorescein and rhodamine (Figure 1.7),'^ each of which has a relatively 
high molar absorption coefficient, excellent fluorescent quantum yield and good water 
solubility. Each fluorophore can be easily conjugated to other compounds through 
reactive ester or amine derivatives. 
COOH COOH 
Figure 1.7: Common classes of fluorescent dyes are based on (A) fluorescein and (B) rhodamine 
Fluorescein- and rhodamine-based dyes are limited by their relatively high rates of 
photobleaching, pH-dependent fluorescence and broad emission and absorption bands. 
In response, new generations of fluorescent dyes based on the core structures of 
BODIPY® and Alexa Fluor® were developed (Figure 1.8).'^' These dyes are less 
10 
C H A P T E R ONE: INTRODUCTION 
susceptible to photobleaching and show negligible fluorescence changes over the range 
of pH 4-9. They also have advantages of fluorescein and rhodamine in their high molar 
absorption coefficients and quantum yields. Again, slight modification of the structure 
gives rise to a change in the fluorescence properties, and dyes are therefore available 
with excitation and emission at various wavelengths across the visible spectrum. 
(A) B H2N 
COOH 
Figure 1.8: Examples of improved organic fluorophores: (A) BODIPY and (B) Aiexa Fluor 488 
Despite their great versatility, the use of organic dyes as luminescent probes is limited 
by the low signal to noise ratios observed in fluorescence microscopy due to their short 
emissive lifetimes and the interference from cellular autofluorescence. In addition, the 
design of organic dyes with large enough Stokes shifts for microscopy applications 
remains a challenge.The utility of organic dyes is further compromised by the fact 
that they have broad and featureless emission profiles, so it is difficult to develop 
ratiometric probes which allow study of the analyte without interference from the 
environment. As a result of these drawbacks, various alternative classes of luminescent 
probes have been explored and developed. 
1.3.2 Fluorescent proteins 
The sophisticated recognition capabilities possessed by biological organisms has driven 
much study towards sensors built from biological components.''" Chief amongst these 
are fluorescent proteins, which are biological in nature, but can easily be tailored for 
specific purposes. 
The first fluorescent proteins to be used in cell biology were the phycobiliproteins, 
which are the pigment proteins involved in photosynthesis in cyanobacteria.'" The 
tetrapyrrole bilin fluorophores are held within a rigid framework, minimising 
deactivation of the excited state, and rendering phycobiliproteins detectable at 
concentrations as low as 10"'^  M . A further advantage of this class of proteins is the 
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42 
emission in the orange-red, thus minimising the interference from auto-fluorescence. 
Phycobiliproteins have found use in antibody conjugates for surface labelling of cells 
for flow cytometry. The use of phycobiliproteins is limited, however, by aspects of their 
uptake. The proteins are very large (200 kDa), and therefore do not readily diffuse into 
and within the cell. In addition, the proteins cannot be genetically expressed in situ as 
the bilin moieties must be physically inserted into the apoproteins. 
The use of fluorescent proteins as cellular probes gained momentum with the 
discovery '^ ^ and molecular cloning of the green fluorescent protein (GFP). The 
fluorescent chromophore of GFP is generated by autocatalytic cyclisation and oxidation 
of three amino acid residues at the centre of the protein. GFP fulfils many of the criteria 
for fluorescent probes outlined above. It can be readily delivered to its targets, as 
introduction of the GFP gene into cellular DNA results in synthesis of the protein. 
Furthermore, as an endogenous species, the protein does not affect the homeostasis of 
the cell. However, the great attractiveness of GFP lies in its adaptability. The protein 
can be engineered to vary the emission wavelengths, generating variants such as cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YPP)."*^ Furthermore, GFP 
can be used to study the cellular localisation of other proteins; the GFP gene can be 
fused to the gene of interest, giving rise to a fluorescent fusion protein. The principal 
limitations of GFP and other related fluorescent proteins lie in their fluorescence 
properties. The Stokes shifts in these proteins are relatively small,"*^ and the 
fluorescence spectra are broad and formless. As a result, it is not possible to elicit 
information from the emission profiles. While GFP and its variants have proved to be an 
invaluable contribution to the library of fluorescent probes, their utility lies primarily in 
the spatial and temporal study of proteins. They are unable to provide information about 
other endogenous molecules, or about biochemical events within the cell. 
1.3.3 Quantum dots 
The development of the third class of luminescent probes, quantum dots, arose from 
Louis Brus' observations that the conductivity of liquids changed with the particle size 
of materials."*^ Brus and his co-workers developed this concept into nanocrystals, which 
he named "quantum dots", whose emission wavelength depends on size.''^ 
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Quantum dots are fluorescent semiconducting nanocrystals of diameters 2-8 nm, 
generally containing elements from groups I I and V I or from groups I I I and V. For in 
cellulo applications, they are surrounded by an amphiphilic polymer coating to ensure 
cell uptake, and ligands can be attached to this coating for interaction with cellular 
species. Principal among their advantages are the size- and composition-tunable 
emission throughout visible and infrared wavelengths, large absorption coefficients and 
high brightness and photostability.''^ Quantum dots can also be employed in 
combinatorial optical coding, in which particles of different colours and intensities are 
combined to encode an array of genes, proteins or small-molecule compounds.^"' ^' 
Quantum dots have been widely used as replacements for fluorescent proteins, for the 
labeling of cellular p r o t e i n s . A challenge in the use of quantum dots is in the 
intracellular delivery of these relatively large particles. An additional limitation is that 
they are unresponsive to their local environment, and can therefore only act as 
fluorescent tags. 
1.3.4 Transition metal complexes 
In parallel to the development of quantum dots, luminescent transition metal complexes 
have arisen in the past twenty years as another alternative to small organic dyes and 
fluorescent proteins.^"' These complexes are primarily based on the d^ and d^ metal ions 
of the platinum group elements including Ru(II), Os(II), Re(I), Rh(III), Ir(III), Pt(II) and 
Co(III). The use of organic ligands which are generally highly conjugated gives rise to 
intense metal-to-ligand and ligand-to-metal charge transfer transitions which are 
symmetry allowed.^'' 
The advantages of such complexes are their long luminescence lifetimes (10'^ to 10"^  s) 
that can allow for time-gating to reduce background noise, their relatively high 
luminescence quantum yields, intense visible absorptions and high thermal, chemical 
and photochemical s tabi l i ty .The photophysical and selectivity properties of transition 
metal complexes can also be modified by simple changes to the ligand structure. One 
recent example of a transition metal complex with potential use as a luminescent probe 
is the phenanthridine-containing RuEth (Figure 1.9A), which binds to RNA.^^ 
Preliminary fluorescence microscopy images were interpreted as demonstrating greatest 
luminescence in RNA-rich regions of the cell, but co-localisation studies would be 
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required to confirm this. Recent studies of Pt(II) complexes containing dipyridyl 
benzene derivatives have also demonstrated promising photophysical and cellular 
behaviour, with great potential for tuning properties for use in two-photon excitation 
microscopy (Figure 1.9B) 57 
n3-
Figure 1.9: Examples of transition metal complexes with potential use as luminescent probes 
(A) [RuEth]'" and (B) PtLCl 
1.3.5 Luminescent lanthanides 
In addition to complexes of the platinum group transition metals, other luminescent 
metal complexes have been investigated for use as luminescent cellular probes. 
Amongst these are the luminescent lanthanide complexes. The appropriate lanthanide 
can be selected to span a wide range of emission wavelengths, and the ligands are 
chosen to allow water solubility and high luminescence quantum yields. Luminescent 
lanthanide complexes have long emissive lifetimes, allowing the use of time-gated 
detection methods. A discussion of the properties of these complexes follows. 
1.4 Luminescent lanthanide complexes 
The term lanthanide is used to refer to the fourteen elements from cerium to lutetium 
which contain a partially-filled 4f o rb i t a l .For all lanthanides, the -i-3 state is the most 
stable in solution, with the only other observed forms being Ce'*'^ , Eu""^ , Yb "^^  and Sm^^ 
of which the divalent ions are rapidly oxidised in aqueous media."''^  
L4.1 Photophysical properties 
In order to account for the emission and absorption spectra of the lanthanide(III) ions, 
the ions can be considered to consist of energy levels described by the Russell Saunders 
coupling scheme, a model which can be applied in this case of strong coupling, although 
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is normally considered most appropriate for weak spin-orbit coupling.^" Neighbouring 
terms are typically separated by an energy gap of 5,000 to 10,000 cm"', with the J levels 
of each term being separated by a further 1,000 cm"'. 
The/-/transitions of the lanthanide(III) ions have a number of important characteristics. 
The small ligand-field splitting (of approximately 100 cm"') gives rise to spectra which 
are largely independent of coordination environment. Just as d-d transitions are Laporte 
forbidden, so are / - / transitions, but they experience less perturbation by ligands, so 
experience a reduced ligand field. The /-/transitions become only partially allowed by 
weak coupling with asymmetric ligand vibrations, resuldng in very low extinction 
coefficients (less than 1 M"' cm"').^' 
In order for a lanthanide ion to be utilised in a luminescent probe, it must have certain 
photophysical characteristics. Most importantly, there must be a sufficient energy gap 
between the ground and first excited states, to ensure that energy will be emitted as 
luminescence rather than being lost by non-radiative processes.To this end, the 
lanthanide ions which lie in the centre of the series - Eu''^ Gd'''^  and Tb^ "^ , with energy 
gaps of 12300 (^ Do ^ ^Fg), 32200 (^ P7/2 ^ 8^7/2) and 14800 (^ D4 ^ ^Fo) cm"' 
respectively, are the most useful. While Eu^ "^  and Tb^'^emit in the visible region of the 
spectrum, Gd'^ "^  emission is in the ultraviolet, rendering it unsuitable for use in 
luminescent probes for biological applications. Subsequent discussion will therefore 
focus on the use of Eu''* and Tb^ "^  complexes as luminescent probes. 
1.4.1.1 The need for sensitised emission 
As a result of the low molar absorption coefficients of the lanthanide ions, the excited 
energy states wil l not be efficiently populated by optical irradiation. It is therefore 
necessary to adopt alternative approaches to populate these states and ensure higher 
efficiency of fluorescence emission. One possible means of excitation is by the use of 
high intensity lasers to ensure sufficient population of the excited state, but such a 
method is not practical for the study of biological systems. Alternatively, efficient 
excitation can be achieved by sensitisation of the metal ion, in which a sensitiser 
(usually an organic chromophore) is attached to a lanthanide ion-containing system 
(Figure 1.10).^ ^ 
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Figure 1.10: Schematic diagram showing the energy transfer from the chromophore to the metal ion in a 
sensitised lanthanide complex 
1.4.1.2 Energy processes of sensitised emission 
The lanthanide excited state is reached after energy transfer from the triplet energy of a 
sensitising chromophore (Figure 1.11). The sensitiser is first excited to a vibrationally 
excited level of the Si (or Sn) band by absorption of a photon. This excited state then 
relaxes, either by non-radiative vibrational relaxation followed by fluorescence, or by 
intersystem crossing to the triplet, T | manifold. There are then three possible pathways 
from the Ti state: back-intersystem crossing to Si, phosphorescence, or energy transfer 
to the lanthanide excited state. 63 
Si 
absorption 
So 
ISC 
sensitiser 
fluorescence 
.3 
sensitiser 
energy 
transfer 
sensitiser 
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em(ss(ve 
state 
lanthanide 
luminescence 
Figure 1.11: Jablonski diagram showing the energy processes by which a lanthanide ion is indirectly 
excited via an organic chromophore. 
For a system in which the chromophore has a high molar absorption coefficient and 
efficient intersystem crossing and energy transfer processes, the effective molar 
absorption coefficient of the metal wil l be greatly enhanced, allowing for significant 
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emission following excitation by conventional light sources. For the case of sensitised 
lanthanide emission, the luminescence quantum yield is defined as the ratio of the 
number of photons emitted through lanthanide luminescence to the number absorbed by 
the sample. This value is the product of the efficiencies of each of the individual energy 
transfer steps involved in reaching the lanthanide emissive state. 
1.4.1.3 Mechanisms of energy transfer 
Electronic energy transfer may occur either radiatively or non-radiatively. Radiative 
energy transfer, in which donor-emitted energy is absorbed by the acceptor, is favoured 
for systems in which donor and acceptor energy levels overlap well, and the emission 
properties of the donor and absorption by the acceptor are maximised. Despite the good 
overlap between chromophore and metal energies for sensitised lanthanide emission, 
radiative energy transfer is unUkely because of the low molar absorption coefficient of 
Ln(III). Energy transfer therefore occurs by a non-radiative mechanism.^ 63 
The electronic energy transfer from the sensitiser to the lanthanide (III) can be described 
by one of three mechanisms of non-radiative electronic energy transfer; the Dexter 
(exchange) mechanism, Forster (dipole-dipole) or a redox electron exchange 
mechanism. The Dexter mechanism involves electron exchange between the sensitiser 
and metal species, with conservation of multipUcity.^ Such a mechanism requires 
overlap of the electronic orbitals of the donor and acceptor species. The Forster 
mechanism involves through-space interactions between the electronic dipole moments 
of the triplet state of the sensitiser and the 4f orbitals of the lanthanide.*^ In the electron 
exchange mechanism, the lanthanide ion takes an electron from the excited sensitiser. 
This electron is then passed back from the Ln(II) ion to the sensitiser, resulting in 
Ln(in) in its excited state.^ ^ 
1.4.1.4 Basic features of europium(III) and terbium(III) spectra 
Much information can be gained from analysis of the well-defined bands that comprise 
the emission spectra of lanthanide ions. Analysis of the fine structure of these bands and 
the ratios of intensities, particularly from the emission spectrum of Eu(III) complexes, 
provides valuable information about the coordination sphere of the lanthanide. 
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Figure 1.12: Partial energy diagrams of Eu(III) and Tb(III) 
Examination of the partial energy level diagrams of the ions (Figure 1.12) allows for a 
correlation with the bands of the emission spectra. The emissive state of Eu(III) 
complexes is ^DQ. The two strongest emissions arise from the ''Do -> ^F| ( A / = 1) 
transition at 590 nm and the ^Do ^FT ( A / = 2) transition at 612 nm. While the A / = 1 
band is magnetic dipole in character and largely independent of the coordination sphere, 
the A / = 2 band represents an electric-dipole allowed transition and is therefore 
extremely sensitive to the nature and symmetry of the coordination sphere. The A / = 4 
(•^DQ—^^4) transition is also relatively intense and sensitive to the ligand field, 
possessing predominantly electric dipole character.^' 
For Tb(in), emission arises from the D^4 level. The -> ^¥5 (AJ - 1) emission band, at 
545 nm, is the most intense and sensitive to the ion environment, but less so than the 
AJ = 2 band of Eu^ "^ . Since the bands can rarely be fully resolved into component 
electronic transitions, analysis of Tb'''^ spectra is less informative about the coordination 
environment of the ion. 
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1.4.2 Ligand design 
In designing luminescent lanthanide complexes, it is important to consider factors that 
wil l best maximise the stability and photophysical behaviour of the complex. In addition 
to the selection of lanthanide, as discussed in Section 1.4.1 above, it is important to 
carefully consider the choice of macrocycle and chromophore. 
1.4.2.1 The choice of ligand 
Selection of an appropriate ligand for a luminescent lanthanide complex requires careful 
consideration of the coordination chemistry of the lanthanides. Coordination numbers of 
7, 8 or 9 are most commonly-observed for lanthanide complexes.^^ The lanthanides are 
also typically hard Lewis acids, and therefore generally form complexes containing N-
and O-donor ligands.''^ 
In order to prevent displacement of the lanthanide ion by competing biological 
molecules, the lanthanide-ligand complex must exhibit high kinetic and thermodynamic 
stability with respect to metal loss. Many of the eariy studies of suitable ligands for 
lanthanide complexes arose from the investigation of gadolinium complexes for use as 
contrast agents, in which there is a similar need for high stability.^^ 
A number of different ligand systems, both linear and macrocyclic, have demonstrated 
utility for luminescent lanthanide complexes. These include linear polyamino 
carboxylates such as DTPA (Figure 1.13A)^^ and their macrocyclic analogues, 
derivatives of DOTA (Figure 1.13B).^^ The latter, cyclen-based ligands, with their very 
high stabilities (logK values of 23-25) have found widespread use in numerous classes 
of lanthanide complexes.^" Other ligand systems include calixarenes (Figure 1.13C)^ ^ 
and Schiff-based ligands, formed from the self-condensation of formyl and amine 
precursors (Figure 1.13D). 
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Figure 1.13: Examples of suitable ligand systems for luminescent lanthanide complexes. 
(A) diethylene triamine pentaacetic acid (DTPA), (B) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA), (C) p-tert-butyl calyx[4]arene teu-aacetamide and (D) condensation product of 2,6-
diacetylpyridine and 1,4-diaminobutane. 
1.4.2.2 The choice of chromophore 
The requirement for a sensitising chromophore is a high molar absorption coefficient at 
an appropriate excitation wavelength. For single photon microscopy, such excitation 
should be in the range 337 - 420 nm; higher energy excitation could cause radiation 
damage to cells, whereas lower energy excitation does not allow intramolecular energy 
transfer to occur. In order for effective activation of the lanthanide excited state, the 
chromophore should have a triplet energy which is at least 1500 cm'' higher than the 
emissive state of the lanthanide (17,240 cm"' and 20,400 cm"' for Eu and Tb 
respectively). A smaller energy difference can lead to decreased lifetime and emission 
intensity due to thermally-accessible back energy transfer, in which energy transfer 
occurs to the triplet state of the sensitiser.^' 
Selection of a chromophore must take into consideration the efficacy of energy transfer 
to the lanthanide ion. For efficient transfer, the triplet state of the chromophore should 
be readily populated; that is, the rate of intersystem crossing must be more rapid than 
the rates of the fluorescence and non-radiative decay processes. Finally, the quantum 
efficiency of energy transfer will be maximised when the sensitiser-Ianthanide distance 
is minimised. This can be achieved through direct coordination of the chromophore to 
the metal centre. Recent work has centred on m-terphenyls,^" phenanthrolines,'' 
tetraazatriphenylenes,^^'^•^ azaxanthones and azathiaxanthones (Figure 1.14).^ "'^ ^ 
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Figure 1.14: Examples of suitable chromophores for luminescent lanthanide complexes. 
(A) m-terphenyl (B) phenanthroline, (C) 10,11,12,13-tetrahydrodipyrido[3,2-a:2',3'-c]phenazine (dpqC) 
and (D) azaxanthone 
1.5 Luminescent lanthanide complexes as cellular probes 
The long luminescence lifetime, information-rich emission spectra and large Stokes 
shifts make luminescent lanthanide complexes ideal candidates for use as cellular 
probes. As discussed above, the primary requirements for a cellular probe are that it can 
provide information about its environment and possesses suitable cellular behaviour. 
Much work in the past has examined one of these two aspects, as will be discussed in 
the following sections. 
1.5.1 Examples of responsive systems 
A common theme of the study of luminescent lanthanide complexes throughout the 
worid has been the design of systems which can report on their environment. As 
discussed in Section 1.2.3.1 above, this requires a stable complex which is sensitive to 
and selective for the analyte, and which exhibits luminescence properties that aid its 
detectability. A number of promising systems have been developed utilising various 
detection methods, examples of which are discussed below. This discussion focuses 
primarily on the detection of species or events which are of cellular relevance, and not 
on the many systems which have been designed to study other species. In addition, only 
Eu''"^  and Tb^ "^  complexes will be considered, as these are of interest for use as 
luminescent probes. 
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1.5.1.1 Probes for pH 
The detection of pH within a cell is important, as acidic environments have been 
observed in a number of disease states, including cystic fibrosis^^ and tumour growth.^' 
A number of luminescent lanthanide complexes have been developed to probe pH, such 
as those shown in Figure 1.15. 
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Figure 1.15: Examples of luminescent lanthanide systems which report on pH 
Complexes l a and lb contain an unmethylated and methylated phenanthridinium 
chromophore respectively.'*' Sensitivity of the complexes to pH arises from direct 
interaction of acid or base with the chromophore, which affects the absorbance 
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spectrum of the base, and hence the luminescence emission intensity. For complex la, 
protonation of the phenanthridyl shifts the absorption spectrum of the chromophore to 
longer wavelengths. Excitation of the complex at these higher wavelengths therefore 
results in markedly higher europium Juminescence for the protonated complex 
compared to the deprotonated form. The pKa of this complex is approximately 4. In a 
similar manner, hydroxide reacts reversibly with the methylated phenanthridinium in 
complex lb, resulting on loss of the absorption band at 360 nm. Measurement of Eu 
Juminescence upon excitation at 360 nm at varied pH therefore results in a pH titration 
curve, with a pKaOf approximately 12. While these complexes exhibit the potential for 
use as pH sensitive complexes, neither would be directly useful as a cellular probe, as 
the pH of all biological processes generally lies between 5 and 7 for normal systems, 
and between 4 and 8 for pathological conditions.*" 
Photoinduced electron transfer (PeT) has been utilised as a mechanism of pH sensing, in 
the terpyridyl-containing Tb complex, 2. In the unprotonated form, PeT from the amines 
to the terpyridyl leads to quenching of the antenna singlet excited state, resulting in poor 
sensitising of the terbium. Upon protonation of the amines, this quenching pathway is 
removed, which leads to a 10-16 fold increase in terbium luminescence.*" 
An additional type of pH probe which has been developed, 3, contains a thiaxanthone 
chromophore and an N-linked methylsulfonamide pendant arm.*^ Protonation of the 
nitrogen on the methylsulfonamide in acidic pH results in a change in coordination 
number from 8 to 7, with a resulting change to the form of the Eu spectrum. The 
ratiometric change of the /iJ=l and j y = 4 peaks can be calibrated to determine the pH of 
an unknown solution. The pKa for this change is 6.15, and the curve was unchanged in 
the presence of a mixture of anions. In the presence of protein, a pKa value of 7.2 was 
calculated. 
1.5.1.2 Probes for endogenous anions 
There are numerous endogenous anions whose concentrations must be kept within small 
windows in order to maintain normal cellular function.*° As a result, it is important to 
develop probes to assess the distribution and concentration of these anions in cellulo. A 
number of luminescent lanthanide complexes have been developed to probe the local 
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concentration of various endogenous anions, some of which are presented below (Figure 
1.16). 
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Figure 1.16: Examples of luminesceni lanthanide systems which report on endogenous anions 
Eu acridone complexes such as 4 have found utility as bicarbonate s e n s o r s . T h e 
complex contains one bound water molecule, but on addition of bicarbonate, the water 
is displaced and a carbonate chelate formed. This results in a marked change to the Eu 
emission spectrum, particularly in the /iJ = 2 / AJ = 1 ratio. The complex could be used 
to determine the bicarbonate concentration in a solution containing other anions such as 
lactate, citrate and phosphate. 
The concept of displacement of a bound water molecule by a chelating anion was also 
used in the development of a citrate sensor based on a thiaxanthone chromophore (5).^ '* 
Citrate forms a stable, 1:1 adduct with this complex, with a resulting increase in the 
AJ = 2 IAJ = 0. This behaviour was shown to be independent of pH. 
An alternative method of measuring anion concentration is through the measurement of 
luminescence quenching. One such system is complex 6, which contains a 
tetraazatriphenylene chromophore.Lanthanide emission from complexes of this type 
86 
is quenched by the cellular oxidant urate, most likely by exciplex formation. The Tb 
complex of 6 is more sensitive to quenching than the Eu analogue, due to its higher 
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excited energy state. As a result, the ratio of Tb to Eu emission decreases with 
increasing urate concentration. This enabled the development of a ratiometric assay for 
the determination of urate concentration in various fluids, including urine and serum. 
1.5.1.3 Probes for metal ions 
Metal ions are essential for a number of biological processes, such as in enzymes and 
ion channels.^^ Examples of luminescent lanthanide complexes which have been 
developed to probe for metals in cells are shown in Figure 1.17. 
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Figure 1.17: Examples of luminescent lanthanide systems which report on intracellular metal ions 
The incorporation of a substituted aniline in complex 7 gave rise to selectivity for Zn 
over Mg'"^ and Ca^ "^ .^ '^ This Zn^ "^  binding gave rise to ratiometric changes to the form 
of both the chromophore and Tb emission spectra which could be used to determine 
Zn^ "^  concentration. The drawbacks of this system are its sensitivity to pH, the moderate 
(less than 50%) increases in luminescence on Zn""*" binding and the low excitation 
wavelengths required (262 nm). 
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An alternative approach to metal ion sensing involves the use of the metal itself to bring 
together the lanthanide and the sensitising moiety.^" The Cu'^-glutathione complex 
[Cu'^-GS ] , which is the primary intracellular form of Cu"^ , catalyses the reaction of an 
alkynyl Eu complex with a dansyl azide to produce the sensitised complex 8. The 
formation can be monitored by europium emission. This effect is independent of pH for 
the relevant biological range of 5-8. Although this system is able to report on Cu'^  
concentrations, it is unlikely to find use as a cellular probe, as the two components are 
likely to be endocytosed and compartmentalised in a very different manner; indeed, they 
may not be in close enough proximity to react within the cell. In addition, it is likely 
that the azide would react with other cellular species, and could also exert cytotoxic 
effects on the cell. 
Another system in which the metal ion draws together the chromophore and the 
lanthanide is complex 9, a K"^  sensor.^' ions are complexed in the ether ring, and 
form cation-Ti interactions with the arene in the chromophore linker. Due to the resulting 
conformational change, the terbium complex and the azaxanthone chromophore are 
brought into close enough proximity to facilitate sensitisation, and a concomittant 26-
fold increase in Tb luminescence. This system exhibits selectivity for K"^  over Na"^  and 
other cations, but this selectivity is modest. In addition, the probe is not ratiometric, and 
intensity changes on binding are strongly pH-dependent. 
1.5.1.4 Probes for sub-cellular events 
In addition to pH, endogenous anions and metal ions, there are a number of cellular 
events which can be detected by the use of a cellular probe. For some such events, 
luminescent lanthanide probes have been developed (Figure 1.18). 
The redox environment of the cell is believed to be important in determining the 
direction of cellular processes.^ ^ A probe for redox state, 10, has been developed, 
containing two cysteine groups.^'' When the probe is in the oxidised form, the formation 
of an intermolecular disulfide bond brings the chromophore close to the terbium ion, 
facilitating the energy transfer process. Upon reduction, the peptide adopts a random 
conformation in which the terbium and the chromophore are spatially separated, 
resulting in decreased luminescence. The reduction potential of the probe, at -0.243 V, 
lies near the cytoplasmic potential of many cell lines, giving it great potential use as a 
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probe for cellular redox environments, however the increase on oxidation is only very 
modest (3-fold), which may limit its ability to report on in cellulo events. 
Tb-NH O 
,N O 
^ C Val-Asn-Gly-Thr N 
n SH "J 
10 
reduction 
oxidation 
Tb-NH O 
0 
Val 
\ 
Gly 
/ 
Thr 
N 
O H 
NH 
0 / 0 
o o 
Figure 1.18: Examples of luminescent lanthanide systems which report on subcellular events 
Many essential biological processes involve phosphorylation and dephosphorylation 
events. These include the generation of adenosine triphosphate (ATP), and the 
numerous cellular phosphorylation cascades involved in signal transduction.^'* One 
method for the detection of phosphorylation events is to use a probe which can signal 
the presence of a phosphorylated amino acid as distinct from its unphosphorylated form. 
Complex 4 fulf i ls this criterion, showing selectivity for phosphotyrosine over tyrosine 
as well as over other phosphorylated amino acids .Binding of phosphotyrosine gives 
rise to marked changes in the luminescence emission spectrum due to displacement of 
the coordinated water molecule. This spectral change was also observed in the presence 
of short polypeptides containing phosphotyrosine, suggesting the potential of this 
system to study larger proteins. 
The generation of singlet oxygen is an important biochemical process, being implicated 
in many pathways of cell death, as well as in cell signalling cascades.A lanthanide 
probe, 11, has been designed for the detection of singlet oxygen, which is based on a 
photoinduced electron transfer (PeT) switch.*^ This system comprises a terpyridyl 
ligand with an attached anthracene group. In its unbound form, the anthracene quenches 
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the europium luminescence, deactivating the excited state of the terpyridyl moiety by 
PeT. Singlet oxygen forms an adduct with anthracene, hindering this PeT process, and 
resulting in increased luminescence. Again, this system is limited in that it is not 
ratiometric. In addition, the adduct formation is irreversible, such that the emission 
intensity increases with time as a function of singlet oxygen concentration. 
1.5.2 Examples of cell-permeating systems 
The previous section has described the many and varied complexes which have been 
designed to report on aspects of the cellular environment. The second criterion for a 
luminescent lanthanide probe is suitable cellular behaviour; the probe must be cell-
permeating, and must be targeted to the particular sub-cellular region of interest. This 
section outlines examples of cell-permeating lanthanide complexes which have been 
reported in the literature. 
A number of studies have demonstrated the cellular uptake of various luminescent 
lanthanide complexes (Figure 1.19). Investigations of the triple-stranded [Eu2(12)3] 
helicate in the human cancer cell line HeLa revealed concentration-dependent 
luminescence in the cytoplasm, with no loss of cell viability. The emission intensity was 
greater in cells which were fixed with glutaraldehyde or ice-cold methanol. There was 
no apparent difference in the emission intensity in cells incubated with the complex at 
37 °C and 4 °C, which was interpreted as evidence of an active uptake mechanism.^* 
However, active endocytosis is energy-dependent and will be inhibited at low 
temperatures.^^ It is more likely that these observations signal a passive mechanism of 
cellular uptake. A later study of related helicates identified greatly reduced uptake at 
100 
4 °C, which is consistent with an endocytotic mechanism of cell uptake. In this study, 
lanthanide uptake was also quantified, allowing for comparison between the behaviour 
of different complexes. More recently, the subcellular localisation of Eu helicates was 
investigated by co-localisation studies with commercially available cellular s t a i n s . I t 
was concluded that the complexes were localised in the lysosomes, particularly those 
vesicles which were associated with the endoplasmic reticulum. This localisation was 
not very well-defined, with the images also indicating a degree of localisation in the 
Golgi apparatus. 
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Figure 1.19: Ligand employed for formation of bimetallic triple-stranded helicate [Eu2(12)3] 
Co-localisation studies have also been utilised for a number of other systems in order to 
define subcellular localisation profiles (Figure 1.20). The europium complex 13 was 
demonstrated to localise in the nucleolus of the cell, confirmed by co-staining with the 
green SYTO RNA-Select s t a i n . T h i s behaviour was observed in a number of cell 
types and for various dosing concentrations, and luminescence intensity did not appear 
to change upon incubation at 4 °C. 
30,Et 
EtOjC 
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Figure 1.20: Cellular localisation profiles of luminescent lanthanide complexes. (A) Luminescence 
microscope image after incubation of NIH 3T3 cells with 13 (100 |.iM, 4h);"'" (B) Luminescence 
microscope images after incubation of NIH 3T3 cells with 14 (i) 0.3 mM, 4h and (ii) 1 mM, 24h;^' (C) 
constitutional isomers IS and 4 which exhibit markedly different cellular locaHsation. 
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In contrast, the europium complex 14, containing the tetraazatriphenylene chromophore, 
exhibited concentration-dependent localisation. Upon incubation with low 
concentrations for short periods of time, luminescence was observed in the lysosomes, 
while dosing at higher concentrations for longer time periods resulted in luminescence 
in the nucleus, and particularly the nucleolus (Figure 1.20B).''' A final example of the 
compartmentalisation of luminescent lanthanide complexes is that of the two 
constitutionally-isomeric complexes 15 and 4, which exhibit very different behaviour. 
While 15 localises to the lysosomes, 4 exhibits a compartmentalisation pattern 
consistent with the endoplasmic reticulum.^''' 
The cellular behaviour of the luminescent lanthanide complexes discussed thus far were 
neither predicted nor controlled by their structural features. In contrast, a number of 
studies have been performed in which complexes incorporate moieties designed to 
influence their cellular behaviour (Figure 1.21). The luminescent europium complex 16 
was designed to allow easy conjugation to biological species.'""^ Conjugation of the 
complex to various serum antibodies and the protein streptavidin resulted in sub-cellular 
localisation, and enabled the probing of a number of antibodies and gene sequences. 
Another targeted probe is a streptavidin-based macromolecular complex, in which 
thyroglobulin molecules are used to attach streptavidin to the europium phenanthroline 
complex 17 to form highly luminescent aggregates, each containing hundreds of Eu"^ "^  
each.'^ '* Streptavidin has very high affinity for the cofactor biotin, and accordingly the 
aggregates were observed to localise in regions of the cell with high levels of biotin. 
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Figure 1.21: Examples of luminescent lanthanide complexes which incorporate targeting moieties. 
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A final example of a targeted luminescent lanthanide probe is 18, which incorporates a 
highly specific ligand for the peripheral benzodiazepine receptor (PBR), which is 
over-expressed in a number of diseases. The luminescence of this complex was readily 
observed within cells, with increased luminescence from cells which were 
over-expressing PBR.'°^ Preliminary co-localisation studies indicated that the complex 
was primarily located in the mitochondria, which are the regions of high PBR 
concentration. 
1.5.3 The challenge of an informative, cell-permeating probe 
Section 1.5.1 demonstrated the great understanding that has been reached into the 
design and synthesis of responsive luminescent lanthanide systems, which are able to 
report on specific cellular conditions. However, these studies have all been performed in 
vitro, and in general have not demonstrated in cellulo applicability. Cellular studies 
have been performed on a largely distinct group of luminescent lanthanide complexes, 
as detailed in Section 1.5.2. These studies revealed the promising cellular behaviour of a 
number of complexes, and illustrate the issues which must be considered in the design 
of cellular probes. In particular, most cellular studies identified distinct sub-cellular 
localisation profiles. It would be useful, then, to combine organelle distribution with 
probe function to make more informative cellular probes. A pH sensor might therefore 
be best localised in lysosomes, in which acidity can signify endosome age or health.'"^ 
Similarly, a probe for phosphorylation might be best directed to the mitochondria, 
where numerous phosphorylation events take place.^ 80 
However, very few studies have investigated the cellular properties of responsive 
lanthanide probes. Studies of the Zn"* sensor 19 in HeLa cells revealed readily-
detectable europium luminescence which increased on the addition of Zn^*, and 
decreased on treatment with a strong Zn^^ chelator.'"' The complex did not clearly 
localise within the cell, limiting the utility of the probe as a reponer of the mean 
intracellular Zn"^ concentration. 
N N 
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There have been cases in which the cellular localisation profiles of responsive probes 
have been determined. The bicarbonate sensor 4 was found to localise to the 
endoplasmic reticulum, confirmed by colocalisation with the stain Brefeldin A.*^ This 
may limit the usefulness of the probe, as there is no evidence that the function of the 
endoplasmic reticulum is dependent on bicarbonate or related anions. Confocal 
microscopy studies of cells treated with the pH probe 3 revealed localisation in the 
nucleolus, as well as more diffuse localisation which was interpreted to correspond to 
the ribosomes.*" However, this probe, with an apparent pKa of 7.2 in the presence of 
protein, would have been more useful if it could have been targeted to the lysosomes, or 
the cytoplasm, for which pH perturbations have greater biological significance. 
It is evident, therefore, that greater attention needs to be paid to the combined cellular 
and responsive behaviour of luminescent lanthanide complexes. Great understanding 
has been reached as to the design of complexes which are selective and informative 
about their environment. The challenge remains to harness this understanding in the 
design and synthesis of complexes which can provide information in a biologically-
relevant context. In order to achieve this aim, it is important to understand better the 
interaction of luminescent lanthanide complexes with biological systems. 
1.6 Objectives 
The aim of the work reported in this thesis is to gain a greater understanding of the 
cellular behaviour of luminescent lanthanide complexes. This involves the study of the 
activity of individual complexes, but also the generalisation of trends for larger groups 
of structurally-related complexes. Importantly, the derivation of structure-activity 
relationships wil l allow for the rational design of complexes with desired cellular 
behaviour. 
Research over the past eight years in Durham has yielded a relatively large library of 
luminescent lanthanide complexes with varying structures and selectivities. As a result, 
study of the cellular behaviour of this library will allow the determination of general 
conclusions concerning the structure-activity relationships of luminescent lanthanide 
probes. This work wil l therefore focus on complexes which have been synthesised in 
Durham, in addition to novel complexes reported herein. 
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Cellular behaviour can be subdivided into a number of important aspects (Figure 1.22). 
In understanding the interaction of a complex with a cell, it is necessary to consider the 
mode of cellular uptake and the mechanisms and determinants of sub-cellular 
localisation. In addition, it is important to establish the cellular fate of the complex, 
considering factors such as its cellular speciation and protein binding as well as its 
metabolism and excretion from the cell. Finally, as these complexes are designed as 
probes of cellular activity, they must cause only minimal perturbation to normal cellular 
function. It is therefore important to determine the effects of the complexes on the 
homeostasis of the cell. 
UPTAKE 
LOCALISATION 
CELLULAR 
E F F E C T S ON CELLULAR 
HOMEOSTASIS 
Figure 1.22: Important aspects of the cellular behaviour of luminescent lanthanide complexes. 
1.6.1 Outline 
This thesis details the work which has been performed to gain a greater understanding 
of the cellular behaviour of luminescent lanthanide complexes. Chapter Two describes 
the synthesis and characterisation of one class of lanthanide complexes, with particular 
reference to the structure elucidation and studies of cellular behaviour. Chapters Three 
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to Six in turn explore the four aspects of cellular behaviour outlined in Figure 1.22: 
Chapter Three describes studies of sub-cellular localisation, Chapter Four details the 
investigations of cellular uptake. Chapter Five discusses aspects of the cellular fate of 
luminescent lanthanide complexes, while Chapter Six presents the effects of the 
complexes on cellular homeostasis. 
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2.1 Introduction 
In order to study trends in the cellular behaviour of luminescent lanthanide complexes, it 
is important to establish an understanding of how biological properties relate to probe 
structure. In striving to establish such structure-activity relationships, it is therefore 
necessary to study well-defined sub-sets of probes systematically. This chapter details 
the synthesis, characterisation and subsequent biological studies of a set of related 
luminescent lanthanide complexes. 
The complexes [Ln.L*] and [Ln.L^]^^, containing the tetraazatriphenylene chromophore 
dpqC, have previously been synthesised and described.^'' [Ln.L"]^"^ was reported to 
exhibit readily-detectable luminescence in cell samples, which was localised primarily in 
the lysosomes. At high concentrations and long dosage times, luminescence was 
detected in the nucleolus. In contrast, the neutral complex, [Ln.L*], was only faintly 
visible by microscopy. 
[LnV] 
I 1 N ; r 
CSSSj-[Ln.L^l'^ 
The aim of this section of the work was to synthesise a series of complexes containing 
the dpqC chromophore, of varying charge and hydrophobicity. This was achieved by 
substitution of the pendant arms of [Ln.L^]''^ for alanine- and phenylalanine-based arms. 
Such arms have previously been successfully incorporated into responsive probes.^ '*' 
The target complexes were the cationic complexes [Ln.L^]^^, containing ethyl ester 
arms, and their neutral analogues [Ln.L"*], in which the ester has been hydrolysed to the 
carboxylate form. In order to assess the effects of absolute configuration, both the (RRR) 
and (SSS) enantiomers were desired. 
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2.2 Synthesis 
The (5j-alanine and (5j-phenylalanine haloacetamide precursors were synthesised by Dr 
Junhua Yu. The corresponding (R) compounds was synthesised according to the 
procedure in Scheme 2.1. Attempts to use chloracetyl chloride to synthesise the 
chloramide yielded an oil which proved difficult to purify, and which readily 
decomposed. The bromamide analogues were therefore prepared for linkage to the 
cyclen moiety, and were isolated as solids, amenable to recrystallisation. 
EtOH 
HCI ,g) .NHaCr O 
Br 
80% 
EtOH 
55% 
HN 
HCI (g) 
77% 
NHjCr o _ 
H ' C H j 66% 
Br 
Scheme 2.1: Synthesis of the {R)-A\a. ester and (R)-Phc ester bromamides 
Synthesis of cyclen-dpqC was achieved by Boc-protection of three of the ring nitrogens 
and subsequent attachment of the dpqC chromophore as a chloromethyl derivative 
(Scheme 2.2). The Boc groups were removed by using trifluoroacetic acid to yield the 
macrocycle-chromophore adduct, cyclen-dpqC. The chiral amide arms were introduced 
under standard conditions (CH3CN, K2CO3) and the ligand purified by column 
chromatography on neutral alumina. Complexation of the lanthanide (III) salt was 
undertaken in hot acetonitrile, with the lanthanide added as an anhydrous triflate salt. 
The triflate anion was subsequently replaced by chloride using anion exchange 
chromatography to enhance the water solubility of the complex. 
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Scheme 2.2: Synthesis of lanthanide complexes of L^" and L^' ' with Ala and Phe ester arms 
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The ester groups in the cationic complexes of [Ln.L^^]'''^ and [Ln.L^'']''"^ were hydrolysed 
to yield the zwitterionic complexes [LnX*^] and [Ln.L'*''] (Scheme 2.3). Hydrolysis was 
achieved by treatment with a dilute aqueous KOH solution, ensuring that the pH did not 
rise above 10 to avoid decomplexation. The progress of hydrolysis was followed by 
HPLC using a reverse phase column. The column used (Synergi 4\i Fusion RP 80A) has 
hydrophobic side-chains which aid the separation of relatively hydrophobic species. The 
hydrolysed complex is more hydrophilic than the parent ester, and hence eluted at 
shorter retention times. HPLC analyses were performed in the presence of 0.1% formic 
acid to ensure that the amide-containing complexes did not adhere to the column. 
The Tb complexes hydrolysed much more readily than the Eu analogues, requiring only 
two days at room temperature compared with up to 10 days at 40 °C necessary for 
hydrolysis of the Eu analogues. For the Eu complexes, it appeared that hydrolysis was in 
competition with metal decomplexation. 
) o 
« J N M 
0.02 M KOH 
40 °C 
H R HN 
^ R =CH3, CHgPh 
Scheme 2.3: Controlled hydrolysis of the ester complexes 
2.3 Structural analysis 
The successful synthesis of complexes [Ln.L'^]'''^ was confirmed by the use of high 
resolution mass spectrometry, which revealed accurate masses for the complexes within 
1 ppm of the calculated mass. Mass spectrometric analysis of the hydrolysed complexes 
[Ln.L'*] was less straight-forward, and accurate high resolution mass spectra could not be 
obtained. In this case, successful hydrolysis was confirmed by monitoring by HPLC. A 
change in the HPLC retention time could signify hydrolysis or decomplexation; the 
former was confirmed by observation of the retained sensitised emission of the two 
samples, through use of the fluorescence channel in HPLC. 
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2.3.1 The method of structural analysis 
In order to completely characterise the complexes, it is necessary to determine their 
absolute configurations. There are a number of possible conformations that complexes 
may take up, based on a cyclen-based system. The archetypal ligand, 1,4,7,10-
tetraazacyclododecanetetraacetic acid (DOTA) will be used as a model for these. In 
Ln(III) complexes of DOTA there are two elements of chirality to consider (Figure 2.1). 
The N-C-C-N torsion angle of each five ring chelate within the macrocyclic ring may be 
+60° or -60° (5 or X), and the N-C-C-0 torsion angle of the acetate arms may be +30° or 
-30° (A or A). 109 
:Ln Ln 
Ln 
, i \ / l > . 
N 
Figure 2.1: Conformations of Ln(IID complexes of DOTA showing the limiting orientations of the cyclen 
ring, and the lay-out of the acetate arms. 
These geometries give rise to four stereoisomers that exist as two pairs of enantiomers. 
The stereoisomers can adopt one of two geometries: A(5555) and ^{XXkX) exhibit a 
square antiprismatic geometry (SAP) with a twist angle of approximately 40° between 
the oxygen and nitrogen planes, while A(kXkX) and A(5555) adopt a twisted square 
antiprismatic (TSAP) geometry with a twist angle of approximately -30°. This geometry 
has been shown to be more favourable for complexes of the larger lanthanides.""' " ' The 
four isomers can interconvert in solution by ring inversion or arm rotation (Figure 2.2). 
Following complexation by Ln(III), the conformation is fixed, since arm rotation is 
inhibited and the ring inversion process is slow."^ The Ln(III) complexes of DOTA are 
9-coordinate due to the presence of a capping water molecule."^ 
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Figure 2.2: The four stereoisomers of Ln-DOTA complexes. Interconversion between enantiomeric pairs 
is possible through successive arm rotation and ring inversion 
The most definitive method of structural analysis is X-ray crystallography, but suitable 
crystals of chromophore-containing complexes have proved to be difficult to cultivate. 
As a result, the structures of novel complexes must be determined in comparison to 
known library members by other spectroscopic techniques. The tetraamide 20 has 
previously been successfully crystallised, and therefore forms the model for comparison 
with other complexes. Crystallographic analysis of this complex determined a 
monocapped square-antiprismatic geometry, designated AiXkXk).^^' 
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Previous comparisons of various spectra of 20 with those of fSSSj^Eu L^]^^ indicated 
that the two adopt a similar confirmation. The axial, capping, position, at which the 
water molecule lies in 20, is occupied by the second nitrogen of the dpqC chromophore 
of fS55j-[Eu.L^]''"^. In this work, therefore, the structure of the complexes [Eu.L^]^'^ and 
[Eu.L''] can be determined in comparison to that of [Eu.L^]^"^ by inspection of spectral 
similarities and differences between the complexes. A number of different spectroscopic 
techniques were employed, which will be discussed in the following sections. 
2.3.2 Emission spectroscopy 
Luminescence emission spectra of [Eu.L^*]'''^ and [Eu.L^'']'''^ and their hydrolysed 
complexes are shown in Figures 2.3 and 2.4 respectively. No ligand fluorescence was 
observed in any case, as expected for complexes of dpqC, which exhibits highly efficient 
intersystem crossing.'^ For both Ala- and Phe-based complexes, there are a number of 
significant changes upon hydrolysis. Notable amongst these changes are the loss of a 
AJ = 2 band at 619 nm and the decreased complexity of the AJ = 4 manifold. Since 
these bands possess electric dipole character, these changes are consistent with the 
changed local environment, and the resultant change in the oscillator strength, which 
arises from the altered side-chains. The emission spectrum of the hydrolysed complex 
[Eu.L''^]^* is similar in form to the emission spectrum of the parent triamide, [Eu.L^]^"^.^^ 
There are also notable differences between the Ala- and Phe-derived complexes, 
particularly in the AJ = 1 and AJ = 2 bands. In the AJ = 1 manifold there are three bands 
which correspond to the A 1 - A 2 , Ai-Ei and A 1 - E 2 energy transitions. For the Ala-derived 
[Eu.L^^]^* and [Eu.L"*^], the splitting between the A 1 - A 2 and Ai-Ei,2 components is 
approximately 155 cm"', whereas for the Phe-based complexes [Eu.L'"*]^"^ and [Eu.L'"'], 
the splitting is smaller (115 cm"'). In addition, the relative intensity of the AJ = 2 band 
compared to z i / = 1 is greater for the Ala complexes (2.5:1) than for the Phe complexes 
(1.5:1). These data indicate a change in the Eu coordination environment, which is 
probably due to a change in the nature of the capping group in the ninth co-ordination 
site."'*' This is consistent with studies of a range of complexes with varied capping 
donor atoms, which demonstrated that the polarisability of this group affects the size of 
the second-order crystal field coefficient, Bo ,^ which in turn influences the splitting of 
the (A/E) components of the AJ = 1 band. 116 
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Figure 2.3: Emission spectra of [Eu.L^"]'" (red) and [Eu.L*"] (blue) solutions (DjO, 295 K, X ,^ = 348 nm) 
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Figure 2.4: Emission spectra of [Eu.L^"]'^* (red) and [Eu.L'*"] (blue) solutions (D.O 295 K, = 348 nm) 
The corresponding Tb emission spectra are shown in Figures 2.5 and 2.6. There is very 
little spectral change on hydrolysis of the esters or following replacement of the Ala 
ligand for the larger Phe side chain. This is not unexpected, given the relative 
insensitivity of terbium emission spectra to the coordination environment. 
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Figure 2.5: Emission spectra of [Tb .L'']''" (red) and [Tb.L"^] (blue) solutions (DjO, 295 K, X^, = 348 nm) 
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Figure 2.6: Emission spectra of [Tb.L^"]'* (red) and [Tb.L""] (blue) solutions (D2O, 295 K, X,, = 348 nm) 
Emission spectroscopy also allows measurement of the lifetime of the excited state (x). 
This can be calculated by exciting the sample, and measuring the emission intensity after 
various time delays. The luminescence lifetimes for the europium complexes ranged 
from 0.69 to L04 ms, while the values for terbium complexes lay between 1.05 and 
1.88 ms (Table 2.1). 
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Table 2.1: Complex luminescence lifetimes in H^O and DjO, and calculated q values (X^x=348 nm, 
298 K)" 
Complex TH^O (ms) T D 3 0 (ms) <l 
[ T b L ' ] ' " ' 1.56 1.72 0.00 
[Tb.L-'°]'" 1.05 1.14 +0.08 
[ T b . L ' " ] ' " 1.57 1.56 -0.32 
[Tb.L*"] 1.58 1.80 +0.09 
[Tb.L""] 1.88 2.07 -0.06 
1.04 1.59 -0.15 
0.85 1.17 -0.18 
0.81 1.34 +0.04 
[ E U . L ' " ] 0.69 0.85 -0.24 
[ E U - L " " ] 0.82 1.22 -0.09 
" lifetimes have an error o f + 10%; q values have an error of ±20% 
values previously reported^' 
Lifetime measurements can also be utilised in the measurement of the hydration state of 
a complex. The number of bound waters, q, can be determined by a comparison of the 
radiative relaxation rates of the lanthanide excited state in both H 2 O and D 2 O , defined by 
the empirically-determined equations 2.1 and 2.2:"^ 
= 1.2 X ik,^^ - k,^^ - 0.25 - 0.075/2) [2.1 ] 
qn^5x{k„^^-k^^^-0.06) [2.2] 
where 
k^^f^ and /c^  ^ are the reciprocals of r^ ^ ,^ and respectively 
n is the number of bound amide groups. 
The calculated q values (Table 2.1) have 0 as their closest integral value, which is 
consistent with complex structures containing no bound water molecules. 
2.3.3 Circularly polarised luminescence spectroscopy 
Circularly polarised luminescence (CPL) spectroscopy is a technique which explores the 
differential emission of left and right circularly polarised light by emissive chiral 
luminescent species."^ Since the excitation is achieved via the antenna chromophore, 
the technique overcomes the limitations experienced in circular dichroism, resulting 
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from the low molar absorption coefficients of the lanthanide ion. Because complexes of 
opposite helicity wil l interact differently with circularly polarised light, CPL can 
elucidate the helicity about the metal centre, and provide some information about the 
electronic and magnetic environment of the lanthanide."^ CPL spectra for the terbium 
and europium complexes were obtained in Glasgow (with Dr R. D. Peacock), and are 
shown in Figures 2.7 to 2.10. As expected for the mirror image complexes of 
(55'5)-[Ln.L^]^'' and (RRR)-[Ln.L^f*, the terbium and europium CPL spectra are equal 
and of opposite sign. One representative set of mirror-image spectra is shown in Figure 
2.7. 
630 65D 670 690 710 
Wavelength / nm 
Figure 2.7: Mirror image CPL spectra of fSSSJ-iEu.L^"]'* (blue) and (RRRHEu.lJ'']'* (red) (DjO, 295 K, 
Xex = 348 nm) 
Figures 2.8 and 2.9 show the CPL spectra for the four Eu complexes. The spectra for 
(SSSj-LEu.L^"]^"" and (555J-[Eu.L**] (Figure 2.8) are very similar to one another, and to 
that of (SSS)-[Eu.lJf'^ in terms of the sign and sequence of the observed bands. On the 
other hand, the CPL spectra of fSSSJ-LEu-L^**]^ ^ and (S55j-[Eu.L'"'] (Figure 2.9) are 
markedly different from the Ala-derived complexes, and also differ from one another. 
The CPL spectra of (SSS)-[Th.L^''f^ and (555j-[Tb.L^'']-^^ (Figure 2.10) also exhibit 
marked spectral differences between the two complexes. 
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Figure 2.8: CPL spectra for fSSSj-lEu.L^"]^* (blue) and (SSS)-[Eu.Ln (red) (D.O, 295 K, A^, = 348 nm) 
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Figure 2.9: CPL spectra for ( 5 5 S ) - [ E U . L ' ' ' ] ' ^ (blue) and (5SS)-[Eu.L'"'] (red) (DjO, 295 K , X^, = 348 nm) 
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Figure 2.10: CPL spectra for (5SS)-[Tb.L' '] '* (blue) and (SSSj-lTb.L^"]'" (red) (D2O, 295 K, 
= 348 nm) 
46 
C H A P T E R TWO: S Y N T H E S I S AND C H A R A C T E R I S A T I O N O F C O M P L E X E S 
Emission dissymmetry factors, gem, are used to indicate the degree of chirality sensed by 
an electronic transition."^ They can be determined by equation 2.3: 
, ^?<LzM (2.31 
where is the intensity of the left (right) circularly polarised component. 
The calculated g-values for the Eu complexes are shown in Table 2.2. 
Table 2.2: Emission dissymmetry factors for Eu complexes (in D2O at 295 K, X,, = 348 nm) 
Complex gem(S90) gem(597) geiii(612) gem(6l5) gi!m(6l8) gem(65l) 
r555)-[EuL^]'" +0.23 -0.16 -0.02 -0.05 +0.09 +0.17 
rSSSj-lEu.L'"]'"" +0.12 -0.07 -0.01 -0.02 +0.02 +0.18 
fSSSj-LEu.L'"]'" -0.09 +0.03 +0.02 +0.02 +0.01 -0.08 
fSS^j-lEu.L"'] +0.19 -0.08 -0.01 -0.05 +0.043 +0.26 
r555)-[Eu.L"'] +0.05 -0.08 +0.01 -0.02 +0.01 +0.04 
The gem values for the two Ala-derived complexes are very similar, in sign and 
magnitude, to those of ('S55j-[Eu.L^]^"'. On the other hand, the CPL spectrum of 
(555j-[Eu.L^'']'^"^ is markedly different, with almost every transition exhibiting the 
opposite sign. The gem values for (55Sj-[Eu.L'"'] differ from those of both the Ala- and 
Phe-derived ester complexes. 
From the CPL spectra and the calculated gem values, f55'5J-[Eu.L^*]'''^ and its hydrolysed 
derivative exhibit the same helicity. These CPL spectra also exhibit the same sign and 
sequence of transitions to (SSS)-[EuL^f'*', which has previously been identified to 
possess a AiXXkX) configuration.^'' These Ala-derived complexes can therefore be 
assigned a A-helicity. The Phe-derived complex, ('555>[Eu.L'"']^"^, on the other hand, 
exhibits opposite g values, suggesting that this complex possesses opposite chirality, 
consistent with a A(5555) configuration. Assignment of the helicity of [Eu.L'"'] is less 
straightforward, as the sign and sequence of transitions appears to be intermediate 
between those of [Eu.L''"]^"^ and [Eu.L^'']'''^. This may be indicative of a more distorted 
local geometry, and could be a twisted square antiprismatic geometry as distinct from 
the square antiprismatic forms of the other complexes. 
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2.3.4 ' H N M R spectroscopy 
Due to the paramagnetic nature of most lanthanide(III) ions, the NMR resonances of 
atoms which are in close proximity to the metal are both broadened and shifted.'"" For 
well-defined coordination geometries, solution NMR can give precise structural 
information. For example, for cyclen-based systems, the pseudoaxial macrocyclic ring 
protons exhibit the greatest shifts in resonance. Of particular interest in NMR analysis is 
the total observed shift r a n g e . T h e dipolar shift varies with the local magnetic 
anisotropy, and is related to Bo', the second order crystal field coefficient. As previously 
discussed, Bo^ is strongly dependent on the nature of the axial donor."'*' 
' H NMR spectra were previously measured and compared at 298 K , but under these 
conditions, spectra were not reproducible and some peaks were very broad. This is likely 
to be due to the exchange process associated with arm rotation, giving rise to exchange-
broadened spectra. ' H NMR spectra were therefore recorded at 278 K to freeze out this 
motion (Figures 2.11 to 2.13). The primary difference between the spectra lies in the 
range of chemical shifts, as summarised in Table 2.3. The NMR spectrum for [Eu.L'*''] 
appears to contain two sets of peaks, one set (the less shifted) corresponding to a major 
form and the other (which are more shifted) corresponding to a minor form. 
Table 2.3: ' H NMR data for Eu complexes (D2O, 278 K, 500 MHz) 
Complex Shift range (ppm) 
[Eu .L^]'* +38 to -24 
[Eu .L'"]'" +43 to-19 
[ E U . L ' " ] ' " +10 to-21 
[ E u . L ' " l +37 to -22 
[Eu.L*"] (major peaks) +14 to -21 
(minor peaks) +38 to -22 
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Figure 2.11: ' H N M R spectrum of [Eu .L^'']Cl3 (DjO, 278 K , 500 MHz) * indicates HOD resonance. 
•0 opm 
Figure 2.12: ' H NMR spectrum of [ E U . L " " ] (D2O, 278 K, 500 MHz) * indicates HOD resonance. 
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Figure 2.13: ' H NMR spectrum of [ E U . L ' " ] (D20, 278 K, 5 0 0 MHz) * indicates HOD resonance 
[Eu.L''*]'''^ and [Eu.L"*^] show very similar chemical shift ranges, which are also 
consistent with those observed for [Eu.L^]^'^. In comparison, the spectrum of [Eu.L'"']'''^ 
is much more condensed. This is consistent with a change in the coordination 
environment, which can result from a number of possible structural changes: the 
replacement of the capping ligand by water, the rearrangement of the structure so that a 
different atom is in the ninth coordinate position, or the adoption of an eight-coordinate 
geometry. The use of other spectroscopy methods allows the possibilities to be 
distinguished. 
The ' H NMR spectrum of [Eu.L"""] suggests that the complex exists primarily in a form 
that is similar to that of [Eu.L^""]^"^, but occurs as a mixture of two isomers, one of which 
possesses a more expanded range of chemical shifts, like those of [Eu.L^^]^"^ and 
[Eu.L'*']. It is likely that in this complex, the two forms are in slow exchange on the 
NMR timescale. 
2.3.5 Infrared spectroscopy 
The use of infrared spectroscopy provides further insight regarding the coordination of 
certain ligand donor groups. In the free ligands L^" and the amide and ester carbonyl 
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Stretching bands appear at 1649 and 1732 cm"' respectively. The IR spectra of both 
[Eu.L^"]-^^ and [Eu.L^"]^^ (Figures 2.14 and 2.15) show that these bands have shifted to 
1619(+2) and 1733(±2) cm"'. This suggests that in each case, each amide carbonyl 
groups is coordinated to the lanthanide(III) ion. 
^ 8 . 4 9 ^ 
BB.40 
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Figure 2.14: Infrared spectrum of [ E U . L ' ° ] ' * (295 K, solid: golden gale) 
SB.52 
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Figure 2 .15: Infrared spectrum of [Eu.L^"]'" (295 K, solid: golden gate) 
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2.3.6 Conclusions of the structural analyses 
The combined information yielded from the various spectroscopic analyses described 
above can be utilised in determination of the structure of the Ala- and Phe-derived 
complexes. The emission, CPL, ' H NMR and IR spectra of [Eu.L"*"] are very similar to 
those of [Eu.L^]'''^. The spectra of [Eu.L^"]^"^ are also very similar, with the emission 
spectra varying only slightly in the AJ = 2 and AJ = 4 bands. Since these bands possess 
electric dipole character, these changes are consistent with the changed local 
environment and hence oscillator strength resulting from the altered side-chains, with no 
overall structural change. The two Ala-derived complexes, [Eu.L^*]"^"^ and [Eu.L'*^], can 
therefore be assigned the same geometry as [Eu.L"]^"^; a A(XXXX) square antiprismatic 
geometry, in which the dpqC nitrogen acts as a capping ligand. 
The spectra of [Eu.L'"']^"^ and [Eu.L'"'], on the other hand, differ markedly from those of 
[Eu.L^]^^. The splitting of the A7 = 1 manifold of the emission spectra, and the chemical 
shift range of the ' H NMR spectra indicate an altered coordination environment that is 
most consistent with a change in the nature of the ninth "capping" donor. This may be 
due to water occupying the ninth coordination site, to the rearrangement of the structure 
so that a different atom is in the capping position, or could even signify the adoption of 
an eight-coordinate geometry, with a non-coordinated amide arm. These possibilities 
were investigated through other spectroscopic methods. 
Occupation of the ninth co-ordination site by water would result in a hydration state of 
one. Determination of the number of bound waters was achieved by comparing the 
relaxation rates of the lanthanide excited state in both H 2 O and D 2 O , as discussed above. 
Al l complexes had a q value of close to 0 (Table 2.1), suggesting no bound waters, 
refuting this hypothesis. 
The hypothesis that the complexes adopt an eight-coordinate geometry requires that one 
of the ligating groups, most likely one of the amide carbonyls, is no longer coordinated. 
If this were the case, the IR spectrum of [Eu.L^*"]^"" would show two sets of amide 
resonances, one corresponding to the free amide, at 1649 cm"', and the other at the 
bound amide frequency of 1618 cm"'. This was not found to be the case, with a single 
band at 1618 cm"' being observed (Figure 2.16). 
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The dismissal of these two hypotheses leaves the remaining possibility that the structure 
has changed such that a different ligand is in the axial position. The effect of varying the 
nature of the ninth capping ligand on the emission and ' H N M R spectra has previously 
been explored in detail for the tetraamide 20. Different solvent molecules in the ninth 
coordinate site (X) were found to give rise to large changes in ' H NMR and emission 
spectral form."^ The range of ' H NMR values and the Ay = 2 / A/ = 1 ratio observed for 
[Eu.L^'']^'^ is similar to that measured for complex 20, in which DMF is the axial ligand. 
This lends support to the hypothesis that the ' H NMR behaviour can be explained by a 
structure in which the capping ligand is different from the dpqC nitrogen, but is instead 
an amide carbonyl nitrogen, that is one of the phenylalanine amide oxygens. 
HN ^ I 
H 0 = ( 
NH 
P h - < 20 
•-1 
The CPL studies indicate that, in addition to this change in the nature of the capping 
donor ligand, there is also a marked difference in complex helicity in [Ln-L *^"]^ "^  
compared to [Ln.L^^]^" .^ This change is consistent with the adoption of the opposite, 
A(5555), configuration. Such a helicity change has previously been observed in studies 
of the addition of amino acids to the tris(a-phenylmethyl) complex 21. 122 
HN 
Ph 0 - - - - L n ^ ^ H , 0 
NH 
21 
Replacement of the water molecules by f^^Met and (R)-A\a yielded a AiXklX) structure 
which was confirmed by X-ray crystallography. This was the opposite chirality to the 
A(5558) diastereomer observed with (S)-A\a. and many other natural amino acids. The 
crystal structures of the two forms are shown in Figure 2.16 and reveal the considerable 
structural difference between the two square-antiprismatic forms. It is feasible, therefore, 
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that [Eu.L^'']''"^ adopts the A(5555) structure. This closed structure could be favoured 
because of the extra steric demand imposed by the benzyl groups of Phe, which 
preferentially point outwards rather than align in the same direction. The CPL spectrum 
of [Eu.L""*] indicates that it appears to adopt a different geometry still, which is 
intermediate to the AilXkX) configuration of [Eu.L^*]^ "^ and the A(5556) configuration of 
[Eu.L^'']^^. This is most consistent with a twisted square antiprismatic geometry. 
Figure 2.16: Crystal structures of the f5)-Ala adduct ( A ( U U ) ; left) and (R)-A\a adduct (A(6558); right) 
of 21,'^ -= 
A combination of the structural characteristics identified from the spectral analysis 
therefore allows assignment of a geometry to each complex. [Ln.L''"]''"^ and [Ln.L"^] 
adopt a AQJJkX) square antiprismatic geometry, with a dpqC nitrogen in the capping 
position; [Ln.L^'']^^ exhibits a A(5555) square antiprismatic geometry with an amide 
capping group, while [Ln.L'"'] adopts a A(kXXk) twisted square antiprismatic geometry 
with an amide capping group. It is clear, therefore, that changing the nature of the amide 
arm can cause considerable changes to the geometry of the complex. 
This series of complexes therefore allows the study of the effects of geometry, as well as 
charge and hydrophobicity, on biological behaviour. The following sections detail the 
studies which have been performed to explore the effect of complex configuration on 
excited state quenching, and on cellular behaviour. 
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2.4 Excited state quenching processes 
The quantum yield of sensitised lanthanide emission can be decreased by a number of 
different deactivation pathways. Quenching can occur at any stage of the energy transfer 
process. The singlet and triplet states of the sensitiser may be quenched by electron or 
vibrational energy transfer p r o c e s s e s . ' ^ ' ^ The quantum yield can also be decreased 
by quenching of the excited state of the lanthanide(III) ion, which is susceptible to 
deactivation by transfer of vibrational energy to N-H, C-H or O-H oscillators."^' '^ ^ 
The 'DO and states of Eu^ "" and Tb^ "", in particular, are quenched by water O-H and 
amine N-H vibrations in a process that exhibits an r"^  dependence on the Ln/XH 
separation, r. The lanthanide excited state can also be quenched by energy transfer to a 
proximal acceptor group of similar energy.'"^ The extent of excited state quenching is 
therefore an important consideration in the design of luminescent lanthanide complexes 
for use as cellular probes. For example, a complex with a very high quantum yield will 
be of less utility if it is very strongly quenched by an endogenous molecule. The 
following sections detail the investigations of the quenching effects on [Ln.L'']^"^ and 
[Ln.L'*] of two classes of cellular molecules, biological reductants and proteins. 
2.4.1 Quenching by urate, ascorbate and iodide 
One hypothesis for the quenching of lanthanides by electron rich species is that the free 
energy of the excited lanthanide ions (Tb and Eu excited states lie at 2.52 and 2.13 eV 
above the ground state respectively) can be used to drive a charge transfer process. The 
feasibility of this process is given by the Weller equation (2.4): 127 
AC^, = - —]Jmor^ [2.4] 
er 
where 
Eox is the oxidation potential of the electron donor (the quencher) 
Ered is the reduction potential of the acceptor (ligand or metal) in the complex 
E''"* is the energy of the lanthanide excited state 
e'/er is the Coulombic attraction correction term associated with the formation of a 
transient ion pair (or radical/ion pair). This term is typically small (< 0.2 eV). 
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The electron-rich species which are commonly studied with respect to their quenching 
effects on lanthanide complexes are halide anions, such as iodide, and low molecular 
weight anti-oxidants, such as ascorbate and urate. Each of these compounds is common 
in biological systems, being present in the cell at concentrations between 
0.1 and 2 mM.^ "* Half equations for the two reductants are shown in Figure 2.17. 
O O HOH2C HOHjC 
N - H ^ - e : ^ „ J ^ N J W ^ o ^ o -H^•e- J ^ ^ - ^ O 
•d O' - ^ N ' |N -O- - N ' q O OH 
Urate (E,/2 = +0.59 V, pKa = 5.4) Ascorbate (Ev2 = 0.30 V, pKa= 4.2) 
Figure 2.17: Half equations for the one electron oxidation of the urate and ascorbate anions. 
The sensitivity of a complex to coUisional quenching can be described by the Stem-
Volmer equation (2.5):^ *^  
^ = \ + k^t,[Q] = \ + K,,[Q] [2.5] 
where 
lo and / are the luminescent intensities in the absence and presence of quencher 
respectively, 
kqh the rate constant for a bimolecular quenching process 
To is the emissive lifetime of the complex in the absence of quencher 
[Q] is the concentration of the quenching species. 
The term ^^5^ is the Stem-Volmer quenching constant, which has units of M"'. K^l is 
commonly quoted for convenience, given in units of mM. This term is equivalent to the 
concentration of quencher needed to reduce the luminescence intensity to half its initial 
value. For a dynamic quenching process, the lifetime decreases concomitantly as the 
luminescence intensity, giving rise to the following equation (2.6): 
^ = i + k^'r,[Q] = \ + K,y[Q] [2.6] 
K^l can therefore be calculated by measuring the change in the luminescence lifetime 
with the addition of quencher. Stem-Volmer plots were obtained for each of the 
europium and terbium complexes in pH buffered solution (100 mM HEPES, pH 7.4), in 
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the presence of sodium chloride (10 mM). Representative plots are shown in Figure 
2.18. 
0.05 
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0.1 0.15 
[Ura te ] /mM 
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Figure 2.18: Stem-Volmer plots for the quenching of [Tb.L^'j^^ (•) [Tb.L""] (•) , [Tb.L^"]''' ( A ) and 
[Tb.L""] (A) by (a) urate, (b) ascorbate and (c) iodide (10 pM complex, 100 mM HEPES, 10 mM NaCl, 
pH 7.4, 298K, X^ x = 348 nm) 
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The Stem-Volmer plots initially have a constant gradient (Figure 2.18), but at higher 
concentrations of quencher, the variation reaches a limiting value. This suggests that an 
upper limit of quencher is reached, above which the rate of change of T Q / T with 
increasing quencher concentration tends to zero. It is not clear why this occurs, but 
suggests an inefficiency of the quenching mechanism, perhaps due to an intermolecular 
interaction between the quencher and the complex. K^l values were calculated only by 
analysis of the linear range. 
Stern-Volmer constants, K'^l, for quenching with urate, iodide and ascorbate for the 
series of complexes are presented in Table 2.4. 
Table 2.4: Stem-Volmer quenching constants for Tb and Eu complexes (10 nM complex, 100 mM 
HEPES, pH 7.4, 10 mM NaCl, 298 K, = 348 nm). 
Urate: Ascorbate: Iodide: 
Complex K^l /mM 
[Tb.L'j * 0.006 0.35 2.10 
[Eu.L'] * 0.11 2.92 >10^ 
[TbL^]^* * 0.025 0.18 0.92 
[EuL^]'* * 0.07 0.39 27 
0.009 0.24 1.64 
[Eu-L-'"]^" 0.049 0.51 8.55 
[Tb.L'"]'" 0.018 0.47 2.35 
[Eu-L-'"]-'* 0.028 0.47 10.8 
[Tb.L*"] 0.046 0.55 2.25 
[ E U . L ' ' ] ' 0.048 1.13 >10' 
[Tb-L^"] 0.030 0.99 3.22 
[Eu.L*"] 0.033 0.96 60 
* values previously reported" 
* values previously reported'"* 
A number of observations and conclusions can be drawn from analysis of the 
Stem-Volmer constants. The terbium complexes for each ligand are more strongly 
quenched than their europium analogues, as has been found in previous studies.''^ ^ '"^  
This is consistent with the predictions of the Weller equation since E^''* is higher than 
E^"*. For each complex, the sensitivities to quenching follow the trend 
urate > ascorbate > I". This is again consistent with previous experimental findings,'^^ 
58 
C H A P T E R TWO. S Y N T H E S I S AND C H A R A C T E R I S A T I O N O F C O M P L E X E S 
but cannot be solely explained by trends in reduction potential, since ascorbate has 
greater reducing power than urate. 
In general, the cationic ester complexes appear to be less sensitive to quenching than the 
zwitterionic hydrolysed complexes. There is no such clear comparison for the Phe series 
against the Ala series. Of all the complexes explored in this study, it is the complexes of 
L'*" and L*"* which exhibit the highest K'^l values. Such a property is desired for cellular 
applications, as a reduced sensitivity to quenching should result in stronger in cellulo 
luminescence. 
These measured Stem-Volmer quenching constants have contributed to a more detailed 
study of quenching mechanisms.A number of pieces of evidence led to the conclusion 
that iodide quenches by a classical collisional encounter mechanism, fitting traditional 
Stem-Volmer kinetics (Figure 2.19). Cationic complexes were more sensitive to 
quenching than neutral or anionic complexes of the same chromophore. For series of 
complexes with a common donor set but varying chromophore, the trends in quenching 
mirror the reduction potential of the heterocycle. These results suggest that quenching is 
sensitive to the local electrostatic environment, which is in keeping with a model of 
collisional quenching. Increasing the temperature led to increased quenching for 
quenching by iodide only, consistent with an increased collision rate. 
A* + D • ( A * D ) - A D ^ A D 
k. i k.2 
A + D 
Figure 2.19: Rehm-Weller kinetic scheme for quenching via excited state electron transfer 
Urate and ascorbate appear to act in a similar manner to each other, with complexes 
showing greater sensitivity to urate than ascorbate. The electrostatic effects observed for 
iodide are much less marked for ascorbate and urate. In general, cationic complexes are 
least sensitive to quenching, suggesting that a quenching mechanism simply involving 
an electrostatic encounter is unlikely. The linearity of the Stem-Volmer plot is lost at 
relatively low concentrations for some complexes, suggesting that the Stem-Volmer 
model cannot be applied. Furthermore, increasing the temperature was shown to result in 
decreased quenching. Based on these findings, the quenching mechanism was 
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hypothesised to occur through the formation of an intermediate excited state complex 
(exciplex; Figure 2.20). 
k k 
A* + D , ^ • ( A * D ) • ^ • A^-D^^ 
k-1 k.2 
1/T„ 1/Xn 
A + D A + D 
Figure 2.20: Suggested kinetic scheme for quenching through exiplex formation 
The stronger quenching by urate than ascorbate can be accounted for by structural 
considerations. Urate incorporates a planar, delocalized electron-rich system, while 
ascorbate is less conjugated and more hydrophilic. Quenching of complexes by the urate 
anion might therefore be expected to be enhanced by a TI-TC interaction between the 
electron-poor chromophore and the electron rich urate anion. 
Recent studies have shed further light on the quenching mechanisms of sensitised 
lanthanide complexes.When the metal was directly excited, no quenching of the 
luminescence lifetime was observed, suggesting that quenching occurs via a charge 
transfer complex with the triplet excited state of the chromophore. This hypothesis was 
further supported in studies in D2O, where the selective incorporation of deuterium into 
the chromophore occurred only for complexes containing an intramolecular quenching 
moiety. 
2.4.2 Quenching by serum albumin 
Proteins represent another important class of endogenous species that could quench 
lanthanide luminescence. Serum albumin has been selected for study as it is the most 
important plasma protein in mammals. Although its intracellular molar concentration is 
of a similar magnitude to that of urate and ascorbate, due to its bulk (MW ~ 70 kDa) it 
has a very high effective concentration within cells. For such a system, quenching is 
likely to result from a ground state binding rather than a transient association of the 
excited state and the Ln(III) complex. The changes in lifetime as a function of added 
bovine serum albumin (BSA) are shown in Figure 2.21. 
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0.1 0.2 0.3 0.4 0.5 
[ B S A ] / m M 
0.8 
Figure 2.21: Quenching of luminescence lifetimes of terbium complexes by bovine serum albumin, 
showing the fit to a 1:1 apparent binding constant derived by least squares iterative analysis. [Tb.L*] (•), 
[Tb.L^l (•) , [Tb.L^"]^* ( A ) , [Tb.L'"]'* (*), [Tb.L"'] (+) and [Tb.L""] (•) (100 mM HEPES, 10 mM NaCl, 
pH 7.4, 30 |iM complex) 
Two factors must be considered in analysing these results: the limiting lifetime change 
observed, which gives information about the quenching properties of BSA, and the form 
of the curve, which allows calculation of a binding constant, Ka. The latter is of greater 
interest towards understanding the cellular behaviour of luminescent lanthanides. The Ka 
values for BSA binding were calculated by non-linear least squares fitting of the curve to 
the observed data points (Table 2.5). 
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Table 2.5: K, values for binding of complexes to BSA (100 mM HEPES, 10 mM NaCl, pH 7.4, 30 pM 
complex)_ 
Complex Ka for protein binding / M Limiting TO/T value 
[Tb.L'] (3.24 + 0.02) X 10^  7.5 
[TbL^]'* (1.18 ±0.26) X 10' 1.4 
[Tb.L^"]'* (6.60 ± 0.1 l ) x 10^  3.4 
[Tb.L^"]'* (9.44 ±0.10) X 10- 3.2 
[Eu.L'"]'* (2.57 ± 0.07) X 10' 1.8 
[Tb.L""] (1.46 +0.09) X 10' 7.6 
[Tb.L""] (2.14 ±0.15) X 10' 3.2 
( E U . L ' " ] ' * (3.58 ±0.10) X 10' 1.8 
Protein affinities were calculated based on the assumption of a 1:1 binding 
stoichiometry, using equation 2.7: 
L + [Eu]f-[Eu]f-
{BSA\ = — [2.7] 
where 
L-L. 
f = 
L = luminescence lifetime — 
T 
Li = initial luminescence lifetime 
Lf= limiting luminescence lifetime 
The results show a marked variation in the Ka values across the range of complexes; 
from the more weakly-bound [Tb.L'] and [Tb.L'"] to the very strongly-bound [Tb.L^]^". 
With its more hydrophobic pendant arms leading to a smaller surface area accessible to 
solvent, the Phe-based complex [Tb.L'"']^'^ might be expected to bind more strongly to 
BSA than the Ala-based [Tb.L^*]^ "". This is not supported by the observed affinity 
constants (Table 2.5), which could reflect the different solution structure adopted by this 
complex, as discussed in Section 2.3. 
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2.5 Preliminary studies of cellular behaviour 
The aim of the work reported in this thesis is to investigate the cellular behaviour of a 
large group of luminescent lanthanide complexes, of which these Ala- and Phe-derived 
complexes comprise one sub-group. The structural changes which result on substituting 
alanine for phenylalanine in the pendant arms allow an investigation of the effects of 
geometry on cellular behaviour. The following section details the preliminary 
microscopy studies which were performed to investigate the uptake and localisation 
profile of the four complexes. 
Two cell lines were selected for preliminary studies; CHO (Chinese Hamster Ovary) 
cells and NIH 3T3 cells, which are derived from the mouse embryonic fibroblast 
(connective tissue). Both cell lines are transformed, and comprise adherent cells, which 
grow in a monolayer. Cells were grown to 60-80% confluence on glass coverslips, and 
the medium dosed with complex at concentrations ranging from 50 to 200 |iM for 
incubation times from 5 min to 24 h. The coverslips were then mounted onto microscope 
slides, and the cells visualised using an epifluorescence microscope. Transmitted light 
was used to obtain a light image, and appropriate filter sets were selected to measure Eu 
or Tb luminescence following excitation of the chromophore. Representative images of 
cells treated with Tb complexes are shown in Figure 2.22. 
Incubation of both CHO and NIH 3T3 cells with each Tb complex resulted in 
luminescence that could be readily detected. When optical sections throughout the cell 
were taken, this luminescence could be observed in most layers, confirming that the 
complexes were successfully taken up into the cells, and were not merely associating 
with the cell membrane. As expected, untreated control cells exhibited no luminescence. 
While only one set of images for each condition is shown here, images were taken at a 
number of points across the slide, with similar localisation patterns observed at each 
position. 
From these microscope images, there appears to be no luminescence in the nucleus, with 
luminescence localised in other organelles in the cytoplasm. The appearance of these 
organelles is most consistent with the size and distribution of late endosomes or 
lysosomes. 
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Figure 2.22: Microscope images of cells treated for 3 hours with 50 |iM complexes. (A) CHO cells and 
(B) NIH 3T3 cells treated with (i) [ T b . L " ] ' ^ (ii) [Tb.L^"]'*, (iii) [Tb.L""] and (iv) [Tb.L""] . G365 ex. 
filter, BP 546±12 em. filter. Image brightness and contrast have been altered. Scale bars represent 20 \xm. 
The observed localisation was confirmed by the use of LysoTracker probes, which are 
commercially available lysosomal stains.'^' An example of a co-localisation study is 
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shown in Figure 2.23. The yellow colour in the overlay image confirms co-localisation 
of the europium luminescence and the LysoTracker green fluorescence. 
Figure 2.23: Fluorescence microscopy images of (a) (S^S^-IEu.L^^] in NIH-3T3 cells (50 \xM complex, 
4h incubation), (b) Lysotracker Green™ and (c) an overlay of the two channels. Scale bar represents 
20 nm. 
Cells treated with the (RRR)-isomeTS of these four complexes showed similar, lysosomal 
localisation under the same conditions. The luminescence was also of similar intensity. 
There also appeared to be no difference between the intensity and localisation of 
luminescence from Eu complexes and Tb complexes. While each complex showed a 
similar localisation pattern, luminescence output varied across the set. It was not 
possible to gain quantitative measures of the luminescence of the system with the 
fluorescence microscope set-up, but alterations in the signal contrast required to give 
approximately equal intensities allowed a rough measure of the absolute intensity. By 
this method, it could be observed that cells treated with [Ln.L^^]'''^ and [Ln-L"*^] 
exhibited greater luminescence than those treated with [Ln-L *^*]^ "^ and [Ln.L'*'']. This 
could reflect a higher cellular uptake of the Ala-derived complexes, or lesser in cellulo 
quenching. Such effects wi l l be discussed in Chapter Four. Notably, however, these 
trends follow the quenching data, which show that the Ala-derived complexes are less 
susceptible to quenching by both common cellular reductants and by BSA. 
What can initially be concluded from these microscopy experiments is that changes to 
the charge and helicity of lanthanide complexes do not appear to affect the localisation, 
with sequestration of all complexes to the lysosomes or late endosomes. 
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2.6 Conclusions 
This thesis investigates the cellular behaviour of a broad range of luminescent lanthanide 
complexes which have been synthesised recently within the Parker group. This chapter 
has described the synthesis, characterisation and preliminary cellular studies of one class 
of such complexes. While the aim of the synthesis was to generate a set of related 
complexes which differed only in charge and hydrophobicity, the structural analysis also 
revealed a variation in helicity within the group. A change in the hydrophobicity of the 
pendant arms, through an additional phenyl group, resulted in an inversion of the 
helicity, which was also accompanied by a change in the nature of the "capping" donor. 
Studies of the changes in the luminescence lifetime with the addition of common cellular 
anions revealed varying degrees of susceptibility to quenching. Quenching of the 
luminescence lifetimes by BSA allowed calculation of an apparent binding constant, 
which varied markedly across the group of complexes. These quenching effects will be 
discussed in greater detail in Chapters Four and Five. 
Preliminary cellular studies using these complexes demonstrated uptake and lysosomal 
localisation of every complex. This behaviour was independent of complex charge, 
identity of the lanthanide ion, chirality of the pendant arms, nature of the axial donor 
atom, and the overall complex helicity. These complexes are therefore examples of 
luminescent lanthanide complexes which exhibit interesting cellular behaviour, and will 
be included amongst the wider range of complexes discussed in the following chapters. 
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3.1 Introduction 
Organelle-specific targeting remains a current challenge in biology and medicine 
alike.'^^ From a therapeutic view-point, delivery of a drug to its target organelle can 
increase efficacy and reduce toxic side-effects. For example, gene therapy drugs act in 
the nuclei while many cancer therapeutic agents exert their effects in the mitochondria. 
From an imaging perspective, the conditions within a specific organelle can give the 
most useful information about a disease state. A number of lysosomal storage diseases 
are characterised by an elevated lysosomal pH, while the cytoplasmic pH is only 
minimally perturbed.'^ ^ Similariy, an increase in mitochondrial Ca^ "^  levels, but not 
intracellular Ca^ "^  levels, has been implicated in the mitochondrial dysfunction that 
accompanies aging and ischaemia.'"''' An increased understanding of biological function 
and dysfunction therefore requires the ability to probe the conditions within specific 
organelles. In order to achieve this, a cellular probe must be delivered to the relevant 
sub-cellular location about which it is to report. 
3.1.1 Mechanisms of sub-cellular trafncking 
The factors and processes involved in compartmentalisation of molecules into 
sub-cellular organelles are not well understood, particularly with respect to exogenous 
species. Indeed, the current understanding is primarily based on studies of the processing 
and trafficking of proteins following ribosomal synthesis. In studying trafficking 
processes, it is important to consider a number of aspects: the signal which triggers a 
specific localisation, the pathways by which a molecule can enter an organelle, and the 
mechanical process by which species can be moved within the cell. 
The sub-cellular fate of a protein depends on a region of the amino acid sequence, the 
sorting signal, which directs its delivery to a particular location in the cell.'^^' '•'^  For 
example, a lysine- and arginine-rich sequence signals import into the nucleus. The 
sorting signal is recognised by complementary receptor proteins which may be involved 
in translocation or membrane transport. Such sorting signals occur only on proteins; the 
structural features which signal compartmentalisation of non-protein species are not 
understood. 
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An important aspect of sub-cellular trafficking is transport into an organelle. This can 
occur by three distinct mechanisms, which vary according to the nature of the organelle 
(Figure 3.1).^^ Gated transport describes the traffic between the cytosol and the nucleus, 
which occurs through nuclear pore complexes. Transmembrane transport describes the 
movement of species through protein translocators from the cytosol to the interior of the 
mitochondria, peroxisomes, plastids and endoplasmic reticulum. In vesicular transport, 
species are ferried between compartments by the consecutive budding and fusion of 
vesicles. 137 
PLASTIDS 
ENDOPLASMIC R E T I C U L U M 
vesicular 
transport 
G O L G I 
NUCLEUS 
gated 
transport 
M I T O C H O N D R I A 
transmembrane 
C Y T O S O L r transport 
P E R O X I S O M E S 
E N D O S O M E S 
1 
L Y S O S O M E S 
Figure 3 .1 : Schematic diagram showing transport of species between compartments by gated transport 
(blue), transmembrane transport (red) or vesicular transport (green). Adapted f rom Alberts et al.^" 
Finally, the mechanisms by which a compound can be physically moved within the cell, 
from one organelle to another, must be considered. The cytoskeleton is the system of 
filaments with varied roles such as the maintenance of asymmetrical cell shape, the 
provision of the scaffolding for the development of the cell and the transportation of 
species within the cell.^ * '^ '^ ^ The primary cytoskeletal elements are microtubules, which 
are composed chiefly of the protein tubulin, and microfilaments, which are composed of 
actin.'^^ Transportation within the cell requires the coupling of motor proteins to the 
cytoskeleton. The principal members the family of motor proteins are kinensin and 
dynein, which bind to microtubles and use the energy from ATP hydrolysis to move 
68 
CHAPTER THREE: SUB-CELLULAR LOCALISATION OF COMPLEXES 
towards the ends of the filament.''"^ Kinensins move species towards the cell surface, 
while dyneins are involved in trafficking towards the interior of the cell. 
While these mechanisms relate to proteins and not to exogenous species, they can 
contribute to an understanding of the factors which affect the localisation of lanthanide 
complexes. For example, it might be expected that there is some structural signal which 
determines the final sub-cellular distribution of a complex. It is also feasible that the 
motor proteins are involved in the trafficking of the complex around the cell. 
3.1.2 Strategies for controlling localisation 
Despite the current paucity of knowledge about sub-cellular trafficking pathways, a 
number of strategies have been developed to assist the delivery of probes to specific 
organelles. One strategy for the control of sub-cellular localisation is to encapsulate the 
compound within a liposome, which usually results in a lysosomal localisation.'^" 
Liposomes are generally internalised by endocytosis into a vesicle which then fuses with 
an endosome.'"*' Lysosomes are the downstream compartment in this endocytotic 
pathway, and it is therefore likely that the compound will remain in the lysosome. 
Another method by which compounds can be directed to a particular sub-cellular 
location is through the identification of structural features which affect localisation. This 
has particular success in achieving mitochondrial localisation. The term 
mitochondriotropic is used to describe complexes which are rapidly internalised in the 
mitochondria. In general, these complexes are cationic, as their positive charge is 
attracted to the negatively charged mitochondrial membrane, and amphiphilic, allowing 
them to cross both outer and inner mitochondrial membranes.'"*" Based on these 
characteristics, a number of structurally diverse mitochondriotropic compounds have 
been synthesised, such as rhodamine 123,'"*^  the gold antitumour complex auranofin''*^ 
and a tetraguanidinium compound '""^  (Figure 3.2). 
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(a) 
H O A C 
H ^^-^H 
Au 
(c) 
H H 
Figure 3.2: Compounds which locahse in ihe mitochondria, (a) rhodamine 123, (b) auranofin, 
(c) letraguanidinium vector 
An additional strategy by which the location of compounds can be controlled is through 
conjugation to moieties which themselves exert control over localisation. Such groups 
are commonly peptide-based, and often contain a natural or synthetic signal peptide such 
as those used in trafficking proteins.'"^ For example, the conjugation of a nuclear 
localisation sequence (NLS) to a platinum complex has been demonstrated to give rise 
exclusively to nuclear localisation (Figure 3.3).'"^ 
H O ' 
. N L S - 0 
0 0 
} - \ . N H 3 
N - P E G — ( Pt 
0 O 
Figure 3.3: A carboplatin-based complex which has been modified to localise in the nucleus. 
NLS = nuclear localisation sequence (Cys-Gly-Gly-Pro-Lys-Lys-Lys-Arg-Lys-Val-Gly-Gly), PEG = 
polyelhylene glycol. 
3.1.3 Localisation of lanthanide complexes 
In order to develop luminescent lanthanide complexes for use as cellular probes, it is 
essential to gain an understanding of the manner and mechanism of their sub-cellular 
localisation. To date, such investigations have been limited to preliminary observation of 
the distribution of some complexes in cells by fluorescence microscopy, as discussed in 
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Section 1.5.2. In this way, complexes have been observed which localise to the 
n u c l e o l i , l y s o s o m e s " ' and endoplasmic reticulum.** 
This chapter describes the work which was performed to broaden the understanding of 
the localisation behaviour of luminescent lanthanide complexes. Complexes will be 
categorised according to distinctive behaviours and structure-activity relationships 
described. 
3.2 Overview 
Work at Durham over the past eight years has generated a library of over seventy 
luminescent lanthanide complexes. This range of complexes allows for the study of 
structure-activity relationships, and the selection of the most suitable complexes for 
further mechanistic studies. Al l complexes are based on the macrocyclic core of cyclen, 
and have a similar common structure (Figure 3.4) consisting of a heterocyclic sensitising 
moiety and two or three pendant arms which may be carboxylate, amide or phosphinate 
based. 
sensitiser 
X = coordinating group (CO2", PRO2", CONHR') 
R = H, Meor / - " ' ^ X 
Figure 3.4: Generic structure of the luminescent lanthanide complexes under study. 
It is not possible to study in detail each member of the library. Accordingly, a subset of 
complexes has been selected for further study throughout the remainder of this thesis 
(Appendix 1). The following section gives general details of each complex. 
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3.2.1 Complexes selected for further study 
The first set of complexes, containing ligands L ' to L* were described and characterised 
in Chapter Two. 
0 - ^ - - L n ; . I 
J I N -
t) Ph 0 - - - - L n - , 
I 11 ' - N N ' -
H o={ 
Ph 
[Ln.L' l [Ln.L2]3 
ElGjC 
E1O2C 
LnC I 
Ln.L-"] 
Ln.L-"] 
I 11 I N 
R = CH3 
CO2E1 
[Ln.L^'']^-
R = CHsPh [Ln.L"']3* 
R = CH3 
R = CHjPh 
Ligands to were synthesised by Benjamin Murray in an investigation of the anion 
binding properties of luminescent lanthanide complexes."'^' ''^ ^ The complexes contain 
azaxanthone or azathiaxanthone chromophores. and differ in the nature of the 
linkage between the chromophore and the cyclen ring. is the octadentate analogue of 
L * , containing three additional pendant arms rather than two. 
8 ,0 
V 
N N 
H,0 O N .' N 
N, I N 
x=o 
x=s 
[Ln.L=»]3* 
[Ln.LSblS* R = OMe, X = 0 
R = OWIe, X = S 
R = OH, X = S 
[Ln.L«»]3-
[Ln.L*'']^-^ 
[Ln.L«'=]2* 
[Ln.LH^* 
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Complexes based on ligands to L*" were synthesised by Craig Montgomery in his 
investigations of luminescent lanthanide complexes for FRET applications. The 
pyrazoyl- and pyridylazaxanthone complexes were demonstrated to give rise to very 
high overall emission quantum yields. 
W N N N ', N 
H2O-
N N 
[Ln.L^l-*- [Ln.L*]^* 
12-,3+ was [Ln.L'']^"^ was synthesised by Junhua Yu as an anion sensor.'^ "^  [Ln.L'"'] 
synthesised by Robert Pal for the same purpose. '^^ [Ln.L"]"" was also synthesised by 
Robert Pal, for use as a pH p r o b e . A l l three sets of complexes contain an 
azathiaxanthone chromophore. 
CO2E1 
N N 
[Ln.L'2] 
o w 
— S - N 
II 
O 
o 
r i l 
o 
[ L n . L " f -
1 ' 
Ligand V* contains an azaxanthone chromophore with various groups at the 7-
position."' '^ ^ These complexes were synthesised by Siobhan Richardson, Filip Kielar 
and Philip Stenson. 
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= 0 
N N 
Ph 0 - - - - L n - - j 
N 
R = H 
R = COOMe 
[Ln.Li*«]3* R = CON(H)Me [Ln.L'*=f * 
[ L n . L " " ' f - R = 'Bu [Ln .L""]^^ 
Complexes based on ligands L ' ^ and L ' ^ were synthesised by Filip Kielar in an 
investigation of methods which could be employed to alter biological behaviour. 
[Ln.L*^]^"^ contains a C12 chain, while [Ln.L'*]'' '^ was synthesised by conjugation to an 
oligoguanidinium moiety. 
HN 
V 
I II I N 
[Ln.L"]3* 16i34 [Ln.L 
3,3 Classification of complexes 
Cellular localisation behaviour of the luminescent lanthanide complexes presented above 
was examined by fluorescence microscopy. CHO, NIH 3T3 or HeLa cells were grown as 
confluent monolayers on a glass coverslip, and were incubated with complexes at 
varying concentrations (20 joM to I mM) for various periods of time (5 min to 1 h). The 
coverslips were subsequently mounted onto glass slides and the cells visualised on a 
fluorescence microscope. For all complexes, the G365 excitation filter (Zeiss) was used, 
which allowed the passage of light between 300 and 400 nm. For terbium complexes, a 
546 ±12 nm band pass filter (Comar) was employed, while europium complexes were 
visualised with a 575-625 nm band pass filter (Zeiss). In this way, the distribution of the 
emissive lanthanide species in the cell could be observed. Localisation was confirmed by 
use of commercially available cellular stains (Invitrogen). Red stains were used for 
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terbium, and green stains for europium to ensure minimal overlap between the complex 
luminescence and the excitation of the fluorophore. The complexes studied could be 
classified into four groups according to their sub-cellular localisation. While the 
complexes in each group were found to have remarkably similar biological properties, 
each class exhibited distinct behaviour. The four classes and their principal 
characteristics wil l be discussed briefly. 
3.3.1 Lysosomally-localising complexes 
The largest group of complexes are those which are observed to localise to the 
lysosomes. A single cell contains an average of 300 lysosomes, which are membrane-
bound organelles of variable size. They contain powerful hydrolytic enzymes which 
digest waste material, whether ingested foreign bodies, worn-out organelles or engulfed 
viruses.'''^ Lysosomes are characterised by their low luminal pH, of between 4 and 5. In 
general, intemalisation into the lysosomes seems to be the default pathway for ingested 
particles, which may ari.se from one of two main mechanisms. I f the particle has been 
taken into the cell by receptor-mediated endocytosis, it will reside in an endosome which 
will age to be become a lysosomal compartment, unless it can escape in some manner.''^ 
If a particle which is not located in the lysosomes is recognised as being foreign, it is 
likely to be ubiquitinated and transported to the lysosome for subsequent degradation. 
It appears that in the case of the range of luminescent lanthanide complexes studied, 
localisation in the lysosomes is the default situation. Complexes with all manner of 
structure were observed to be distributed throughout lysosomal or late endosomal 
bodies. This localisation was confirmed by co-staining with LysoTracker probes 
(Invitrogen). Example fluorescence microscopy images of luminescence from 
complexes which have localised in the lysosomes are shown in Figure 3.5. 
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(a) (b) (c) 
Figure 3.5: Fluorescence microscopy images of CHO cells treated with [Eu.L ]Cl3 (50 ^iM, 4h) and 
LysoTracker Green (LTG; 100 n M , 15 min). (a) Europium luminescence, (b) LTG fluorescence, (c) image 
overlay. Scale bar represents 20 jxm. Image brightness and contrast have been adjusted. 
3.3.2 Mitochondrially-Iocalising complexes 
In contrast to the lysosomally-localising complexes, a much smaller group of complexes 
was observed to localise to the mitochondria. Mitochondria are centres of aerobic 
respiration through the electron-transport chain and oxidative phosphorylation.'^^ Most 
importantly, they are involved in the generation of adenosine triphosphate (ATP), which 
is an essential energy source for many cellular processes 160 
H,0-
R = OMe, X = O 
R = OMe, X = S 
R = OH, X = S 
[Ln.L^']=* 
[Ln.L«'']3-
The europium and terbium complexes of three related ligands, L , exhibited 
mitochondrial localisation following incubation times of 5 min to 12 h.'°* Localisation 
was confirmed by co-staining with MitoTracker probes (Invitrogen; Figure 3.6a). After 
24 h incubation, the luminescence pattern was no longer consistent with a mitochondrial 
distribution, but instead co-localised with LysoTracker probes (Figure 3.6b). After a 
further 12 h incubation, very little luminescence could be observed within the cell. This 
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suggests that after longer periods of time, the complexes are being transported to the 
lysosomes for degradation and removal from the cell. 
(a) 
(i) 
(b) 
(1) 
(•>) 
(iii) 
. T V 
1 1 
("'i. ^ 1 1 
Figure 3.6: Fluorescence microscopy images of CHO cells treated with [Eu .L ] " * (50 | iM) and 
MitoTracker Green (MTG; 200 nM, 15 min) for (a) 4 h and (b) 24 h showing (i) Eu luminescence, (ii) 
MTG fluorescence and (i i i ) overlay image. Scale bar represents 20 j im. Image brightness and contrast 
have been altered. 
3.3.3 Complexes which localise to the mitochondria and lysosomes 
The complexes described above exhibit distinct distribution patterns, with observed 
localisation in only one organelle. An additional class of complexes appear to be 
simultaneously localised in both the lysosomes and the mitochondria. 151 These 
complexes; [Ln.L^]''"^, [Ln.L*]^"^ and [LnX']^"^, contain azaxanthone chromophores 
which are coupled to the cyclen ring through a pyrazole, pyridine and amide group 
respectively. 
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The localisation profile was confirmed by co-staining with LysoTracker and 
MitoTracker probes, in which both probes showed overlapping fluorescence with the 
lanthanide luminescence profile. For example, the localisation of Eu luminescence from 
[ E U . L ' ] C 1 3 does not completely overlap with either LTG or MTG fluorescence (Figure 
3.7). Both the bright spots consistent with lysosomal staining, and the more diffuse 
pattern characteristic of mitochondrial localisadon can be observed. 
(a) (b) (C) 
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F i g u r e 3.7: Fluorescence microscopy images of CHO cells treated with [Eu.L ]Cl3 (50 p,M, 4h) and (i) 
MitoTracker green or (ii) LysoTracker green, (a) Eu luminescence, (b) tracker luminescence, (c) overlay 
image. Scale bar represents 20 fim. Image brightness and contrast have been altered. 
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3.3.4 Complexes which localise to the nucleoli 
The nucleolus is a sub-nuclear, protein-rich structure which is primarily involved in 
ribosome assembly.'^' The first complex which was observed to show nuclear 
localisation was when administered to cells at relatively high concentrations 
and for long incubation times.^ "^  Subsequently, [Eu.L*^]^"^, which was synthesised as a 
citrate sensor, was observed to localise to the nucleolus."^" This sub-cellular distribution 
was confirmed by co-localisation studies with SYTO-RNA (Figure 3.8). The yellow 
colour visible in the overlay image is evidence of overlap between the red Eu 
luminescence and the green SYTO fluorescence. The microscope images also reveal 
luminescence in regions of the cytoplasm. These were interpreted as corresponding to 
the ribosomes, because of their close functional relationship with the n u c l e o l i . T h i s 
could not be confirmed, however, as no ribosomal stain is available. 
i 
IN 
N N 
• N N 
EtOjC 
N 
Ph 
[Ln .L^^f -
Figure 3.8: Confocal microscopy images of NIH 3T3 cells treated with [Eu.L"]triflate (100 j i M , 4h) and 
sytoRNA (500 nM, 30 min). (a) Eu luminescence, (b) SYTO fluorescence, (c) overlaid image."*' 
Scale bar represents 10 | im. 
Subsequently, a number of complexes have been observed to localise in the nucleolus.*^' 
154, 162 -j^ggg complexes were synthesised as anion or pH sensors, and have structural 
similarities to [Ln.L^^]^"^, bearing an azathiaxanthone chromophore, two amide-based 
pendant arms and a different group (which may be a free NH, a sulfonamide or a methyl 
group) on the fourth cyclen nitrogen. For example, [Ln.L^^] and [Ln.L^^]^" exhibit 
nucleolar localisation. 
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When these localisation experiments described in previous studies were repeated, 
variable results were found. In particular, the nucleolar distribution of luminescence was 
not reproducible. Accordingly, the observed nucleolar localisation was studied in more 
detail. 
3.4 Understanding nucleolar localisation 
Based on the results of previous studies, it was initially believed that the complexes 
which showed nucleolar localisation belonged to a fourth, distinct group from those 
exhibiting other localisation behaviours. Attempts to repeat the experiments performed 
in these studies, however, were unsuccessful, and did not yield reproducible results. 
Indeed, there were a number of pieces of evidence that nucleolar localisation represented 
abnormal behaviour. 
3.4.1 Evidence for altered behaviour 
The first piece of evidence was that attempts to repeat the microscopy studies reported 
previously failed to show nucleolar localisation in most cases. Instead, localisation 
appeared to be lysosomal. Figure 3.9 shows the fluorescence microscope image of CHO 
cells treated with [Eu .L"]^"^ , in which there is clearly no luminescence within the 
nucleus. In cases where nucleolar localisation could be observed, it was in cells which 
appeared to be detaching from the glass coverslip, and losing membrane integrity. This 
behaviour is consistent with a loss of viability. 
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Figure 3.9: Fluorescence microscopy images of CHO cells treated with [Eu.L"]Cl3 (100 | i M , 4h). 
Scale bar represents 20 ^im. Image brightness and contrast have been altered. 
The second piece of evidence was that other complexes which demonstrated clearly 
lysosomal or mitochondrial localisation, were found to show distribution consistent with 
the nucleolus when administered at high concentrations. 
Figure 3.10: Fluorescence microscopy images of CHO cells treated with [Eu.L' ' ' ' ]Cl3 (1 mM, 4h). 
Scale bar represents 20 ^m. Image brightness and contrast have been altered. 
The final piece of evidence was obtained through the assessment of the cytotoxicity of 
the complexes. These cytotoxicity measurements and their results will be discussed in 
detail in Chapter Six. Importantly, [Eu.L^JCls was found to have an IC50 value of 
110 )xM, indicating that only 50% of a cell population is viable after 24 h incubation at 
this concentration. This indicates that at 1 mM concentrations, the conditions under 
which nucleolar localisation was observed, most of the cell population would be 
expected to be non-viable. This was not true, however, of all complexes with 
demonstrated nucleolar localisation: for other complexes, luminescence had been 
observed in the nucleolus at concentrations below the IC50 value. This observation gave 
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rise to the hypothesis that nucleolar localisation might arise in conditions under which 
the cell is stressed, and in which the cell membrane has therefore become more 
permeable. Further studies were therefore performed to test this hypothesis. 
3.4.2 Studies of a permeabilised membrane 
In order to test the hypothesis that nucleolar localisation of lanthanide complexes could 
be attributed to an increased cellular permeability, the cell membrane was permeabilised 
according to the method of Johnson et a/.,'^'' in which cells were cooled to 0 °C by 
incubation with sequentially colder solutions of phosphate-buffered saline (PBS), 
followed by a 15 min incubation with the permeabilising solution. Cells were then 
brought back to 37 °C by a series of PBS washes prior to incubation with the complex. 
Initially, three different permeabilising solutions were used: the surfactant Triton X-100 
(1%), the glycoside saponin (0.5 mg/mL) and a 70% ethanol solution. It was found that 
70 % ethanol caused cells to become detached from the glass coverslips, so subsequent 
studies used only Triton X-100 and saponin. 
Propidium iodide (PI) was used to confirm successful permeabilisation of the cell 
membrane. PI is a common DNA stain which is membrane impermeant, and is therefore 
excluded from viable cells.'^ "^ Examples of complexes which localised in the lysosomes, 
mitochondria and in both organelles were studied by this method, and gave identical 
results. Cells treated with both saponin and Triton X-100 also gave similar microscopy 
images. One set of microscopy images is shown in Figure 3.11. In the absence of the 
permeabilising agent, the expected luminescence distribution was observed. No PI 
fluorescence could be seen, which is consistent with an intact cell membrane. 
Permeabilisation of the cell membrane by saponin or Triton X-100 was confirmed by the 
PI fluorescence in the nucleus. In the same cells, lanthanide luminescence was now also 
observed in the nucleolus. 
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(a) (b) 
(ii) 
Figure 3.11: Fluorescence microscopy of CHO cells treated with [Tb.L^lCl.-, (50 tJM, 4h) and propidium 
iodide (1 |xM, 5 min) without (i) and with (ii) saponin treatment (0.5 mg/mL, 15 min). (a) Eu luminescence 
and (b) propidium fluorescence. Scale bar represents 20 (xm. 
This experiment provides confirmation of the hypothesis that luminescence in the 
nucleolus could be attributed to an increased permeability of the cell membrane. This 
explains why complexes were visualised in the nucleolus when administered to cells at 
concentrations far above their IC50 values, as loss of membrane integrity is one of the 
first events in necrosis.^° For complexes which were sometimes observed in the nucleoli 
at lower concentrations, however, this explanation is insufficient. Instead, the complexes 
themselves must induce permeability in the cell membrane. 
One possible explanation for the increased permeability of the cell membrane is the 
presence of free lanthanide ion in the complex samples. It has previously been 
demonstrated that low concentrations of lanthanide ions can enhance the permeability of 
the cell membrane.'^^ For example, the addition of 100 | J M TbCb to ovarian carcinoma 
cells led to an eight-fold increase in the uptake of cisplatin.'^^ Atomic force microscopy 
studies revealed that Ln^"^ bound to the cell surface, and induced the formation of pores 
in the membrane.'^'' The optimal Ln'''^ concentration for this effect was found to be 
10 nM. It was possible, therefore, that the presence of free Ln"*"^  in the complex solution 
could be causing increased permeability of the cell, leading to nucleolar localisation. 
This possibility was investigated by performing microscopy studies of CHO cells treated 
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with 1, 10 or 100 nM TbCb in addition to [Tb.LY"" or [Tb.L^^]^^. In each case, the 
expected, lysosomal/mitochondrial or lysosomal distribution was observed rather than a 
nucleolar pattern. In addition, cells were treated with propidium iodide in the presence of 
TbClj, but no PI fluorescence was visible in the nucleus. These results indicate that Tb'''^  
has not induced sufficient pore formation for the transport of either lanthanide 
complexes or PI. This suggests that Ln" '^*'-induced permeability is unlikely to account for 
the observed nucleolar localisation. 
Another possible reason for this permeabilising effect is that the complexes reported to 
localise in the nucleolus were administered as triflate salts,*'' while all other 
experiments reported here involve chloride salts. It is possible, therefore, that the triflate 
itself is causing the cell membrane to become more permeable. This hypothesis was 
tested by performing a similar study to that described above, but by pre-treating with 
sodium triflate (10 mM) rather than saponin. In this study, neither propidium iodide 
fluorescence nor complex luminescence could be observed in the cell, suggesting that 
triflate does not induce cell membrane permeability. An alternative explanation is that 
the cationic complex is able to cross the membrane in the form of an ion pair with the 
triflate anion. It has previously been shown that triflate anions associate more closely 
with lanthanide complexes than other anions.'^* The very hydrophobic nature of the 
triflate anion could contribute to the membrane permeability towards this ion pair.'^' 
3.4.3 Understanding transport across the nuclear membrane 
To this point, the studies which have been described have focussed on the movement of 
complexes into the cell. It is important to also consider how the complexes reach the 
nucleoli. In order for complexes to localise in the nucleoli, they must be transported 
across the nuclear membrane. Small molecules, like PI, can freely diffuse across the 
nuclear membrane, but most compounds are trafficked through nuclear pore complexes 
which selectively allow passage of complexes into the nucleus.' 
170 
Nuclear transport was studied by extracting the nuclei and investigating the processes of 
trafficking across the membrane of the isolated organelles. Nuclei were extracted using 
the Nuclei EZ Prep Kit (Sigma). Cells were treated with trypsin to detach them from the 
flask and incubated on ice with the provided lysis buffer. The resulting contents of the 
lysed cell were then centrifuged at 500g to pellet the nuclei, which are the most dense of 
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the sub-cellular components.'^' The pellet was resuspended in lysis buffer, and the 
mixture centrifuged once again to yield a cleaner nuclear fraction (Figure 3.12). 
lysis centrifugation 
disposal of 
supernatant 
resuspension 
in lysis buffer 
centrifugation 
disposal of 
supernatant 
pellet containing_ 
isolated nuclei 
Figure 3.12: Schematic diagram showing the process of nuclear extraction. 
The nuclei thus obtained could be mounted onto a microscope slide and visualised by 
fluorescence microscopy, but because of their small size it was difficult to locate 
individual nuclei by transmission light. Nuclei were therefore stained with trypan blue, a 
nuclear stain which absorbs strongly in the blue spectral region but is not fluorescent.'^" 
In order to study nuclear transport, extracted nuclei were incubated with 50 | J M complex 
for 1 h prior to visualisation by fluorescence microscopy. In addition, some nuclei were 
treated with PI as a control. Prior to incubation with complex, nuclei were treated for 
15 min with one of four substances. Saponin and Triton X-100 were used at dosages 
similar to the whole cell experiments, in order to assess whether they enhanced complex 
uptake to the nucleus. The third treatment was lysolecithin (5 pg/mL), which inserts 
itself into lipid membranes and induces permeability.'^^ Lysolecithin has been used in a 
number of studies to permeabilise the nuclear membrane.''''• The final treatment was 
with sodium triflate (10 mM), to assess the effect of the triflate ion on the nuclear 
membrane. A l l complexes studied behaved in nuclei in a similar manner. A 
representative set of results of the nuclei extraction experiments is shown in Figure 3.13. 
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Figure 3.13: Fluorescence microscope images of extracted nuclei treated with [Tb.L'jCls (50 \iM, Ih) and 
propidium iodide (1 ^iM, 5 min) (a) with no pre-treatment and after 15 min pre-treatment with (b) saponin 
(0.5 mg/mL), (c) lysolecithin (5 ng/mL) and (d) sodium triflate (10 mM). (i) transmitted light images, (ii ) 
propidium fluorescence, ( i i i ) Tb luminescence. Scale bars represent 20 fxm. 
The results confirm that the nuclear membrane is permeable to propidium iodide, as it is 
visible even in nuclei which have not been pre-treated with any permeabilising agent. 
Unlike PI, however, lanthanide complexes do not passively cross the cell membrane, nor 
can they be induced to do so by the addition of saponin, Triton X-100 or lysolecithin. 
This suggests that complex uptake into the nucleus occurs via an active transport 
pathway, which cannot occur in extracted nuclei in the absence of specific cytoplasmic 
species. The treatment of the nuclei with sodium triflate also failed to induce 
permeability towards the complexes, indicating that it is not by this means that nucleolar 
uptake is achieved. 
3.4.4 Conclusions regarding nucleolar localisation 
These studies have partially elucidated the factors which effect the observed distribution 
of some complexes in the nucleoli. Complex luminescence in the nucleolus is consistent 
with systems in which the permeability of the cell membrane has been enhanced. In 
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some cases, this may be due to the cytotoxic effects of the complexes. For other 
complexes, which at lower concentrations localise to the nucleoli, the presence of the 
triflate counterion could contribute to the localisation. 
What is clear, however, is that nucleolar localisation only occurs in cells in which some 
biological processes have been perturbed. These complexes are therefore less promising 
candidates for use as probes of normal cellular function. 
3.5 Structural factors affecting localisation 
In addition to this group of complexes which show nucleolar localisation under some 
conditions, the localisation of complexes appears to fall into one of three categories: 
lysosomal, mitochondrial and a lysosomal-mitochondrial shuttling behaviour. In order to 
understand these distributions further, it was important to establish any relationships 
between the structure of a complex and its localisation profile. There are a number of 
structural aspects which could affect the in cellulo distribution pattern of the complex. In 
order to assess the importance of each structural component, series of complexes were 
studied in which only one feature was varied. In many cases, more than one series from 
the total library available was studied in order to confirm the conclusions reached. Only 
one example for each structural feature is provided here. 
3.5.1 Effect of chromophore 
There are a number of ways in which the chromophore can be altered in the synthesis of 
luminescent lanthanide complexes. The nature of the chromophore itself may vary, or 
remote substituents altered. In addition, the point of attachment to the cyclen ring, or the 
linking moiety, can be changed. Each variation will be considered in turn. 
The nature of the chromophore itself does appear to have an effect on the localisation of 
the complex. Replacement of the dpqC chromophore of [Ln.L^]^"^ for the pyrazole-linked 
azaxanthone of [Ln.L*]^"^, for example, resulted in a changed localisation from 
lysosomal to a lysosomal-mitochondrial distribution. 
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Small modifications to the chromophore structure, on the other hand, do not appear to 
influence the complex localisation. Al l forms of [Tb.L"]' '" ' , in which the group attached 
to the 7-position of the chromophore is varied, exhibited lysosomal localisation. 
Likewise, hydrolysis of the ester group in [Eu.L**]'''^ to the acid form in [Eu-L*"]^"^, as 
well as conversion of the azaxanthone chromophore to an azathiaxanthone, in 
[Eu.L*'']^'^, did not change the mitochondrial localisation of the complexes. 
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A marked change in localisation occurred on alteration of the linkage between the 
chromophore and the cyclen ring. This had previously been observed for 
constitutionally-isomeric complexes in which an acridone chromophore was linked to 
cyclen in different m a n n e r s . ^ In this study, a similar observation was made regarding 
the lysosomally-localising [Ln.L^]^"^, containing a methylene linkage, and the 
mitochondrially-localising [Ln.L*]^"^, in which linkage occurs through an amide moiety. 
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3.5.2 Effect of pendant arms 
In considering the effect of the pendant arms on the localisation of complexes, it is 
important to consider both the nature and number of pendant arms. The series of 
complexes of ligands L ' to L ' ' contain pendant arms which differ considerably in 
hydrophobicity and charge, as discussed in Chapter Two. Al l complexes, however, 
exhibit identical localisation patterns in the lysosomes. It appears, therefore, that the 
nature of the pendant arms does not affect the sub-cellular localisation. 
V 
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[Ln.L^]'^* 
lysosomal 
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lysosomal 
R = CH3 [Ln.L'"]^* 
R = CH2Ph [Ln.L3'']3* 
In contrast, the number of pendant arms, or ligand denticity, does appear to influence the 
distribution of the complex in cellulo. Complexes [EU.L']^"^ and [EU.L']^"^ contain three 
identical, chiral amide pendant arms, and localise similarly, to the lysosomes and 
mitochondria. Removal of the pendant arm opposite the chromophore, giving complexes 
[EU.L'*^]''"^ and [EU.L'*']''"^ respectively, resulted in a change of distribution. 
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3.5.3 Effect of charge and counterion 
Most of the ligands synthesised for use in luminescent lanthanide complexes are neutral, 
giving rise to a complex with an overall charge of 3+. Some neutral and anionic 
complexes have also been synthesised, and it is therefore important to consider the effect 
of charge on the localisation of the complex. Cationic and anionic complexes must be 
administered to the cells with a counter-ion, so the influence of this ion must also be 
considered. 
There is no evidence to suggest that complex charge has an effect on sub-cellular 
localisation. The cationic [Ln.L^]^"^ complexes and their neutral analogues, [Ln.L'*], for 
example, all exhibit lysosomal distributions. 
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The counterion which is most commonly employed for cationic complexes is chloride. 
Cellular studies were also performed in which acetate, nitrate and triflate complexes 
were administered to cells. These did not reveal any change in the sub-cellular 
localisation, except in the case of the nucleolarly-localising complexes, for which the 
triflate counterion could act to promote cellular permeability. 
3.5.4 Effect of geometry 
Geometry in biological systems is very important due to the chiral environment of the 
cell, and the specific shape of the protein binding sites. It is therefore important to 
consider the geometry of the complexes, and how this affects their sub-cellular 
trafficking behaviour. 
For a number of ligands, synthesis was performed using both 5 and R enantiomers of the 
pendant arms, giving rise to opposite complex configurations. In all cases, no difference 
in sub-cellular localisation was observed between the two enantiomers. 
[Ln.L^^]^"^ and [Ln-L^**]^"^ not only exhibit different configurations, but the arrangement 
of the ligands around the mono-capped square antiprism is also varied, as discussed in 
Chapter Two. Despite these dramatic changes to the complex geometry, there was no 
resultant change to the localisation. 
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3.5.5 Effect of lanthanide ion 
The final structural feature which must be considered is the lanthanide ion itself. It is not 
expected that the lanthanide should affect the cellular behaviour of the complex, as it is 
buried within the ligand structure. For most ligands, both Eu and Tb complexes were 
synthesised and their sub-cellular localisation analysed. These studies confirmed that the 
nature of the lanthanide ion had no effect on the cellular distribution, or indeed, on any 
other aspect of cellular behaviour. 
3.5.6 Deriving structure-localisation relationships 
These investigations reveal that the localisation of a complex is affected by the nature of 
the chromophore and, more significantly, its point of attachment to the macrocycle, as 
well as by the ligand denticity. At this stage, it is important to consider whether it is 
possible to predict the sub-cellular localisation of a novel complex. The complexes 
which have been investigated comprise a relatively small library of chromophores and 
pendant arms. The information which has been gained from this structural study allows 
the prediction of the localisation of a complex composed of elements from this library. 
For entirely new complexes, however, which contain different chromophores or pendant 
arms, such predicfion is less straight-forward. 
For example, an analogue of [Eu.L*"]^^ bearing amino acid-based pendant arms, such as 
23 might be expected to localise to the mitochondria since modification of pendant arms 
was not found to affect localisation, but the amide-linkage on the chromophore 
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determined mitochondrial localisation. In this way, the selectivity of the complex could 
be optimised without altering the sub-cellular distribution. 
COjEt 
3.6 Assessing for nuclear localisation 
The discussion in this chapter has relied on the fluorescence microscopy evidence of 
sub-cellular localisation. It is important to consider whether this reveals the complete 
picture. For example, it is possible that the complex is localised elsewhere in the cell, but 
its luminescence quenched. This is most likely to be the case for a nuclearly-localised 
complex whose luminescence is quenched by DNA. It was therefore important to test for 
any such DNA quenching. 
3.6.1 DNA quenching studies 
The interaction of complexes with DNA has previously been extensively studied.'^^ This 
study was therefore primarily concerned with observation of possible quenching of the 
total luminescence, or the luminescence lifetime, of complexes upon addition of DNA. 
For this study, calf thymus DNA was utilised, and was prepared as a 1 mg/mL solution 
in HEPES buffer (pH 7.4). This DNA solution was added incrementally to solutions of 
complex (30 f jM) , and the emission spectrum collected and luminescence lifetime 
measured. For every complex, the luminescence lifetime remained unchanged upon 
titration of DNA. 
For some complexes, there was marked quenching of the emission intensity on addition 
of DNA. The titration curves for selected Eu and Tb complexes are shown in Figures 
3.14 and 3.15 respectively. [Eu.L^]^"" and [Tb.L^"^ show the most dramatic changes on 
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addition of DNA, with the emission intensity rapidly dropping ten-fold. This quenching 
effect does not appear to be stereospecific: the intensities of (RRR)-[Tb.li^] and 
f55S>[Tb.L*] decrease in a very similar fashion. While a number of complexes are 
clearly quenched by DNA, the emission intensities of many complexes remained 
unchanged. It is interesting to note that those complexes whose emission was quenched 
by DNA bore the same chiral phenylmethyl amide pendant arms. These groups may be 
mediating this interaction with DNA. 
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Figure 3.14: Changes in the relative emission intensity of [Eu.L^JClj ( A ) , [Eu.L*"] ( • ) , [Eu .L^ lC l j ( • ) 
and [Eu.L'"]Cl3 (•) on incremental addition of DNA. (100 m M HEPES, 10 m M NaCl, pH 7.4, 30 [M 
complex, = 615 nm) 
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Figure 3.15: Changes in the relative emission intensity of [Tb.L 'j ( • ) , [Tb.L^JClj ( A ) , [Tb.L^'']Cl3 ( • ) , 
f555>[Tb.L*]Cl3 ( • ) and (RRR)-[Tb.L^]Ch ( ) on incremental addition of DNA. (100 m M HEPES, 10 
mM NaCl, pH 7.4, 30 ^ M complex, A,;„ =543 nm) 
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It is possible, therefore, that those complexes whose emission was dramatically 
quenched by DNA may be present in the nucleus, but not visible. It was important to 
perform further studies to explore this hypothesis. 
3.6.2 Nuclear extraction experiments 
In order to test for the presence of complex in the nucleus, nuclear extractions were 
performed as described in Section 3.4.3, and the lanthanide content determined by 
inductively coupled plasma - mass spectrometry (ICP-MS). This value was then 
compared to the lanthanide content of the whole cell, and of the mitochondria, which 
were extracted in a similar manner, using a mitochondria isolation kit (Pierce 
Bioscience). 
Inductively coupled plasma mass spectrometry (ICP-MS) is an important technique for 
the analysis of trace elements, allowing determination of the concentration of an element 
in a sample with detection limits of the order of ppb.'^^ The sample is atomised and 
ionised by injection into an argon plasma, and the resulting ions are passed through a 
series of cones to a quadrupole mass spectrometer. The observed ion signal is 
proportional to the concentration, which can be determined by calibration with elemental 
standards. In this way, ICP-MS can be used to give an indication of the total amount of 
lanthanide within a sample. 
Cells were grown in cell culture flasks, and treated with 50 ^ M complex for 4 h. 
('555)-[Tb.L*]Cl3 was used as an example of a complex whose emission was quenched 
by DNA, while [Eu-L**^] was selected for comparison, as it was not quenched by DNA. 
Cells were either analysed as whole cells, or their nuclei or mitochondria extracted. Al l 
experiments were performed in triplicate. The calculated lanthanide uptake values are 
shown in Figure 3.16. The results indicate very similar behaviour for each complex, with 
approximately 30% of the total intracellular lanthanide measured in the nuclear fraction. 
This fraction is similar to the amount of lanthanide in the mitochondria. There is some 
doubt cast on the results of this experiment, however, as it might be expected that since 
the luminescence of [Eu.L^^JCb is not quenched by DNA, its presence in the nucleus 
should be observable by fluorescence microscopy. This is not the case, as no 
luminescence is visible in the nucleus of cells treated with [Eu.L^^JC^. This large 
measured uptake into the nucleus could instead result from the experimental procedure. 
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The nuclear isolation process relies solely on separation according to density (Figure 
3.12). It is possible that some large cytoplasmic proteins, or even portions of the lysed 
cell membrane, have a similar density to nuclei, and are therefore collected with this 
fraction. The complexes could be non-covalently bound to these fragments, and 
therefore be measured among the nuclear fraction. 
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Figure 3.16: Measured concentration of lanthanide in the nucleus and mitochondria relative to the amount 
in the whole cell for CHO cells treated with [Eu.L^^jCl.i (blue) and [Tb.L^JCl, (purple) (4h incubation, 
50| iM complex). 
3.6.3 Further experiments 
Since the nuclear extraction studies do not clearly indicate the presence or absence of 
complex in the nucleus, it is important to perform further studies. This could be achieved 
by using another method to gain a cellular localisation profile to supplement the 
information gained from fluorescence microscopy. For example, transmission electron 
microscopy or X-ray fluorescence spectroscopy, have been successfully used to study 
sub-cellular distributions of other metal complexes.'^*' This would enable a 
determination of whether fluorescence microscopy studies provide an accurate reflection 
of the true localisation of the complex. 
3.7 Understanding trafficking 
The sequestration of complexes into specific sub-cellular compartments, and the 
movement of complexes between organelles, requires complex trafficking processes 
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within the cell. This is of particular importance for the class of complexes which have 
been simultaneously observed in both the lysosomes and the mitochondria. A 
preliminary investigation of these trafficking mechanisms was performed using FRET 
techniques. 
Forster resonance energy transfer (FRET) is based on the principle that i f two 
fluorescent moieties are in close proximity (usually 2 - 1 0 mm), there can be a non-
radiative energy transfer from one to the other. This wi l l be observed as a decreased 
fluorescence intensity of one (the donor) and increased intensity of the other (the 
acceptor). In order for FRET to occur, the emission spectrum of the donor and the 
excitation spectrum of the acceptor must overlap." From a biological perspective, FRET 
studies can be useful in giving information about the proximity of two species within the 
cell.'^" 
This study aimed to investigate the interaction between lanthanide complexes and 
tubulin and actin, which are the main components of the microtubules and 
microfilaments respectively. In this way, the role of the cytoskeleton in sub-cellular 
trafficking can be investigated. This was achieved by using forms of tubulin and actin 
which were tagged with red fluorescent protein (REP). Luminescent terbium complexes 
can act as good donors for RFP fluorescence (Figure 3.17). 
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Figure 3.17: Excitation (—) and emission (—) spectra of [Tb.L*]^"" (blue) and RFP (red). 
RFP spectral data obtained from Evrogen.'*' 
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The RFP-labelled tubulin and actin were sourced from Invitrogen in the form of protein 
expression constructs utilising an insect virus (baculovirus) to promote cellular delivery 
and expression.'*^ CHO cells were treated with the construct for four hours, after which 
time the cells were incubated for twenty-four hours to allow protein expression. The 
cells were then incubated with [Tb.L*]Cl3 (4h, 50 \M). It is likely that any FRET which 
occurs wil l do so with only very low emission intensities. For this purpose, the 
fluorescence microscope system utilised for other experiments may not be sufficiently 
sensitive. The cells were therefore visualised using a confocal microscope system. Three 
channels were set up, as shown in Table 3.1, to measure the Tb luminescence, the RFP 
fluorescence, and FRET. 
Table 3.1: Microscope channels employed for study of cells treated with [Tb.L^JClj and RFP-labelled 
protein. LP = long pass filter 
^ Laser excitation Emission 
Channel Purpose , 
^ wavelength fj,ter 
1 Tb luminescence 405 nm 505-550 
2 RFP fluorescence 543 nm LP 650 
3 FRET 405 nm LP 650 
The results of this experiment are shown in Figure 3.18. The RFP fluorescence channel 
confirms successful transfection, although only approximately half of the cells showed 
staining for RFP. This is likely to be due to the fact that not all cells had completed a full 
cell cycle, and were not expressing the recombinant protein. There was no detectable 
fluorescence in the FRET channel for either protein, indicating that the complex is not 
close enough in space to actin or tubulin. There is, however, co-localisation of the Tb 
luminescence and the RFP fluorescence for the RFP-labelled actin, indicated by the 
yellow colour in the overlap images. This suggests that, although the complex is not 
associating directly with actin, it is still relatively close. This might indicate that the 
microfilaments play a role in transporting the complex within the cell. 
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Figure 3.18: Confocal microscopy images of CHO cells treated with [Tb.L^^* (50 nM, 4h) and (a) 
tubulin-RFP or (b) actin-RFP. (i) Tb luminescence, (ii) RFP fluorescence, ( i i i ) overlay of Tb luminescence 
and RFP fluorescence, (iv) FRET channel. 
3.8 Conclusions 
The range of complexes synthesised in Durham exhibit various sub-cellular localisations 
which can be divided into four main categories. Two distinct groups rapidly localise to 
the mitochondria and to the lysosomes, while a third appears to be distributed between 
both types of organelle. From a molecular imaging perspective, it is generally desirable 
for a probe to localise in only one organelle type, in order to provide specific 
information about the environment of that particular region of the cell. Future design of 
luminescent lanthanide complexes might therefore attempt to avoid such localisation 
behaviour. Structural studies indicated that it was complexes with three identical pendant 
arms which exhibited this intermediate localisation. By removing one pendant arm, the 
complex should localise in a single organelle type. This is unlikely to be a hindrance to 
complex design, as many responsive complexes contain a free amine at the fourth cyclen 
nitrogen. 
The fourth class of complexes exhibited nucleolar localisation under certain conditions. 
Further studies of this behaviour showed it to be due to increased membrane 
permeability, induced by necrotic conditions or other effects of the complexes 
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themselves. Trafficking across the nuclear membrane was found to require active 
transport processes, evidenced by the fact that complexes could not be induced to enter 
extracted nuclei. 
This work has demonstrated that it is not necessary to employ complex strategies to 
effect mitochondrial, lysosomal or even nucleolar localisation. I f other sub-cellular 
organelles were to be targeted, however, other approaches might be necessary. These 
might involve more drastic structural modifications, or incorporation of peptides which 
target different sub-cellular locations. 
While this study has focussed on sixteen different ligand types, it is not possible to 
continue all other investigations of cellular behaviour on such a large set of complexes. 
The classification of complexes into four groups of distinct types of behaviour will assist 
in the rational selection of examples of each type for the further studies which are 
described in subsequent chapters. 
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4.1 Introduction 
In order for a probe to report on sub-cellular conditions, it must be able to enter the cell 
by crossing the cell membrane. This chapter explores the studies which have been 
performed to understand the permeability of the cell membrane towards the luminescent 
lanthanide complexes, and the manner in which they are taken up into cells. 
The design of cell-permeating compounds is a key challenge in many fields, most 
notably in the pharmaceutical industry, in which it is essential to ensure that drugs reach 
their intracellular targets.'"^' In some cases, compounds utilise endogenous mechanisms 
of intemalisation, but for non-permeating cases, it might be necessary to perform 
modifications to ensure cellular uptake. The following section explores modes of cellular 
uptake. 
4.1.1 Cellular uptake pathways 
The mechanisms by which species can be transported across the cell membrane can be 
divided into a number of classes (Figure 4.1).'''^ The term passive transport 
encompasses those pathways which do not require energy input: the driving force for the 
transport is instead the movement of molecules down their concentration gradient. 
Osmosis is the movement of water from a region of low solute concentration to a region 
of higher concentration, while diffusion describes the movement of any molecule down 
its concentration gradient. Oxygen and carbon dioxide, for example, readily diffuse 
across the cell membrane. Facilitated diffusion describes the movement of species 
through protein channels in the cell membrane. While this process is primarily involved 
in the intemalisation of small ions and molecules such as Na"^ , Ca^ "^  and glucose, some 
metal complexes have been observed to enter cells through ion channels. For example, 
183 
cisplatin is thought to enter cells through the copper transporter Ct r l . 
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M E M B R A N E TRANSPORT 
passive transport active transport 
diffusion osmosis primary secondary vesicular 
active transport active transport transport 
facilitated 
diffusion , 
exocytosis endocytosis 
Figure 4.1: Methods of membrane transport 
Active transport pathways, on the other hand, are those which require the input of 
energy. Primary active transport involves the use of specific membrane-bound carriers or 
channels to move species across the cell membrane. For example, the NaVK'^-ATPase 
uses the energy from ATP to simultaneously move three sodium ions out of the cell and 
two potassium ions into the cell. In contrast, secondary active transport uses an ion 
gradient which is established by the simultaneous transport of a second species. An 
example is the glucose symporter, SGLTI, which co-transports one glucose molecule 
into the cell with every two sodium ions which are imported.' 184 
The third major class of active transport is vesicular transport, which is the least 
understood mechanism of membrane transport.'^^ Endocytosis and exocytosis are 
essentially reverse processes, enabling the movement of species into and out of the cell 
respectively. For the purposes of this study, therefore, cellular uptake, or endocytosis, is 
of primary interest. Endocytosis describes the process by which the membrane 
encapsulates an extracellular particle into a vesicle which is subsequently internalised. 
The process can occur via one of a number of mechanisms (Figure 4.2). 
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Figure 4.2: Putative mechanisms of membrane transport by endocytosis 
Endocytosis can be divided into two broad categories: pinocytosis involves the uptake of 
extracellular fluid and any particles it may contain, while phagocytosis describes the 
transport of large multimolecular particles such as dead cells, bacteria and viruses.^'' 
Phagocytosis is performed by specialised white blood cells, phagocytes, on materials 
which have been identified as foreign or diseased. The cell membrane engulfs the solid 
particle to form a phagosome, which is delivered to the lysosome for degradation. The 
products are released intracellulariy for further processing, or extracellulariy via 
exocytosis 172 
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Pinocytosis can be further divided into classes according to mechanism. The best 
understood endocytotic route is clathrin-mediated endocytosis, which occurs at specific 
regions of the cell membrane called coated pits, which have high concentrations of 
specific proteins such as clathrin and the adaptor protein These proteins 
facilitate the invagination, constriction and fission of the cell membrane to form a 
vesicle. The membrane proteins are then recycled to form a new coated pit. Clathrin-
mediated endocytosis is the principal mechanism of intemalisation for proteins, 
membrane-localised receptors and ion channels. 
It was initially believed that clathrin-coated pits were the only form of specific 
pinocytosis. However, studies of the uptake of the virus SV40 revealed an alternative 
mechanism, via caveoJae.'^ '^ '^ ^ Caveolae are flask-shaped invaginations of the cell 
membrane,'*^ which are coated with a number of lipids and proteins, notable among 
which is the integral membrane protein caveolin.'^° Caveolae internalise species by 
potocytosis, a term which specifically describes the sequestration and transport of small 
molecules by caveolae.Invagination of a caveola results in the formation of a 
caveolosome, which then delivers its contents to one of a number of locations: the 
cytoplasm, endoplasmic reticulum or other organelles, or the cell membrane for 
re-release or repositioning in the plasma membrane. 
Clathrin- and caveolae-dependent endocytosis rely on ligand-binding to a receptor to 
signal vesicular formation. In contrast, macropinocytosis is a non-specific mechanism 
for intemalisation, for which ligand binding is not required.'^" Instead, vesicles are 
formed by ruffling of the membrane in response to cell stimulation. This ruffling results 
in the formation of large, irregular vesicles called macropinosomes. This process is 
driven by actin, and the mechanism of membrane invagination is similar to that of 
phagocytosis. It is not understood how the contents of the macropinosome are processed. 
Macropinosomes can fuse with one another, and can reassociate with the cell membrane, 
but in most cell lines do not seem to associate with early or late endosomes.'^^ 
Observation of persistent endocytosis even in the presence of drugs blocking the 
clathrin- and caveolae-dependent pathways has led to the hypothesis of an additional 
pathway, non-clathrin non-caveolae dependent endocytosis.'^^ This process is not well 
understood, but has been observed for the intemalisation of the cholera toxin in some 
cell lines.'^ "^ 
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4.1.2 Strategies for celluJar delivery 
While many exogenous molecules have been observed to enter cells by the above 
mechanisms, in a number of cases it is necessary to assist the transport of drugs or 
probes across the cell membrane. There are a number of means of achieving such 
cellular uptake. 
A common challenge for drug delivery is to facilitate a hydrophilic drug molecule to 
cross the lipophilic cell membrane. This can be achieved by encapsulating the drug in a 
liposome or micelle which will carry it into the interior of the cell.'^^ In a similar 
manner, viral vectors can be generated in which the protein coat of the virus can 
encapsulate a molecule, usually comprising nucleic acids.'^^ The vector then harnesses 
the mechanisms by which viruses efficiently transport their genomes into infected cells. 
An additional mechanism for enhancing cellular uptake is to incorporate a peptide 
domain which wil l be recognised and internalised by the cell. This may be a ligand 
domain which can bind to a receptor involved in endocytosis, or a signal peptide which 
enhances membrane translocation. Such peptides, which are called cell-penetrating 
peptides (CPPs), have recently gained popularity as drug delivery vehicles.'"*^ For 
example, the conjugation of synthetic import peptides to oligonucleotides has been 
demonstrated to increase the cellular transport of the oligonucleotide.'^^ 
4.1.3 Uptake of lanthanide complexes 
While there has been no comprehensive study of the cellular transport of lanthanide 
complexes, the uptake behaviour of a number of example complexes has previously 
been reported. One important consideration is whether structural characteristics 
determine the ability of a complex to enter the cell. Previous studies of [Ln.L^]^"^ 
demonstrated clear in cellulo luminescence, consistent with good cellular uptake. In 
contrast, microscopic investigations of cells treated with its neutral and anionic 
analogues (Figure 4.3) showed no readily-detectable luminescence, with the conclusion 
that cell uptake is very low for these cases.'^ ^ This led to the hypothesis that for efficient 
membrane transport, a complex should be relatively lipophilic, have an overall positive 
charge and contain one or more planar aromatic heterocycles. " However, this same 
work also reported inductively coupled plasma - mass spectrometry (ICP-MS) 
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measurements of cells treated with [Ln.L^]^"^ and its analogues which indicated 
comparable intracellular concentrations of each complex. This suggests that the poor 
visibility of the neutral and anionic complexes in vivo might be due to a mechanism 
other than reduced uptake. 
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Figure 4.3: Structures of [Ln.L"]^* and its neutral and anionic analogues. 
Microscopy studies of Eu and Tb complexes of at various timepoints and 
concentrations revealed that the Eu complex could be more readily observed at early 
timepoints than the Tb analogue. This was initially interpreted as being due to faster 
uptake of the Eu complex. In contrast, there was no significant difference between the 
uptake of the A and A enantiomeric forms.'^^ 
A number of studies have drawn preliminary conclusions regarding the mechanism of 
cellular uptake of various lanthanide complexes. The size and charge of [Ln.L^]^"^ was 
believed to preclude its passive entry to the cell, while the lack of vesicular structures in 
the fluorescence microscopy images were at variance with an endocytotic mechanism.''^ 
This was further supported by the observation that microscopy images collected at 4 °C 
appeared to be similar to those collected at 37 °C.^^ At low temperatures, energy 
dependent processes such as endocytosis are inhibited. As a result, [Ln.L^]'''^ was 
believed to enter cells through a transporter or pore in the cell membrane. Such a 
mechanism was also hypothesised for the citrate sensor [ L n . L ' Y ^ . for which 
considerable uptake at 4 °C was again identified.'^^ 
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In contrast, studies of a range of other lanthanide complexes have identified minimal 
cellular uptake upon incubation at 4 °C. This led to the conclusion that, in these cases, 
uptake is likely to be due to an endocytotic mechanism.'""^ 
It is evident, therefore, that conclusive studies must be performed in which the cellular 
uptake of a broad range of complexes is assessed with reference to the structure of the 
complex, and that more detailed mechanistic studies are required to elucidate the mode 
of cellular uptake. The following sections describe the work which has been performed 
to that end. 
4.2 Exploring effects of structure on cellular uptake 
An understanding of the structure-uptake relationship is important in the study of 
luminescent lanthanide complexes, as it enables the design of probes which are most 
likely to exhibit sufficient cellular uptake. Previous studies of the uptake of various 
complexes led to the conclusion that pooriy visible neutral and anionic complexes were 
not able to efficiently cross the cell membrane. These observations served as a starting 
point for this investigation. 
Earlier microscopy examinations noted that while [Ln.L^]''"^ was visible by fluorescence 
microscopy, [Ln .L ' ] could not readily be observed.'^^ These two complexes were 
therefore selected as examples of readily and poorly visible complexes respectively. 
Microscopy studies were performed to repeat these experiments. Representative 
microscope images for Tb complexes in CHO cells are shown in Figure 4.4. 
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Figure 4.4: Luminescence microscopy images showing terbium luminescence of CHO cells treated for 
3 h with 50 | iM (a) [Tb.L*] and [Tb.L^JCls. Scale bar represents 20 nm. Image brightness and contrast 
have been altered. 
It is evident that both [Tb.L*] and [Tb.L^jCb give rise to in cellulo luminescence, 
confirming that both are able to cross the cell membrane. The fact that previous studies 
were unable to observe [Tb.L^] by microscopy could be due to the use of emission filters 
which were not optimal. However, as previously observed, repeated experiments in both 
CHO and NIH 3T3 cells, and for both Tb and Eu complexes, showed that the 
luminescence of [Ln.L^] was considerably weaker than that of [Ln.L^]^"^. It was not 
possible to quantify the luminescence output with the microscope system employed. 
Such a measurement would require the use of a laser scanning confocal microscope, in 
which the laser power could be accurately measured. 
The challenge remains, therefore, to explain this varying in cellulo visibility. Such a 
difference could result from two primary causes: a decrease in the permeability of the 
cell membrane to some complexes compared to others, or a quenching of the 
luminescence in the cell. Each possibility will be explored in turn. 
4.2.1 Comparing the absolute cellular uptake 
Determination of the amount of complex which has been intemalised by the cell requires 
a method other than luminescence microscopy, which can be biased by factors such as 
quenching. In order to achieve this, the intracellular concentration of lanthanide was 
determined by ICP-MS. In order to compare the uptake of different samples, however, it 
is necessary to measure the number of cells in the sample to allow calculation of an 
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intracellular lanthanide concentration. In previous investigations, this was achieved by 
the use of flow cy tome t ry . ' ^^ 
Flow cytometry is a technique which uses fluorescence to count and sort populations of 
cells (Figure 4.5).'^^ The cell suspension is inserted into the flow chamber and focused 
to a stream of droplets, each containing a single cell. The stream of cells is then 
interrogated with a laser which excites the fluorophore with which the cells have been 
treated. The emitted light is collected and the droplets are given an electrical charge that 
varies depending on their fluorescence profile. This allows them to be separated into 
different populations according to their charge. 
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Figure 4.5: Schematic diagram sliowing the process of flow cytometry. 
Cells typically move through the flow chamber at a speed of 1 to 25 ms'', so they are 
only very briefly illuminated by the laser. Indeed, this interrogation time is shorter than 
the luminescence lifetime of lanthanide complexes, so they are not practical for use as 
fluorophores in flow cytometry. As a result, a second fluorophore must be added. In this 
case, live cells were labelled with the acetylmethoxy ester, calcein A M , a dye which is 
used to assess cell viability and cytotoxicity of eukaryotic cells. Calcein A M is retained 
in cells that have intact membranes, but not in dead cells, and is rapidly lost under 
conditions that cause cell l y s i s . W h i l e calcein A M is not fluorescent, it is hydrolysed 
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by the intracellular esterases present in viable cells to calcein, which exhibits green 
fluorescence detectable in flow cytometry. 
In this investigation, cells were treated with both calcein A M and the lanthanide 
complex, allowing live cells containing the lanthanide complex to be selectively sorted 
and dead cells to be discarded. It has previously been demonstrated that in more than 
97 % of cells examined by microscopy, both the green fluorescence of calcein and the 
red fluorescence of various europium complexes could be observed.'^ ** 
NIH 3T3 cells were treated with 50 \iM complex for varying time periods. For the last 
half hour of incubation, calcein A M was added to the medium. After incubation, the 
complex-containing medium was removed and the cells rinsed with phosphate-buffered 
saline (PBS). Cells were immediately harvested and subjected to flow cytometry, in 
which calcein-positive cells were collected. The cell samples were then submitted for 
analysis by ICP-MS. Prior to injection of the sample into the mass spectrometer, samples 
were treated with nitric acid to digest the cell membrane and to ensure that the complex 
did not adhere to the sample vial. The results of these uptake studies are shown in Figure 
4.6a. 
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Figure 4.6: Uptake (a) and egress (b) of [Tb.L'] (•) and [Tb.L^jClj (A) (50 [M) in NIH 3T3 cells over a 
period of 3 h. A mean cell volume of 4000 |im' is assumed. 
It can be seen that [Tb.L^] and [Tb.L^jCb are initially transported across the cell 
membrane at a very similar rate. At the 90 min time-point, both complexes have 
accumulated to a concentration of approximately 10 pM. The values have diverged by 
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180 min, with approximately twice as much [Tb.L^JClj as [Tb.L^] within the cell. This 
could result from decreased uptake, or increased excretion of [ T b . L ' ] . The results clearly 
show that, despite its poor visibility, [Tb.L^] does show appreciable cellular uptake. A 
previous study of the uptake of [ E U . L ' ] and [Eu.L^JCb in CHO cells gave intracellular 
concentrations of 12 and 26 | J M respectively.'"^ While the values obtained in this 
experiment cannot be directly compared due to the different cell line and lanthanide ion 
that were used, they show similar magnitude and relative difference. 
A concurrent experiment was performed to study the egress of the complexes from the 
cells. The experimental procedure was similar to that described above for the uptake 
studies, and differed only in the incubation procedure. A l l cells were incubated with 
50 pM complex for 3 h, after which the medium was removed and replaced with PBS. 
The cells were then harvested at various time-points over the subsequent 3 h (Figure 
4.6b). The aim of this experiment was to study the transport of the complex across the 
cell membrane under conditions of high intracellular concentration, and low 
extracellular concentration. 
Figure 4.6b highlights the very rapid egress of the complexes, with over 80% of both 
complexes being lost from the cells in the first five minutes. However, the entire process 
of harvesting the cells and performing flow cytometry takes at least twenty minutes, 
during which time it would be expected that complex would be rapidly leaving the cells. 
This means that the actual intracellular concentrations throughout this experiment are 
likely to be higher than those measured. It was therefore necessary to use a different 
method for subsequent quantification of intracellular lanthanide concentrations, as will 
be discussed in Section 4.4.1 below. The conclusions of this uptake experiment are, 
nevertheless, valid, as all cells were treated in an identical manner and meaningful 
comparisons of the intracellular concentrations of the two complexes can be drawn. It 
appears, therefore, that the poor visibility of [Tb.L^] cannot be attributed to its poor 
uptake. 
It is also important to note that the intracellular concentrations of both [Tb.L^] and 
[Tb.L^]Cl3 are of a similar magnitude to the dosage concentration of 50 |aM. This 
indicates good transport of complexes across the cell membrane; it is not necessary to 
dose the cells with very high concentrations of complex to force only small amounts to 
enter. This is a particularly valuable property for complexes which may be cytotoxic at 
higher concentrations, 
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4.2.2 Comparing in cellulo quenching 
The second hypothesised explanation for the lower visibility of [Ln.L^] compared with 
that of [Ln.L^]'^"^ is that the former is more susceptible to quenching in cellulo. 
Stem-Volmer quenching constants are shown in Table 2.4 in the Chapter Two (page 58), 
and illustrate no marked differences between the two sets of complexes in terms of their 
sensitivity to quenching by urate, ascorbate or iodide. These values were, however, 
calculated from measurements made in a buffer system which bears little resemblance to 
cellular conditions. In order to more closely mimic a cellular environment, the urate 
quenching experiment was repeated in the presence of BSA (Figure 4.7). 
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Figure 4.7: Urate quenching curves for (a) [Tb.L'] and (b) [Tb.L^]'* in the absence (•) and presence (•) 
of 0.4 mM BSA. (100 mM HEPES, 10 mM NaCl, pH 7.4) 
These quenching curves show a marked difference between the behaviour of the two 
complexes. The presence of BSA completely suppresses the quenching of [Tb.L^]"'*. 
[Tb.L^], on the other hand, is still quenched in the presence of BSA, although the value 
of K~l has increased from 0.0058 mM to 0.0095 mM. It might be expected, therefore, 
that [Tb.L*] experiences considerable luminescence quenching in cellulo, even in the 
presence of proteins such as BSA. This could therefore contribute to its poorer visibility. 
Similar results were observed for the Eu complexes, and for quenching by ascorbate in 
the presence of BSA. This difference between the two complexes can be attributed to 
two factors. Firstly, the structure of [Ln.L^] is more open than that of [Ln.L^]^^ and is 
therefore more accessible to quenching. Secondly, [Ln.L^J binds more weakly to protein, 
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as illustrated in Figure 2.21 (page 61), and will therefore be less shielded from approach 
by urate and ascorbate than [Ln.L^].^^' ''^ 
4.2.3 Conclusions regarding poorly visible complexes 
These studies of [Ln.L^] and [Ln.L^]^"^ have indicated that it is quenching which caused 
poor visibility within cells, rather than a reduced uptake as previously thought. This 
could explain the earlier observation that the in cellulo luminescence of Tb complexes 
increases more slowly with time than that of their Eu analogues. While this was 
attributed to a slower rate of uptake,'^^ it is in fact more likely to reflect the greater 
susceptibility to quenching of Tl? complexes than Eu complexes. 
This section has demonstrated that cellular uptake cannot be assessed on the 
luminescence output observable by microscopy alone. Microscopy is still, however, a 
valuable tool to survey a broad array of complexes, since even the strongly quenched 
[Tb.L'] could be observed after increasing the gain and contrast. The following section 
describes the general observations which have been made regarding the uptake of a 
broad array of complexes. 
4.2.4 General observations of cellular uptake 
At Durham, a set of more than seventy luminescent lanthanide complexes has been 
synthesised. These complexes differ in geometry, charge, chromophore, pendant arm 
and lanthanide ion. The cellular uptake behaviour of a large proportion of these 
complexes has been determined by luminescence microscopy. CHO or NIH 3T3 cells 
were treated with 50 (iM complex for time periods between 5 min and 24 h. While the 
absolute emission intensity varied across the range of complexes, as discussed above, all 
complexes exhibited a similar rate of uptake - luminescence could be observed within 
the cell after 5 min. This luminescence intensity increased over the first hour, and then 
generally remained constant for the subsequent hours. After 24 h incubation, 
luminescence was again lower, which is likely to reflect degradation or efflux of the 
complex. 
These initial studies therefore indicate that all complexes, regardless of their structural 
features, exhibit similar uptake behaviour. The following sections detail more rigorous 
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Studies which were performed on selected complexes to gain a better understanding of 
the nature of the cel lular uptake. 
4.3 Determining the energy dependence of uptake 
As discussed in Section 4.1.1, cellular transport mechanisms can be divided into passive 
and active pathways according to their need for energy input. In order to determine the 
mode of cellular uptake for lanthanide complexes, it is therefore necessary to first 
categorise the mechanism as active or passive. This was achieved by studying the 
lipophilicities of the complexes, and performing preliminary low-temperature 
experiments, 
4.3.1 Correlating lipophilicity with uptake 
The ability of a compound to partition between lipophilic and hydrophilic substances 
greatly affects its cellular behaviour. In order for a compound to diffuse through a cell or 
organelle membrane, it must be sufficiently hydrophobic to partition into the lipid 
bilayer, but hydrophilic enough to ensure that it will be able to leave the bilayer again.''" 
This partitioning ability is of particular importance in the absorption of drugs "°" 
The standard model for the assessment of lipophilicity is the partition coefficient log/'oct, 
which can be calculated by equation 4.1. 
logP„„ =log 
^[solute] ^ 
[solute]^,^ 
[4.1] 
The measurement or calculation of \ogP is important in pharmacokinetics, where a high 
logP correlates with poor permeation into cells.^"^ LogP is of interest in this study, as it 
has been shown that the rate of passive diffusion correlates with logP. 
, 204 
In order to measure logP, it is necessary to have some method of measuring the 
concentration of complex in octanol and water. This has been achieved in the past in 
various ways, such as scintillation counting of radio-labelled complexes'''^ and flame 
atomic absorption spectroscopy.^''* In this study, lanthanide luminescence was used to 
calculate concentrations. For all complexes, standard curves were constructed over 
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appropriate concentration ranges for solutions in both 1-octanol and water. For all 
studies, water was saturated with 1-octanol and vice versa to ensure that any miscibility 
effects were constant throughout the experiment. 100 \iM aqueous solutions of the 
complexes were used to prepare mixtures containing various water : 1-octanol solvent 
ratios. A concentration of 100 \xM was selected after preliminary trials, as it ensured 
measurable luminescence in 1-octanol even for the most hydrophilic complexes. In 
total, three replicates of three different water : 1-octanol ratios were prepared, and 
shaken overnight to ensure complete partitioning. The luminescence of both the water 
and 1-octanol layers was then measured and the calibrations curves used to calculate 
concentrations of complex in each solvent. This allowed calculation of average \ogP 
values, shown in Table 4.1. A range of complexes was studied which represented 
various structures and localisation behaviours. 
Table 4 .1 : LogP„a values for various lanthanide complexes, with standard deviations (SD) 
SD 
[Eu.L^jCb - 1 . 3 4 0 . 1 0 
[Eu.L'"]Cl3 - 2 . 1 0 0 . 4 0 
[TbL^"]Cl3 - 2 . 0 6 0 . 0 9 
[Eu.L''']Cl3 - 1 . 1 5 0 . 2 0 
[ E U . L ' " ] - 1 . 7 4 0 .37 
[TbL**"] - 1 . 5 6 0 .25 
[ E U . L " " ] - 0 . 1 6 0 .03 
[Eu.L*'']Cl3 - 1 . 3 6 0 . 1 8 
[Eu.L*"]Cl3 - 1 . 5 6 0 . 0 9 
[Tb.L'']Cl3 0 .05 0 . 0 4 
[Eu.L']Cl3 - 0 . 0 6 0 .03 
[ E U . L " ] ( O T 0 3 1.06 0 . 1 3 
[Eu.L"]Cl3 0 . 4 9 0 . 1 1 
[Eu.L'^] - 1 . 5 2 0 .05 
NazlGd.L"] - 0 . 2 8 0 . 0 6 
The measured partition coefficients range from hydrophilic (-2.10) to lipophilic (-1-1.06). 
The nature of the lanthanide ion does not appear to affect the logF value, but variation of 
the counterion does have a significant effect, with the triflate complex being more 
lipophilic than the chloride form. This is consistent with previous observations of the 
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hydrophobicity of triflate.'^^ Charged complexes have more negative logP values than 
their neutral analogues, consistent with a greater aqueous solubility. 
Importantly, the results reveal that complexes with very similar cellular behaviour, such 
as the lysosomally-localising [Ln.L']^"^ and [Ln.L"], exhibit very different logP values, 
from -0.16 to -2.10. Indeed, while all the complexes had been observed to cross the cell 
membrane at a similar rate, they vary greatly in partitioning behaviour. This suggests 
that cell uptake does not occur by passive diffusion, as in such a case diffusion rates 
would mirror trends in log P. 
4.3.2 Preliminary low-temperature experiments 
A common method which has been used to study the uptake of lanthanide complexes in 
the past is the incubation of cells at 4 °C. Lowering the incubation temperature for cells 
results in blocking of all endocytotic, energy-dependent processes.^ '^ '"^ Similar uptake 
at 4 °C compared with that at 37 °C would therefore be evidence of a passive diffusion 
mechanism. In this preliminary study, microscopy was used as a means to observe 
changes in the uptake caused by incubation at low temperature. Cells were treated with 
various complexes, and incubated at either 4 "C or 37 °C. They were then visualised by 
fluorescence microscopy as previously described. It was important to rapidly view the 
cells, as at room temperature any endocytotic processes would be again switched on. 
Representative microscopy images for two complexes are shown in Figure 4.8. The 
luminescence from the cells treated at 37 °C is readily observable, showing lysosomal 
and mitochondrial distribution for [Eu.L^]^"^ and [Eu.L*'']^'^ respectively. In cells treated 
at 4 °C, the luminescence is much weaker, and does not show clear localisation. Indeed, 
the luminescence intensity is not significantly greater than that observed for background, 
untreated cells. The cellular uptake is therefore greatly decreased at low temperatures, 
suggesting that uptake occurs by an active, energy-dependent process. More quantitative 
confirmation of these findings was obtained by ICP-MS studies, as will be presented in 
Section 4.5.3. 
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Figure 4.8: Fluorescence microscopy images showing CHO cells treated with [Eu.L^lCl, (50 pM, 4h) at 
(a) 37 °C and (b) 4 °C, and with [Eu.L*'']Cl3 (50 ^M, 4h) at (c) 37 °C and (d) 4 "C. Scale bar represents 
20 nm. 
4.3.3 Further evidence for active transport 
The partitioning and low-temperature studies provide good evidence that uptake occurs 
via an active transport mechanism. This is further supported by the large size of the 
complexes - most have molecular weights exceeding 1 kDa - which has previously been 
shown to greatly hinder passive diffusion.^"'' 
Another effective method which could be adopted to assess for passive transport is the 
use of synthetic liposomes. Such liposomes, comprised of lipids such as 
phosphocholines, are good models for the lipid bilayer of the cell membrane in the 
absence of any proteins. Observation of the movement of a complex in or out of the 
liposome would therefore be evidence of its ability to passively diffuse across the cell 
membrane.'"^ Preliminary attempts to use this method were unsuccessful, as the 
complex adhered to dialysis tubing which was used in the preparation and separation of 
the dosed liposomes. There was, nevertheless, sufficient evidence to assume that the 
lanthanide complexes were not passively diffusing across the cell membrane. 
117 
C H A P T E R FOUR: C E L L U L A R U P T A K E O F C O M P L E X E S 
Investigations were therefore directed towards the determination of a possible active 
mechanism for cellular uptake. Before this could be achieved, however, it was necessary 
to refine the methods for measuring uptake. 
4.4 Refining uptake measurements 
4.4.1 A new method for quantifying uptake 
The flow cytometry process necessitates a relatively long time period between 
harvesting and collecting the cells, as discussed in Section 4.2.1. Over this time period, 
complex could leave the cells, and would not be measured by ICP-MS. It was therefore 
necessary to use a different method to count the number of cells. 
One possible solution was to count the number of cells using a haemocytometer, as in 
previous studies of the uptake of metal complexes.'"^ This could be performed 
immediately before plating, or on an aliquot of the sample to be submitted for ICP-MS. 
A number of trials were performed in which cells were counted and the cell count 
confirmed by flow cytometry, but the results proved neither sufficiently accurate nor 
precise. 
Another method which is commonly adopted in cell uptake studies is the use of a protein 
assay kit to determine total protein content.^"''"" While this method does not give a total 
number of cells, the protein content is proportional to the number of cells, and allows for 
calculation of a relative concentration, which can be used to compare samples. 
The protein assay kit which was selected for use is the BCA Protein Assay Kit (Sigma). 
It is based on the reduction of Cu^ "^  to Cu"^  by protein in alkaline conditions. The Cu"^  
then forms a complex with bicinchoninic acid (BCA) to form a complex which absorbs 
strongly at 562 nm (Scheme 4.1).^'^ 
~ N ' O O 
bicinchoninic acid (BCA) 
Scheme 4.1 
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4.4.2 Testing the uptake method 
In order to test this alternative method for assessing cellular uptake, a similar experiment 
to that described in Section 4.2.1 was performed, again using [Tb.L^JCls in NIH 3T3 
cells. In this case, however, the relative cell number was determined using the BCA 
protein assay kit. The values obtained were then compared to those previously 
determined by the flow cytometric method (Figure 4.9). The two methods give different 
units of intracellular concentration, and the values themselves cannot be compared, but 
the trends can be examined. Most notably, the egress of the complex from the cells 
(Figure 4.9b) appears to be less rapid by the BCA method. This is likely to be due to the 
very high rate of complex loss which could occur during the processes of harvesting and 
flow cytometry. Similarly, the intracellular concentration appears to increase more 
rapidly according to the BCA protein assay method, which again is likely to result from 
greater retention of complex prior to analysis. It appears that this modified method does 
circumvent the problems experienced in early experiments, and was therefore used for 
all subsequent studies. 
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Figure 4.9: Uptake (a) and egress (b) of [Tb.L^JClj over a period of 4 h, measured by f low cytometric 
method (•) and BCA protein assay ( A ) (50 n M complex, N I H 3T3 cells). 
4.4.3 Determining the optimum incubation time 
In order to further study the cellular transport of lanthanide complexes, it is necessary to 
compare the relative uptake under different conditions. It is therefore important to 
establish the optimum incubation time which will allow for the greatest cellular uptake 
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but avoiding any metabolism or excretion which might occur at longer time-points. To 
determine this, the uptake of two complexes was monitored over a 24 h period (Figure 
4.10). For both complexes, the intracellular concentration increases rapidly over the first 
four hours. For the subsequent twenty hour period, there is only a very moderate further 
increase. An incubation time of 4 h was therefore chosen for all subsequent uptake 
experiments. 
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Figure 4.10: Uptake of [Tb.L^JClj (•) and [Eu.L^^lClj ( A ) over a period of 24 h (50 pM complex, 
N I H 3T3 cells). 
4.5 Determining the mode of endocytosis 
The experiments described in Section 4.3 indicate an active uptake mechanism. 
Investigations therefore turned to the exploration of a possible endocytotic pathway for 
cellular uptake. 
4.5.1 Selection of inhibitors and activators 
A common method which has been employed to determine uptake mechanisms for 
various molecules such as cell-penetrating peptides,'''' modified RNA^'"* and 
liposomes,'"*' is the treatment of cells to selectively block or enhance different pathways. 
A number of treatments were selected from the literature, shown in Figure 4.11 and 
Table 4.1. Literature concentrations of all substances were used as a guideline, with non-
toxicity confirmed by examining cells by microscopy. 
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M A C R O P I N O C Y T O S I S C L A T H R I N -
M E D I A T E D I  C A V E O L A E 
esters wortmannin chlorpromazine , \ 
glycerols amiloride <:,,rrn<=p. "''P'" 
phorbol esters 
fatty acid glycerols 
macroplnosome 
ear 
endosom 
clathrin-coated 
vesicle .•" 
chlorpro azine 
sucrose 
caveolosorne^^^^ .. 
( ) 
late 
endosome 
chloroquine 
monensin 
acidification* 
lysosome 
Figure 4.11: Schematic diagram illustrating the three endocytotic pathways in addition to the intracellular 
maturation of endosomes to lysosomes. Inhibitors (-) and activators (+) of each pathway are indicated. 
Table 4.2: Inhibitors and activators for different endoytotic pathways 
Treatment Dosage Effect Mechanism 
Sucrose 50 m M Inhibitor of clathrin-
mediated endocytosis 
Unselective inhibition of 
clathrin-coated pit ' ' ' ' 
Chlorpromazine 50^lM Inhibitor of clathrin-
mediated endocytosis 
Dissociates the clathrin 
lattice 
Filipin 1 mg/mL Inhibitor of caveolae Binds to cholesterol-'*-^" 
Wortmannin 300 n M Inhibitor of 
macropinocytosis 
Inhibitor of phosphatidyl 
inositol-3-phosphate 
Amiloride 3 m M Inhibitor of 
macropinocytosis 
Inhibits N a W p u m p ^ ' " 
Phorbol 12-myristate-
13-acetate 
50 
ng/mL 
Stimulator of 
macropinoc ytosis 
Protein kinase C activator 
220 
1,2-Dipalmitoyl-rac-
diacylglycerol 
500 
ng/mL 
Stimulator of 
macropi noc ytosis 
Protein kinase C activator "^ ^^  
Monensin 2 nM Inhibitor of endosome 
maturation 
Prevents acidification of 
endosomes 
Chloroquine 10 HM Disruption of lysosomes Prevents acidification of 
endosomes; causes lysosome 
swelling 
Poly-L-lysine 0.01% Disrupts interaction with cell 
membrane 
Non-specifically binds to cell 
membrane 
4 ° C - General inhibitor of 
endocytosis 
99 207 
Depletion of energy ' 
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In order to determine the mode of uptake, it is important to compare the uptake of 
complex by control cells with the uptake by cells which have been treated with one of 
the drugs. CHO, NIH 3T3 and HeLa cells were grown to confluence in 12-well plates. 
The cells were pre-treated for 30 min with the drugs at concentrations shown in Table 
4.2. Lanthanide complexes were then added (50 yM) and the cells incubated for a further 
4 h. Uptake was then measured by one of two experiments. Microscopy studies were 
performed to give a visual indication of uptake changes. The second experiment 
involved quantification of the intracellular lanthanide concentration by using ICP-MS. 
4.5,2 Microscopy studies of uptake 
Microscopy studies using inhibitors and activators were performed using complexes 
[Eu.L-]Cl3, [Eu.L^'']Cl3, [Eu.L*'']Cl3, [Eu.L'^'JCb, [Tb.L^JCb, [EuV]Ch and 
[Eu.L**]Cl3. Al l complexes were studied in CHO, HeLa and NIH 3T3 cells. Some 
representative images, of CHO cells treated with [Tb.L^JCb, are shown in Figure 4.12. 
The control cells (Figure 4.12a) show the lysosomal distribution typical of [Tb.L^JCb 
after 4 h incubation. Upon treatment with chloroquine (b), the lysosomes appear to be 
larger. This is likely to be due to the inhibition by chloroquine of the maturation of the 
endosomes to lysosomes .The relative luminescence intensity, however, remains 
unchanged. Cells which had been pre-treated with chlorpromazine (c) and filipin (d) 
show a similar luminescence pattern and intensity to the control cells. In contrast, 
treatment with wortmannin (e) results in a marked reduction in the luminescence 
intensity, while cells treated with the diacylglycerol (f) exhibited a higher level of 
luminescence, which was evident in the requirement for a shortened image acquisition 
time. 
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Figure 4.12: Fluorescence microscopy images showing luminescence of (a) [ T b . L ' l C l j (50 nM, 4h) in 
CHO cells (a) without pre-incubation and following 30 min pre-incubation with (b) 10 nM chloroquine, 
(c) 50 n M chlorpromazine, (d) 1 mg/mL fi l ipin , (e) 300 nM wortmannin and (f) 500 ng/mL 1,2-
dipalmitoyl-rac-diacylglycerol. 
For all the complexes and cell types studied, a comparison could be made of the 
luminescence intensity relative to that of the control. A summary of results is shown in 
Table 4.3. While the assessments of the relative luminescence intensity are somewhat 
arbitrary, they nonetheless demonstrate clear trends in the behaviour. Treatment with 
sucrose, chlorpromazine, filipin, monensin, chloroquine and poly-L-lysine did not result 
in significant luminescent changes. Treatment with wortmannin and amiloride, on the 
other hand, generally resulted in decreased luminescence intensity, while treatment with 
phorbol 12-myristate-13-acetate and 1,2-dipalmitoyl-rac-diacylglycerol gave rise to 
increased luminescence intensity. Since these are inhibitors and activators of 
macropinocytosis respectively, the microscopy results provide evidence for this 
endocytotic mechanism. 
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Table 4.3: Summary of microscopy results for various lanthanide complexes in (a) CHO, (b) NTH 3T3 and (c) HcLa cells. 
Symbols indicate the strength of the effect ranging from (— much weaker to +++ much stronger luminescence than from control cells), O denotes luminescence intensity 
approximately equivalent to the control. 
Complex 
Treatment [Eu. L ' l C b [Eu.L " i C l j [Eu.L "]Cl3 [Eu.L ""IClj [Tb .L ' lCb [Eu. L ' l C l j [Eu.L "]Cl3 
a b c a b c a b c a b c a b c a b c a b c 
Sucrose o 0 + 0 + 0 o o 0 - - 0 + 0 o - 0 + 0 0 o 
Chlorpromazine 0 + o 0 ++ o 0 0 0 o - 0 o o o - - o + o o 
Filipin - o - o o o -- 0 - 0 0 0 - o 0 - o - o o 
Wortmannin - - -- . . . - - -- -- - - - -- - . . . - -- . . . - -- - . . . -
Amiloride - . . . -- -- . . . -- -- . . . . . . . . . . . . - - . . . -- - . . . - . . . -- -
Phorbol 12-myristate-13-acetate ++ ++ + ++ +++ ++ +++ ++ + +++ + ++ + +++ 0 ++ +++ + +++ ++ ++ 
1,2-Dipalmitoyl-rac-diacylglycerol ++ ++ o +++ ++ + +++ o ++ ++ +++ + +++ ++ + + ++ ++ ++ 0 + 
Monensin 0 0 + + 0 o 0 o - -- - o 0 + o + 0 o 0 0 -
Chloroquine 0 -- 0 - o + 0 o + 0 - + 0 o ++ 0 0 + 0 - -
Poly-L-lysine + o 0 0 - + o + + o 0 o + 0 o 0 o o ++ + o 
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While this method did not provide quantitative results, it allowed study of a broad range 
of complexes and cell types. Examination of the morphology of the cells also enabled 
confirmation that the drugs were not being administered at cytotoxic concentrations. It 
was necessary, however, to confirm the conclusions drawn from these observations by a 
quantitative method. 
4.5.3 Results of ICP-MS analysis 
The intracellular concentration of lanthanide was therefore determined by a combination 
of the BCA assay and ICP-MS. Immediately after incubation with complex, cells were 
lysed with 500 nL lysis buffer. Three 25 aliquots were taken for analysis by the BCA 
assay, and a 400 \JLL aliquot submitted for ICP-MS. In this way, any lanthanide that was 
within the cell at the end of the incubation time was measured by ICP-MS. In this 
method, it was important to thoroughly rinse the cells with PBS prior to lysis to ensure 
that only intracellular complex was being measured. 
Initial studies of the BCA assay using both CHO and NIH 3T3 cells revealed that CHO 
cells gave more consistent results. This cell line was therefore used for all subsequent 
uptake studies. A range of complexes was tested by this method, which exhibited 
varying lipophilicities and localisation behaviour. 
The uptake results are shown in Figure 4.13, and demonstrate a behaviour that is 
consistent with macropinocytosis. Both wortmannin and amiloride result in decreased 
uptake of all complexes, while the phorbol ester and fatty acid glycerol enhance uptake. 
The other drug treatments did not result in significant variations from the control. 
The strongest inhibitory effect on uptake was observed when cells were incubated at 4 
°C. This indicates that an energy-driven cellular process is responsible for cellular 
transport, which provides further support for the conclusions drawn in Section 4.3. 
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Figure 4 .13: Relative changes in uptake of [Eu.L^lCl j (blue), [Tb.L*"] (red), [Eu.L*"]Cl3 (green), [ T b . L ' l C l , (yellow), [ E U . L ' J C I J (purple) and 
[Eu .L"] (0Tf )3 (pink) following drug treatments (CHO cells, 50 | i M complex, 4h incubation). n=4 
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While Figure 4.13 shows all intracellular concentrations relative the control case, it is 
valuable to compare their magnitudes. Table 4.4 shows the intracellular concentrations 
measured for CHO cells treated with each complex alone. The values are all of a similar 
order of magnitude, and do not appear to vary according to structure. For example, 
[Tb.L^JCb and [Eu.L' jCh, which are the most structurally similar exhibit the greatest 
difference in intracellular concentration. 
Table 4.4: Intracellular lanthanide concentration after 4 h incubation (CHO cells, 50 | i M complex) 
Complex [Ln]i (nmol / mg protein) 
[Eu .L ' jC l j 4.13 
[Tb.L^"] 2.87 
[Eu.L*°]Cl3 5.15 
[Tb .L ' lC l j 10.7 
[Eu.L' jCU 0.95 
[Eu.L"]Ci3 7.42 
4.6 Exploring the macropinocytotic pathway 
4.6.1 Confirmation of macropinocytosis 
The microscopy and ICP-MS studies therefore indicate that endocytosis occurs via 
macropinocytosis. An uptake mechanism of macropinocytosis suggests that the 
lanthanide complexes should be localised within the macropinosomes at eariy time-
points. A co-localisation study was therefore performed to confirm this hypothetical 
transport pathway. The fluorescein-labelled dextran conjugate (MW 70 kD) has been 
shown to be internalised by macropinocytosis, and can therefore be successfully used as 
a marker for the macropinosomes in fluorescence microscopy studies. '^"'" "'^ 
CHO and NIH 3T3 cells were incubated with 100 nM [Eu.L' jCh, [Eu.L^^JCh or 
[Eu.L ' jCbfor 15 min in the presence of FITC-dextran (2.5 mg/mL), after which time the 
cells were visualised by microscopy. In every case the europium luminescence showed 
good co-localisation with the fluorescein fluorescence. An example set of images is 
shown in Figure 4.14. This study confirms the hypothesised endocytotic mechanism 
established above. 
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Figure 4 . 1 4 : Fluorescence microscopy images of CHO cells treated with [Eu.L^^jCh (100 nM) and FITC-
dextran (70 kDa, 2.5 mg/mL) for 15 min. (a) Eu luminescence, (b) fluorescein fluorescence and (c) 
colocalisation image. Scale bar represents 20 juti. 
4.6.2 Implications of uptake by macropinocytosis 
There is very strong evidence, therefore, for an uptake mechanism of macropinocytosis. 
It is important to consider whether the observed behaviour of the complexes is consistent 
with the current understanding of this pathway. 
Both clathrin-coated pits and caveolae contain receptors to which a ligand must bind to 
induce endocytosis.'^* This binding event has a high structural specificity. It is unlikely 
therefore, that the broad array of complexes, which differ so markedly in geometry, 
charge and lipophilicity, should all bind to these receptors. Macropinocytosis, on the 
other hand is not a receptor-mediated process; macropinosomes do not concentrate 
receptors,'^ '^ ^ and the intemalisation process is relatively non-specific."^^ The observation 
that the broad range of lanthanide complexes studied are all internalised by 
macropinocytosis is consistent with its lack of specificity. 
While macropinocytosis is not a receptor-mediated process, it does require a number of 
signalling factors. Ruffling of the cell membrane is mediated by various GTPases 
belonging to the Ras superfamily,"' while closure of the ruffles to form the 
macropinosomes requires different signals including phosphatidylinositol 3-kinase.'^* 
Further work would be required to determine what triggers such signalhng pathways in 
the case of the lanthanide complexes. 
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A second imponant consideration in examining endocytotic pathway is the fate of the 
generated vesicles. The downstream route of the macropinosome has not been fully 
elucidated, and appears to differ between cell t y p e s . W h i l e macropinosomes in 
macrophages have been observed to fuse with endosomes,"^ in fibroblasts they appear 
not to transfer their contents to the endosomal p a t h w a y . T h e large size of the 
macropinosomes compared to other vesicles is believed to render them more leaky, 
readily releasing their contents into the cytoplasm.^^^ It is possible that, from there, they 
are then trafficked to different locations within the cell. The fact that the 
macropinosomes do not deliver their contents to a single location is consistent with the 
observation that all lanthanide complexes studied are endocytosed by the same 
mechanism, despite their very different subsequent sub-cellular localisations. 
4.7 Conclusions 
In designing luminescent lanthanide complexes for use as cellular probes, it is important 
to assess whether the cell membrane is permeable towards these complexes. If, for 
example, only certain complexes were transported across the cell membrane, then their 
structural features would need to be conserved in future complex design. I f no 
complexes showed sufficient cellular uptake, it would be necessary to make structural 
modifications, such as the conjugation of a cell-penetrating peptide or encapsulation into 
a liposome. 
The results of this study have shown that all lanthanide complexes investigated are able 
to cross the cell membrane. Cases in which complexes are only poorly visible by 
microscopy can be attributed to higher in cellulo quenching rather than to decreased 
uptake. Each lanthanide complex studied seems to enter cells by the mechanism of 
macropinocytosis. It is likely that this pathway contributes to the fact that such a broad 
range of complexes is internalised, and that complexes show diverse distribution patterns 
within the cell. 
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CHAPTER F I V E 
SUB-CELLULAR SPECIATION 
OF COMPLEXES 
C H A P T E R F I V E : S U B - C E L L U L A R SPECIATION O F C O M P L E X E S 
5.1 Introduction 
Chapters Three and Four have discussed the localisation and uptake behaviour 
respectively of the luminescent lanthanide complexes. Another important aspect of 
cellular behaviour is the fate of the complexes in cells, and the form which those 
complexes will take in cellulo - that is, their sub-cellular speciation. 
The cell contains many species which can interact with an exogenous compound and 
alter its function. For example, complexes may be oxidised, reduced, methylated or 
hydrolysed by various enzymes. In addition, they may be conjugated to amino acids, 
sugars or thiols, or they may bind to proteins.'"" These interactions may exert negative or 
positive effects on the function of a probe or drug. 
There are many examples of drugs which are inactivated by metabolic events. The main 
challenge in the design of orally-active drugs, for example, is to prevent any such 
inactivation from occurring before the drug reaches its target." '^ Furthermore, drug 
metabolism to toxic forms has been implicated as the principal source of hepatotoxicity 
in clinical drug trials.^^'' While considerably less work has been performed 
concerning the inactivation of probes by cellular events, it can be assumed that the same 
principles apply. 
In contrast, many drugs and probes are activated by sub-cellular events. In order to 
overcome the toxicity effects which drugs may exert as they travel from the point of 
administration to the point of activity, much drug design utilises pro-drugs, which are 
activated by metabolic events in the cell.^ '^' This principle has also been applied to the 
design of molecular imaging probes. There are many examples of probes which are 
administered as cell-permeable, but less fluorescent, esters, and are then hydrolysed by 
esterases within the cell to a fluorescent form.'^ For example, hydrolysis of the ester 22a 
to the ketone 22b results in dramatic changes in the fluorescence emission and excitation 
spectra (Scheme 5.1). 235 
22a 22b 
X a^x (abs) = 773 nm, X r m , (em) = 796 nm W (abs) = 500 nm, X ^ ^ (em) = 597 nm 
Scheme 5.1 
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Another example of an activatable probe is an avidin-rhodamine X complex, which is 
self-quenching. The avidin has an affinity for the lectin expressed on cancer cells, and 
the complex is therefore endocytosed by cancer cells, before being transferred to the 
lysosomes. Here, the protein is hydrolysed, resulting in release of the rhodamine X, and 
a concomitant return of fluorescence. In this way, the complex can act as a selective 
marker for cancer cells 236 
In assessing the suitability of a cellular probe, therefore, it is important to consider its 
speciation, and whether it affects the intended purpose. This chapter describes work 
which has been performed to study sub-cellular speciation of certain complexes, by 
presenting examples of four specific cellular interactions: hydrolysis, dissociation, anion 
binding and protein binding. 
5.2 Sub-cellular speciation 
5.2.1 Enzyme hydrolysis 
The observation of enzyme hydrolysis requires that the hydrolysed and non-hydrolysed 
form of the complex have different spectral properties. This is the case for the series of 
complexes [EU.L']^"^ and [Eu.L''], in which hydrolysis of the ethyl ester arms results in a 
marked change in the luminescence emission profiles. This change is most evident for 
the alanine system, [Eu.L^*]^"^, for which there are large changes in the AJ = 2 and = 4 
bands (Figure 5.1). 
EtOjC 
eto,c 
H,C-{ 
COjEt 
[Ln.L^'f 
•o,c 
•OjC 
HN / 1 
CH3 0-i:_--lni:j 
NH 
H 3 C - ( 
C02-
(Ln.L* 
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Figure 5.1: Emission spectra of [Eu.L^"]^" (red) and [Eu.L*"] (blue) solutions (DjO, 295 K, ) ^ ,= 348 nm) 
In order for this hydrolysis event to be observable in cells, the complex must be a 
substrate for hydrolytic enzymes. To study this, an aqueous solution of [Eu.L''*]^^ was 
treated with two different hydrolytic enzymes, and the emission spectrum monitored 
over time. The two enzymes selected were chymotrypsin and pig liver esterase (PLE). 
Chymotrypsin is a proteolydc enzyme which cleaves on the C-terminal side of the 
aromadc amino acids tyrosine, tryptophan and phenylalanine." PLE is a 
238 
carboxylesterase which is commonly employed in organic synthesis. The complex 
soludon was prepared using phosphate buffered saline (pH 7.4), and the experiment 
performed at 37 °C to mimic biological condidons. 
Treatment of [Eu.L^"]^^ with PLE did not give rise to any changes in the emission 
spectrum over a two week period. Treatment with chymotrypsin, on the other hand, 
resulted in a very rapid decrease in the band at 6 2 0 nm (Figure 5.2). In addidon, an 
overall quenching of luminescence was observed. This is consistent with the findings 
presented in Chapter Two (page 58) , which showed that [Eu.L**] is more susceptible to 
quenching by endogenous anions than [Eu.L''^]''"^. The change in the rado of intensities at 
614 nm and 620 nm over time indicates that the hydrolysis occurs over the first ten 
minutes, and then remains constant (Figure 5.2 inset). The I6i4nm/feonm ratio for 
[Eu.L'*^] and [Eu.L^^]^"" are 3.2 and 1.0 respectively, while the value reached on enzyme 
treatment is 2.2. This indicates that enzyme hydrolysis has not gone to completion. 
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Time / mm Increasing 
time 
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Wavelength / nm 
Figure 5.2: Emission spectra (X x^ = 348 nm) of [Eu .L^^lClj (blue) and 10 min (red) and 4 h (green) after 
U-eatment with chymotrypsin (37 °C, pH 7.4). Inset: Change in the luminescence intensity ratio 
I6i4nm / l620nni w'th time after treatment with chymotrypsin 
These results indicate that [EuX^"]^"^ is susceptible to hydrolysis by biologically-
occurring enzymes. It was therefore of interest to assess the in cellulo speciation of the 
complex, by collecting an emission spectrum of the complex in whole cells. This was 
achieved by incubating cells with the complex (50 ^tM, 4h), washing the cells thoroughly 
with PBS to ensure only complex in the cell would be measured, and rapidly harvesting 
the cells. The cell pellet was resuspended in 1 mL PBS and an emission spectrum 
collected. It was important that all steps were performed as quickly as possible to 
minimise complex egress from the cell. Over the time required to collect the emission 
spectrum, the cells began to settle to the bottom of the cuvette, resulting in decreased 
signal at higher wavelengths as the cells were no longer in the path of the beam. 
Multiple spectra were therefore obtained at a faster scan rate, and averaged to minimise 
noise. The mixture was shaken well between each data collection to ensure that the 
maximum amount of signal could be measured. 
The emission spectrum recorded from CHO cells treated with [Eu.L^ ]^^ "^  is shown in 
Figure 5.3. The spectral profile is very similar to that of the enzyme-treated complex in 
Figure 5.2. The I6i4 nm / l620 nm ratio, of 1.8, indicates that reaction has not gone to 
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completion. This result is consistent with expectation, as the cell contains a large range 
of esterases which would be expected to hydrolyse the complex. 
0.5 . 
0.4 
0.3 
<n I 0.2 
c 
0.1 
0.0 
570 600 630 660 
Wavelength / nm 
690 720 
Figure 5.3: Emission spectrum (A,, = 348 nm, PBS, pH 7.4) of CHO ceils treated with [Eu.L '°]Ci3 
(50 p M , 4h) 
5.2.2 Complex dissociation 
As discussed in Section 1.4.2.1 (page 19), the luminescent lanthanide design was based 
on the cyclen macrocycle in order to afford stable complexes. It is possible, however, 
that decomplexation may occur in cells. This was found to be the case for [Eu.L^']^^ 
<N 
HjO 0={ 
^ 
Previous studies of [Eu.L^"]'''^ described the formation of precipitate in solutions of 
NaHC03 or NaHP04, which was attributed to decomplexation of Eu(III) from the 
ligand."** It was therefore expected that such an event should be observable in cellulo. 
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CHO cells were treated with [Eu.L^^JCb (50 | j M ) , and prepared for microscopy as 
previously described. In addition to the standard filter set designed to measure Eu 
luminescence, a filter set was also selected to capture ligand fluorescence. A set of 
microscopy images obtained after 1 h incubation are shown in Figure 5.4. There is an 
observable difference between the distribution of Eu luminescence and ligand 
fluorescence, suggesting that dissociation has indeed occurred. The complex 
luminescence and ligand fluorescence for a number of other systems were visualised, but 
for no other complex was this phenomenon observed. 
(a) (b) (c) 
• *• 
Figure 5.4: Fluorescence microscopy images of CHO cells treated with [Eu.L^^JClj (50 ( iM, Ih), (a) Eu 
luminescence, (b) ligand fluoroescence and (c) image overlay. Scale bar represents 20 [xm. Image 
brightness and contrast have been altered. 
5.2.3 Anion binding 
Many of the luminescent lanthanide complexes that have been synthesised in Durham 
bind selectively to anions such as carbonate or phosphate. It is possible, therefore, that in 
cells, these complexes are bound to anions. [Eu.L* ]^^ "^ was studied for this purpose. 
Previous studies had identified selectivity for citrate and bicarbonate, and a marked 
change in the emission spectrum in the presence of a number of anions such as 
bicarbonate and phosphate.'""^  An emission spectrum of CHO cells treated with 
[Eu.L*^]Cl3 (50 ^iM, 4h) was therefore obtained (Figure 5.5). 
135 
C H A P T E R F I V E : S U B - C E L L U L A R S P E C I A T I O N O F C O M P L E X E S 
14 
12 
10 
8 
6 
4 
2 
0 
570 600 630 660 
Wavelength / nm 
690 720 
Figure 5.5: Emission spectrum (X^, = 335 nm, PBS, pH 7.4) of CHO cells treated with [ E U . L ' ° ] C 1 3 
(50 | i M , 4h). 
While the emission profile collected from cells is not sufficiently well resolved to allow 
accurate calculation of intensity ratios, it does reveal valuable information about the 
relative intensity of transitions, which can be used to determine the species which are 
bound to the complex. Taking into account the tail of the protein fluorescence (from 
approximately 400 to 600 nm), AJ = 2 / AJ = 1 and AJ = 2 / AJ = 0 ratios can be 
calculated and compared to that of the complex alone, and in its various bound forms 
(Table 5.1). 
Table 5.1: Relative peak intensities for [ E U . L ' ° ] ' * after various treatments. 
Treatment M = 2/\J = 1 \J = 2/M = 0 
Complex alone ^  2.2 3.3 
HCO3" (0.5 mM)^ 2.2 7.2 
HPO4^"(0.5 mM)^ 2.3 9.0 
HSA (0.35 mM) ^ 2.3 5.4 
HSA (0.35 mM) + HCO3" (30 mM) ' 3.3 15 
CHO cells 3.1 14 
^ Values previously reported"" 
The AJ = 2 I AJ - \ and AJ = 2 / AJ = 0 ratios observed from the complex in cells are 
most similar to the complex in the presence of both bicarbonate and HSA. This suggests 
that, in addition to being associated with protein in cellulo, the complex is also binding 
to intracellular bicarbonate. These results indicate that [Eu.L*^]^"^ has potential utility as 
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a probe of bicarbonate concentration, but that calibration would need to be performed in 
the presence of protein. 
5.2.4 Protein binding 
Due to the high intracellular concentration of protein, a number of studies have 
investigated the effect of protein binding on the in vitro properties of luminescent 
lanthanide complexes . '^^ '^ The studies reported in Section 2.4.2 (page 60) of the 
variation of luminescence lifetime with the addition of BSA revealed a range of 
affinities, which span a 2-log range. These association affinities do not appear to 
correlate with lipophilicities (Table 5.2). In addition, these complexes, despite their 
vastly different protein association behaviour, exhibited identical lysosomal localisation. 
Table 5.2: Comparison of protein binding data to logP values for complexes with common ligands 
Ligand 
Ka for protein binding 
(Tb complex) 
Limiting T O / T value 
(Tb complex) 
LogP 
(Eu complex) 
1.18 X 10' 1.4 -1.34 
6.60 X 10^  3.4 -2.06 
9.44 X 10- 3.2 -1.15 
1.46 X 10- 7,6 -1.56 
2.14 X IC* 3.2 -0.16 
To date, these studies have assumed that this association of lanthanide complexes with 
protein observed in vitro also occurs in cellulo. It is important, however, to demonstrate 
that complexes do interact with protein in a cellular environment. Analysis of the 
emission spectrum of [Eu.L**]'''^ described above (Figure 5.5) provides evidence for 
intracellular protein binding. Further evidence was obtained from the study of 
[EU.LY^' ' ' 
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V 
[Eu.L*] 
Addition of aqueous solutions of citrate (0 .13 mM) or HSA (0.4 mM) to [EU.L"]^"^ led to 
a reduction in the intensity of the europium emission, in addition to changes in spectral 
form (Figure 5.6). In each case, the europium emission lifetime changed by less then 
10%. These spectral changes are consistent with dissociation of the chelating nitrogens 
of the sensitiser. 
I 
400 450 500 550 600 
Wavelength / nm 
650 700 
Figure 5.6: Emission spectra (Xe, = 355 nm) of [ E U . L ' J C I I (red) and in the presence of 0.13 mM citrate 
(green) and 0.4 m M HSA (blue). 
CHO cells were treated with [Eu.L']Cl3 (50 |aM, 6h) and an emission spectrum recorded, 
as described above (Figure 5.7). Cells treated in an identical manner were also visualised 
by fluorescence microscopy, and at this time-point a predominant lysosomal localisation 
was observed. This confirmed that the emission spectrum obtained corresponded to 
intracellularly localised complex. The spectral form collected in this manner is very 
similar to that of the spectrum of complex in the presence of HSA (Figure 5.6). This 
suggests that the in cellulo form of [EU.L'JCIS is protein-bound. 
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Figure 5.7: Emission spectrum (A,, = 355 nm, PBS, pH 7.4) of CHO cells treated with [ E U . L ' J C I . I 
(50 nM, 6h) 
These results have demonstrated that protein binding is an important aspect of sub-
cellular speciation. It is therefore important to consider the effect of protein binding on 
other aspects of probe behaviour. One species for which this is relevant is [Tb.L*]^"^, 
which was demonstrated to have a clear and reversible variation of intensity on changing 
pH.'^' It was therefore postulated that [Tb.L*]"''^ may have potential utility as an in 
cellulo pH probe. In order to test this behaviour, the pH titration was repeated in the 
presence of HSA (0.4 mM; Figure 5.8 overleaf)-
o 
N N 
[Tb.n-'* 
The resulting titration curve indicates very different behaviour to that observed in the 
absence of protein. This could be due to the fact that in the presence of protein, the 
chelating nitrogens of the sensitiser are dissociated at all pH values, while in the absence 
of protein this dissociation event only takes place at relatively high pH. The altered 
spectral properties may also be due to the fact that the intensity ratio utilised measures 
the ratio of Tb^^ emission intensity against the residual ligand fluorescence. The HSA 
itself, however, fluoresces in the same region as the ligand fluorescence, thus interfering 
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with the measurement. As a result of this investigation, it was concluded that [Tb.L^]^"^ is 
not a suitable candidate for use as an intracellular pH probe. This work highlights the 
importance of testing probe behaviour in a biologically-relevant context. 
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Figure 5.8: Variation of the ratio of Tb''* emission intensity versus residual ligand fluorescence with pH 
for [Tb.L*]^^ in the absence ( • ) and presence (•) of HSA (0.4 mM) (295 K, 0. I M NaCl) 
This pH study of [Tb.L*]^"^ provides an example of how protein binding can strongly 
perturb probe behaviour. However, protein interaction can also have positive effects on 
such activity. The clearest example of this is the alleviation of quenching which has been 
observed in the presence of protein, as discussed in Section 4.2.2 (page 112) and 
elsewhere.* '^ '"^ ^ This behaviour ensures that, even in the presence of intracellular 
quenchers, the probe has sufficient in cellulo luminescence to be visible by microscopy. 
It is therefore important to assess the effects of protein binding on the behaviour of each 
potential probe. The following section discusses one specific case of protein binding, 
which was found to exhibit unprecedented behaviour. 
5.3 Stereoselectivity of protein interactions 
As discussed in Section 2.4.2 (page 60), the binding of complexes to protein can be 
studied by measurement of the emission lifetime. This enabled comparison of the 
binding associations of a range of complexes with BSA. Complexes such as [Tb.l] 
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exhibited only weak, non-specific interactions, while [Tb.2]^"^ showed apparently strong 
1:1 binding. 
IN 
• — L n ; . I 
The stereospecificity of the association was investigated by comparing the binding 
isotherm for f555)-[Tb.L^]^^ to that of the enantiomer, (RRR)-[Th.lJf^ (Figure 5.9). 
Incremental addition of BSA to f555j-[Tb.L^]^^gave rise to a well-defined binding curve 
reaching a limiting-value, consistent with an interaction with one major protein binding 
site. The corresponding curve for (RRR)-[Th.L^]^'^ was more complex in form, 
suggesting that the complex is interacting with up to three protein binding sites of 
different affinities, which have different effects on the emission lifetime. This suggests 
that the two enantiomers interact differently with BSA. 
1.8 
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Figure 5.9: Quenching of the luminescence lifetime, t , upon addition of BSA to (SS5j-[Tb.L \ * (•, 
showing the fit to the observed data for a 1:1 complex, logK = 5.1) and (RRR)-[Vo.\}f* ( A ) (295 K, 
pH 7.4, 0.1 M HEPES, 10 \M NaCl, 30 (iM complex, Xex= 348 nm) 
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5.3.1 CPL studies in the presence of protein 
In order to study these enantiospecific effects in more detail, CPL spectroscopy studies 
were performed in the presence of BSA, and the resulting spectra compared to the 
spectra of the complexes alone. Addition of BSA to (SSS)-[Eu.L^f'^ resulted in a marked 
change in the CPL spectrum (Figure 5.10). Most transitions are inverted in sign, in 
addition to the decreased overall emission resulting from quenching by the protein. '^"^  
630 660 Veao 720 
Wavelength / nm 
Figure 5.10: CPL spectra for (SSSj-tEu.L^]'* in the absence (blue) and presence (red) of 15 (xM BSA 
(DjO, 295 K, = 348 nm) 
The same experiment was performed with the enantiomer, (RRR)'[Eu.L^]^'^ (Figure 
5.11). While the CPL spectrum of the complex alone is the mirror image of that of its 
enantiomer, the spectrum of the BSA-treated sample is markedly different; in this case, 
it follows the same form as the untreated sample. This suggests that the complexes 
interact with BSA in a stereospecific manner, in agreement with the observed 
differences in the quenching behaviour (Figure 5.9). 
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Figure 5.11: CPL spectra for (RRR)-[Eu.h^]^* in the absence (blue) and presence (red) of 15 (iM BSA 
(D2O, 295 K, A^, = 348 nm) 
The same effect was observed for Tb^ "^  complexes: there was a marked change in the 
spectral form for (5S5j-[Tb.L^]'^ (Figure 5.12) but not for (RRR)-[Tb.L'] 2^ 3-^  
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Figure 5.12: CPL spectra for r5SS)-[Tb.L^]'* in the absence (blue) and presence (red) of 15 nM BSA 
( D 2 O , 295 K, A^, = 348 nm) 
Attempts were then made to identify any other complexes which behaved in a similar 
fashion. The only complex for which similar behaviour was observed was the activated 
form of [Ln.L^]^*, in which the pendant arm opposite the chromophore was converted 
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into an ester form for conjugation to other groups. The CPL spectra of a number of other 
complexes, including [Ln.L^]'^ [Ln-L^*], [Ln.L*^] and [Ln.L***], were obtained in the 
presence of BSA. In no case did the addition of protein change the form of the CPL 
spectrum. The spectra of f55S>[Eu.L''']^'^ before and after BSA addition are shown as an 
example (Figure 5.13). [Ln.L^]^^ and [Ln.L'*] possess the same chromophore as 
[Ln.L^]^^ while [Ln.L*^]^^ and [Ln.L""]^^ bear the same pendant arms, and yet neither 
set of complexes exhibits this enantiospecific behaviour. It appears, therefore, that it is 
the specific structure of [Ln.L^]^^, and not any one component of its structure, which 
interacts with BSA in this peculiar fashion. 
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Figure 5.13: CPL spectra for (555)-IEu.L^"]^* in the absence (blue) and presence (red) of 15 n M BSA 
( D 2 O , 295 K, X^, = 348 nm) 
The CPL profile of (SSS)-[Eu.L^f* in the presence of BSA is similar to the spectrum of 
(555;-[Eu.L^'']^* (Figure 5.14). The characterisation described in Chapter Two 
concluded that fS55)-[Eu.L'"']^^ adopted a A(8858) configuration, in contrast to the 
A(klXk) configuration observed for (5S5)-[Eu.L^]"^'^. It appears, therefore, that binding to 
BSA induces a helicity change in the complex. 
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Figure 5.14: Comparison of the CPL spectrum for (SSSj-lEu.L*"]^^ (blue) widi that of (S55)-[Eu.L^]''' in 
the presence of 15 nM BSA (295 K, = 348 nm) 
The effect of HSA on the CPL spectra was also studied, with spectra showing a similar 
form to BSA-treated spectra, as can be seen from the calculated emission dissymmetry 
factors (gem; Table 5.3). This is consistent with findings that HSA and BSA display 
approximately 76% sequence homology, with strict conservation of the disulfides which 
maintain the overall structure.^ '*' Furthermore, studies of the binding sites of the two 
proteins have indicated similarities in these regions.^ "*' 
Table 5.3: Emission dissymmetry factors for Eu complexes (in D 2 O at 295 K, A^, = 348 nm) 
Complex gein(S<W) gem(597) geni(616) geni(620) gein(624) gein(651) 
(SSSj-lEu.L^]'"' H-0.22 -0.31 -0.048 -1-0.10 -1-0.048 +0.27 
(SSSj-lEu.L^]'-" + BSA -1-0.018 -0.14 -1-0.020 -^0.017 -0.023 -0.066 
fSSSj-lEu.L^l'^H-HSA -t-0.051 -0.25 +0.040 -1-0.042 -0.023 -0.21 
(5SS)-[Eu.L^]^* + A A G -1-0.083 -0.11 -0.021 -f-0.032 +0.027 +0.035 
(RRR)-lEu.lJf* -0.17 -1-0.22 -1-0.041 -0.071 -0.042 -0.23 
(/?/?/?j-[Eu.L^]^*-i-BSA -0.14 -1-0.19 -1-0.043 -0.085 -0.061 -0.17 
(RRR)-[Eu.l/]^ + HSA -0.095 -1-0.13 -1-0.12 -0.036 -0.020 -0.082 
(RRR)-lEu.Vf^ + A A G -0.14 -1-0.16 -1-0.024 -0.032 -0.035 -0.10 
In order to further study this phenomenon, the effect on CPL behaviour of another 
conmion protein was studied. Oi-Acid glycoprotein (AAG) is a major serum 
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carbohydrate-containing protein which has been isolated and characterised from many 
mammals.'^ '*'' Addition of A A G to each enantiomer of [Eu.L^]^* resuhed in a 
reduction in the gem values, but no change in the sign of the transitions (Table 5.3), 
suggesting that the change observed for the serum albumins is not typical of all proteins. 
The effect of the interaction of the two complexes with a chiral anion was studied by 
addidon of R and S enantiomers of phenylsuccinate. This salt was selected due to its 
negative charge, which wi l l encourage ion-pairing with the cationic complex. There was 
no change in the CPL spectra on addition of these salts. 
In order to better understand the changes in the helicity, a series of CPL spectra were 
obtained with increasing concentrations of BSA (Figure 5.15). The spectra changed 
considerably on addition of BSA up to 1 0 | j M , and then remained constant. Monitoring 
the CPL intensity at individual wavelengths confirmed these observations. 
Increasing 
[BSA] 
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0.3 
0.2 
i 0 
- -0.1 
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Figure 5.15: C P L spectra for rS5S)-[Eu.L^]'* in the absence (blue) and presence 2 (red), 5 nM 
(green), 10 |iM (purple) BSA ( D 2 O , 295 K, A^, = 348 nm). Inset: Change in the C P L intensity at 590 nm 
(•) and 616 nm ( A ) with increasing BSA. 
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A final experiment which was peri'ormed using CPL spectroscopy was the study of the 
spectrum obtained from cells treated with f555j-[Eu.L^]^^. CHO cells were treated and 
prepared as described in Section 5.2.1 above, and a CPL spectrum recorded (Figure 
5.16). A CPL spectrum of untreated cells was also obtained, which shows only 
background noise. The CPL spectrum of the complex in CHO cells is most similar in 
form to the spectrum obtained in the presence of 2 or 5 |a.M BSA. Since the intracellular 
concentration of albumin is likely to be of the order of 10 to 100 times higher, it appears 
that only a fraction of the complex is bound to albumin. It is possible that the complex is 
more strongly bound by other proteins in the cell. 
0.2 ! 
720 
-0.8 Wavelength / nm 
Figure 5.16: C P L spectra of CHO cells alone (blue) and cells treated with (555)-[Eu.L^]-^'' (red; 50 [M, 
4h; spectra collected in H 2 O , 295 K, X^^ = 348 nm) 
5.3.2 Probing the protein binding site 
The quenching and CPL studies suggest that f555J-[Eu.L^]^"^ binds to serum albumin in a 
different manner to the binding of other lanthanide complexes. This aspect was studied 
further by seeking to identify the binding site of serum albumin with which the complex 
interacts. Since most previous experiments of serum albumin behaviour concentrate on 
HSA, further experiments were conducted with this isoform alone. HSA contains two 
major binding sites, named site I and site I I (Figure 5.17).^ '^ ^ Early investigations of the 
binding sites of HSA revealed a number of fluorescent probes which bind to each site 
and are non-fluorescent in solution, but fluoresce in the ultraviolet-blue on HSA 
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binding.^"^^ These studies established the commonly-employed fluorescence method for 
determining the binding site targeted by a particular compound, in which the 
displacement of these fluorescent probes is monitored by measuring emission changes. 
This technique has been successfully utilised for the study of lanthanide complexes in 
examining the interactions of various gadolinium complexes, used as contrast agents for 
drug 
site I 
drug site II 
Figure 5.17: Structure of HSA as defined by crystallographic studies, showing the two drug binding sites. 
Adapted from Ghuman et a/.""' 
In order to perform binding site studies, dansyl sarcosine, a marker for drug site I I , was 
synthesised by condensation of dansyl chloride with sarcosine in aqueous acetone 
(Scheme 5.2). 
o I o 
OH 
OH 
NMe2 NMe2 
Scheme 5.2 
Attempts were made to study the displacement of the site I markers warfarin and dansyl-
L-asparagine, and the site I I probes, dansyl sarcosine and dansyl proline, by both Eu and 
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Tb complexes of L^, using the fluorescence methods reported in the literature. This 
proved to be unsuccessful as the complexes themselves perturbed the fluorescence of the 
dansyl group. Titration of the complex into a solution of the probe (in the absence of 
HSA) led to a linear increase in the fluorescence. For example, addition of one 
equivalent of ('55'5>[Tb.L^]"'"^ to dansyl sarcosine led to a 37% increase in fluorescence, 
while addition to dansyl proline led to a 230% increase. As a result, the probes would 
still fluoresce, even on displacement from the protein. These results indicated that this 
method could not be utilised for the study of the binding of these complexes to HSA. An 
alternative method was therefore required. 
Previous studies had revealed marked changes in the relaxivity of (SSSHGd.L^f'^ on 
73 protein binding, with a greater than four-fold change in relaxivity on binding of HSA 
It was therefore postulated that changes in the relaxivity could be utilised to study 
binding site interactions. Experiments were performed in 5% MeOH to overcome the 
insolubility of warfarin, which was used as a probe of drug site I . Addition of HSA to 
(RRR)-[Gd.lJ'f'*^ resulted in a very similar relaxivity curve to that of its enantiomer 
(Figure 5.18). Based on these titration curves, an HSA concentration of 0.4 mM was 
selected for subsequent studies to ensure complete binding of the complex to the protein. 
14 
12 . 
10 
4 
2 
0 
• A " 
A 
. A 
0.1 0.2 0.3 0.4 0.5 
[HSA]/mM 
0.6 0.7 0.8 
Figure 5.18: Variation of the proton relaxivity (310 K, 60 MHz) of fSSSMGd.L^]'* ( A ) and 
(RRRHGd.h^f-im) with added HSA. 
Dansyl sarcosine and warfarin were titrated into the [Gd.L^]^*: HSA mixture for both 
(SSS) and (RRR) isomers, and the relaxivity monitored. The relaxivity of ('5SSj-[Gd.L^]^'' 
rapidly decreased on addition of dansyl sarcosine, reaching a limiting value of 
approximately 3 mM''s"', which is similar to the relaxivity of the free complex (Figure 
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5.19). This suggests that dansyl sarcosine is able to displace the complex from drug site 
I I . In contrast, the identical experiment with (RRR)-[Gd.L^]^^ resulted in no such 
decrease in the relaxivity. The limiting relaxivity value is reached after addition of 
approximately 1.2 equivalents of dansyl sarcosine. This suggests that both 
(SSS)-[Gd.L^f'^ and dansyl sarcosine have very similar affinides for HSA. This is 
consistent with the reported logK for dansyl sarcosine of 5.2,""^ which is similar to the 
measured value for (5S5)-[Gd.L^]^'' of 5.1, reported here (Table 2.5, page 62). 
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Figure 5.19: Variation of the proton relaxivity (310 K, 60 MHz) of a mixture of HSA (0.4 mM) and 
1.7 mM[f5S5)-Gd.L^]'"'( A ) or [(RRR)-G±V]^ (•) with added dansyl sarcosine. 
The same experiment was performed with warfarin, a marker for drug site I (Figure 
5.20). For neither (5S5)-[Gd.L^J^'^nor (RRR)-[Gd.Vf^ was there a large decrease in the 
relaxivity, suggesting that neither complex binds to drug site I . 
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Figure 5.20: Variation of the proton relaxivity (310 K, 60 MHz) of a mixture of HSA (0.4 mM) and 
1.7 mM [(555)-Gd.L^]'*( A ) or l(RRR)-Gd.lJ]^(m) with added warfarin. 
It appears, therefore, that f555)-[Gd.L^]^"' binds to drug site I I of HSA, and that 
(RRR)-[Gd.lJ'f'^ binds to neither drug site. This differential binding between the two 
isomers is consistent with previously-reported findings that drug site I I is 
stereosf)ecific.''*^ The change in the CPL spectrum on interaction with HSA suggests that 
not only is f555)-[Gd.L^]'''^ binding to the protein, but its structure and helicity is also 
being altered on binding. 
For the f555j-[Gd.L^]^^ curve (Figure 5.18), saturation is reached at a protein 
concentration that is approximately one tenth of the complex concentration, suggesting 
that several complexes are binding per protein. This is likely to correspond to one 
complex in drug site I I , and the others associated with but not bound to protein. The 
relaxivity titration curve was obtained with an excess of complex, so reflects the 
relaxivity of a large proportion of associated complex, and a smaller proportion of bound 
complex. This explains the similarity with the relaxivity curve obtained for (RRR)-
[Gd.L^]^^, for which all complex is associated. On the other hand, CPL spectra were 
obtained with an excess of HSA. The complete change in the helicity observed in the 
CPL spectrum of (SSSHGd.L^f^ in the presence of HSA indicates that only bound 
complex is present. This indicates that the complex preferentially binds to drug site I I of 
HSA, rather than associating with multiple sites, which occurs only in cases of excess 
complex. 
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5.3.3 NMR studies of protein binding 
A further study designed to understand the complex binding properties involved 
saturation transfer difference (STD) NMR spectroscopy experiments, which were 
performed by Prof. Carlos Geraldes, Joao Teixeira and David Dias at the University of 
Coimbra (Portugal). Saturation transfer NMR spectroscopy is a technique which is 
commonly used to characterise the binding in ligand-receptor complexes.""^" The method 
involves saturation of the protein by selective irradiation. Any ligand protons that 
interact with the protein will also be saturated. Due to the equilibrium between bound 
and free form, the partially-saturated bound ligand will at some times be in solution. An 
NMR spectrum of this saturated form can therefore be collected (Figure 5.21). A 
spectrum of the non-saturated protein and ligand is also acquired, and the spectra 
subtracted, to give a saturation transfer difference spectrum. Only those ligand protons 
which were saturated (that is, which were bound to the protein) will appear in this 
difference spectrum. In this way, STD NMR can give information about the mode of 
binding of a ligand. 
in ^ irradiation / s a t u r a t i o r i ; ^ / ^ 
of protein^ ^ ^ C K ; ^ 
ligand 
NMR spectrum A NMR spectrum B 
STD spectrum = spectrum B - spectrum A 
Figure 5.21: Schematic diagram summarising the process of STD NMR 
In order to use the STD NMR technique, it was necessary to select a diamagnetic metal, 
which does not induce a shift in the ' H NMR spectrum of the complex. Yttrium(III), 
which is diamagnetic, is a good model for europium and terbium, with an ionic radius 
that is only 0.02A smaller than terbium(III) in nine-coordinate systems. As a result, the 
yttrium complex was synthesised from \ } using yttrium acetate. In the past, it was not 
possible to fully assign the ' H NMR spectra of \ } or [Eu.L^]^"^ because of the 
conformation flexibility of the ligand, and the broad peaks observed in the Eu complex. 
As a result, only the aromatic protons could be clearly identified. [Y.L'JCb, on the other 
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hand, was found to exist primarily as only one isomer which gave rise to sharp peaks. In 
addition, because of the close coupling of the protons, it was possible to obtain a well-
defined COSY spectrum (Figure 5.22), which aided the characterisation process. This 
enabled the assignment of most protons of the complex (see Section 8.2 for complete 
analysis). It was observed that while the protons of the aromatic regions of two pendant 
arms lay at approximately 7.3, the other set of protons lay more upt'ield, near 6.3. This 
suggests a deshielding ring current effect due to a through-space interaction with another 
aromatic system. Due to structural constraints, it was determined that such an interaction 
would arise between the chromophore and an adjacent pendant arm. 
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Figure 5.22: C O S Y NMR spectrum of f5SSj-[Y.L^]Cl3 (600 MHz, 295 K) showing partial assignments 
The aims of the STD NMR studies were to test for any difference between the behaviour 
of the (RRR) and (SSS) enantiomers, and to define the regions of the complex which bind 
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to HSA. STD NMR spectra were acquired with pre-saturation of the protein at -0.5 ppm. 
The resulting spectra are shown in Figure 5.23. 
} I I 
8 5 8.0 7.5 7,0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 
ppm 
9 5 9 0 8.5 8^ 0 7^ 5 7^ 0 6!5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 
p p m 
Figure 5.23: 'H STD NMR spectra of (SSS)- (upper) and (RRR)-[Y.V]Ch (lower) in the presence of 
30 )iM HSA (1 mM complex, 25 °C, DjO, 600 MHz, -0.5 ppm saturation) 
On first inspection, the spectra of the two enantiomers seem very similar. As a result, the 
STD amplification factor was calculated in order to better compare the spectra. The STD 
amplification factor is the relative intensity of the STD signal compared to that of a 
signal of the protein.^^' STD amplification factors for the two complexes are shown in 
Table 5.4. For all but three peaks, the difference in the relative amplified STD intensities 
is greater than 10%, indicating a significant difference between the ' H NMR STD 
spectra of the (RRR)- and (SSS)- enantiomers. This confirms that the two enantiomers 
interact differently with HSA, as was observed by CPL and binding site studies. 
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Table 5.4: STD amplification factors and relative STD (to the most shifted proton) for (555)- and (RRR)-
[Y.L^lClj in the presence of HSA 
ppm 
(RRR) S T D 
amplification 
Rel. 
S T D ( % ) 
(SSS) S T D 
amplincation 
Rel. STD 
(%) 
%(SSS) • 
%(RRR) 
9.86 3.51 100 4.08 100 -
9.72 2.50 71.2 3.86 94.6 23.4 
9.50 1.46 41.5 2,41 59.0 17.5 
8.53 2.63 75.0 3.24 79.5 4.5 
7.91 1.40 39.9 2.27 55.6 15.8 
7.59 1.94 55.3 2.69 65.9 10.6 
7.04 1.88 53.6 3.19 78.1 24.5 
6.69 2.48 70.8 3.75 91.8 21.1 
3.38 1.65 47.1 2.67 65.4 18.2 
2.18 1.74 49.6 2.86 70.0 18.5 
1.93 2.54 72.5 2.79 68.3 -4.2 
1.77 0.62 17.6 1.03 25.2 7.6 
1.39 1.34 38.2 2.07 50.8 12.5 
0.96 1.21 34.6 2.11 51.7 17.1 
In order to determine the region of the complex which interacts with HSA, the ' H STD 
N M R spectrum of (SSSHY.Vf* was compared to that of the standard ' H N M R 
spectrum. By this method, the protons which appear in the standard N M R but not the 
STD N M R can be identified, and classified as protons which do not bind to HSA. In 
addition, the peaks which were shown from the amplification analysis to vary least 
between (RRR) and (SSS) enantiomers are also likely to correspond to non-binding 
protons. The classification of peaks is shown in Figure 5.24. The cyclen ring and amide 
methylene protons do not appear to interact with protein, which is consistent with their 
structural location towards the centre of the complex, shielded by the pendant arms and 
chromophore. In addition, while the pendant arm which interacts with the chromophore, 
and the cyclohexyl ring of the chromophore do not appear to interact with HSA, the 
phenanthrene region of dpqC may be involved in binding. These results suggest that it is 
the two other phenylmethyl pendant arms and the aromatic region of the chromophore 
which lie in the binding site of the protein. This is consistent with findings that 
complexes with the same dpqC chromophore but different pendant arms do not exhibit 
the same HSA-binding behaviour. 
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I I 
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4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 
Figure 5.24: Comparison of the ' H N M R spectrum of (SSSj-lY.L^jCl, (upper) with the S T D N M R 
spectrum of the same complex, and the structural conclusions, indicating protons which exist in the ' H 
N M R but not the S T D N M R specuiim (•) and protons for which there is only a modest difference 
between the S T D behaviour of (SSS) and (RRR) enantiomers (•) . 
An additional STD NMR experiment was performed using dansyl sarcosine as a 
competitive binder, to supplement the information obtained from the competition 
studies. Dansyl sarcosine (2 mM) was added to the mixtures of HSA and (RRR)- or 
(SSS)-[Y.L^f^, and STD NMR spectra obtained as described above. STD amplification 
factors were calculated for each peak, and compared to those measured in the absence of 
dansyl sarcosine (Table 5.5). For the (RRR)-isomeT, the difference between the relative 
STD in the presence and absence of dansyl sarcosine ranges from -17 to +24%, with an 
average change of +1.5%; the corresponding changes for the f5SSj-enantiomer range 
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from -63 to -15%, with an average of -33%. This indicates that the spectrum of the 
(5S5)-isomer is more dramatically perturbed than that of the (/?/?/?j-enantiomer upon 
addition of dansyl sarcosine. This is consistent with release of the (SSS) complex from 
drug site I I by dansyl sarcosine, as observed in the relaxivity studies. 
Table 5.5: Changes in the relative STD (to the most shifted proton) for (555)- and f/?/f/?)-[Y.L^]Cl, upon 
the addition of dansyl sarcosine (2 mM) 
ppm (RRR) Rel. STD (%) (555) Rel. STD (%) 
Without 
dansyl 
sarcosine 
With 
dansyl 
sarcosine 
Change 
Without 
dansyl 
sarcosine 
With 
dansyl 
sarcosine 
Change 
9.86 100 100 - 100 100 -
9.72 71.2 80.0 8.8 94.6 64.1 -30.5 
9.50 41.5 53.5 12.0 59.0 22.2 -36.8 
7.91 39.9 63.8 23.9 55.6 30.9 -24.7 
7.04 53.6 54.1 0.5 78.1 15.3 -62.8 
6.69 70.8 86.2 15.4 91.8 54.1 -37.7 
3.38 47.1 30.6 -16.5 65.4 24.3 -41.1 
2.18 49.6 36.5 -13.1 70.0 36.2 -33.8 
1.77 17.6 12.7 -4.9 25.2 10.6 -14.6 
1.39 38.2 27.4 -10.8 50.8 20.2 -30.6 
0.96 34.6 34.1 -0.5 51.7 35.8 -15.9 
5.3.4 A unique example of dynanuc helicity inversion 
Molecular recognition of a substrate by a protein binding site often involves "induced 
fit", in which the conformation of one or both species changes to enable binding."^' Very 
few cases have been observed in which binding of a chiral system induces inversion of 
helicity, although such an event is believed to be of importance in gene expression as 
well as other cellular processes.'^"^ For example, binding of right-handed B-DNA to 
spermine and phenanthrolines can lead to alteration in its conformation to left-handed Z-
DNA. A number of synthetic systems have been observed to undergo helicity 
inversion upon interaction with an external stimulus, including helical organic 
compounds^^^' and metal coordination c o m p l e x e s . F o r example, a slowly 
epimerising complex has been observed to switch configuration at the Ru and N 
stereogenic centres on binding to jV-ethylguanine and 5-DNA." 261 
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While biological systems are commonly enantioselective, there appear to be no previous 
examples where this is accompanied by selective inversion of one enantiomeric form. 
Studies of (55S)-[Ln.L^]^'^ have revealed that it binds enantioselectively to drug site I I of 
serum albumin, and that this binding is accompanied by helicity inversion. In this 
behaviour, this complex is a unique example of dynamic helicity inversion. 
5.4 Conclusions 
The studies of cellular fate have identified complexes which exhibit a range of sub-
cellular speciation states. In cellulo hydrolysis of ester-containing pendant arms was 
observed by changes in the relative emission intensities of a Eu(III) complex with Ala 
pendant arms. Cellular demetallation of a different complex, which had been observed in 
previous in vitro studies, was visualised by microscopy. Analysis of the intracellular 
anion binding of a complex by luminescence spectroscopy indicated that the complex 
was bound competitively by serum albumin and bicarbonate, and serum albumin-
binding was observed for another complex, highlighting the need to assess the effect of 
protein binding or association on probe behaviour. 
This work has highlighted the importance of investigating the in cellulo behaviour of a 
probe early in the design process. In some cases, the effects of sub-cellular speciation 
can enhance the ability of a probe to report on its environment, but in other cases they 
can be a hindrance. 
One case of protein binding which was studied in more detail revealed that 
{(SSS)-Ln\}'^'*' binds in an enantioselective fashion to drug site I I of serum albumins. 
This binding is likely to involve the phenyl rings of two of the pendant arms and the 
chromophore itself, and is signalled by a change in the helicity as demonstrated by the 
change the circularly polarised emission. This complex is therefore a unique chiroptical 
probe for albumin binding, and could find use in the tracking of protein association in 
vitro and in cellulo. This could be best achieved by construcfion of a CPL microscope, 
which would give information about the circularly polarised emission of a complex at 
defined positions in a cell. 
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C H A P T E R SIX: E F F E C T S O F C O M P L E X E S ON C E L L U L A R HOMEOSTASIS 
6.1 Introduction 
The function of a cellular probe is to report on the physiological conditions of a cell. It is 
important, therefore, that the probe reports on these conditions without interfering with 
cellular processes. In assessing the suitability of a probe, its effect on cellular 
homeostasis is an essential consideration. The primary indicator of this is the toxicity of 
the probe. In considering the cellular behaviour of the luminescent lanthanide 
complexes, it is important to assess the effects of the probe itself as well as those of its 
metabolites. 
Very few studies have assessed the effect of luminescent lanthanide complexes on the 
homeostasis of the cell. The cellular toxicity of a set of acridone-containing luminescent 
lanthanide complexes was assessed by addition of Trypan Blue, which stains only non-
viable cells. By counfing the ratio of dead to live cells, it was determined that the 
complexes were non-toxic at concentrations of 1 mM.^^ This method does not, however, 
allow for the generation of quantitative data by which to compare a range of complexes. 
No reported study has addressed any other aspect of the effect of complexes on cellular 
homeostasis. 
This chapter explores the effects of luminescent lanthanide complexes on the 
physiological conditions of the cell. Two principal aspects will be considered: the 
cytotoxicity of the complexes, and their effect on the mitochondrial membrane potential. 
6.2 Cytotoxicity 
The cytotoxicity of a compound refers to ability to effect cell death. In order for a 
complex to act as a cellular probe, it is essential that it is non-toxic at the concentrations 
at which it will be used. The cytotoxicities of the luminescent lanthanide complexes 
under study were therefore measured. 
6.2.1 Measuring cytotoxicity 
The method selected for the assessment of cytotoxicity was the MTT assay. This test 
makes use of the conversion of M T T (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) into a purple formazan product by the mitochondrial 
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reductase present in viable cells (Scheme 6.1).'*^ The amount of formazan is therefore 
proportional to the number of viable cells. The insoluble formazan can be dissolved in 
DMSO, and quantified spectrophotometrically. 
mitochondrial 
/ T A / ' N ' ^ - - ^ reductase ^„ 
\ / \ - 1 ^ ^ N-
MTT 
Scheme 6.1 
Cells were grown overnight in a 96-well plate to allow them to adhere to the base of 
each well. After this time, cells were dosed with varying concentrations of complex and 
incubated at 37 °C. For the final 4 h of incubation, M T T was added to the medium. 
Following incubation, the medium containing MTT was decanted and DMSO added. It 
was found that the process of decanting the medium resulted in loss of cells which were 
poorly adherent to the base of the wells. This was particularly noticeable in cells which 
had been incubated for shorter time periods. For these studies, therefore, an incubation 
time of 24 h was selected as this was the longest incubation time used in any microscopy 
study. In addition, CHO cells did not appear to adhere sufficiently well to the base of the 
wells. Al l reported cytotoxicity values were therefore measured in NIH 3T3 cells. 
The data points derived from the MTT assay of L^*" are shown in Figure 6.1. The 
percentage viability was calculated from the relative absorbance of a well compared to 
that of untreated cells. In many cases, the cells treated with the lowest concentration 
were more viable than untreated cells. This is likely to due to hormesis, the phenomenon 
that defines how low doses of toxic substances can stimulate biological sys tems.Af ter 
this point, the viability of the cells decreased exponentially with increasing 
concentrations of compound. When the concentrations were plotted on a logarithmic 
scale, a linear relationship could be observed. This allowed calculation of the 
concentration which inhibits viability by 50%, termed the I C 5 0 value. 
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Figure 6.1: Example data for L ' ^ showing variation of cell viability with concentration on (a) a linear 
scale and (b) a logarithmic scale (NIH 3 T 3 cells, 24h incubation). Data-points represent the average of 
three separate measurements. 
By this method, the IC50 values for a range of complexes and ligands were calculated 
(Table 6.1). 
Table 6.1: Cytotoxicity data for selected complexes and ligands in NIH 3 T 3 cells following 24 h 
incubation, showing standard deviations (SD) 
Complex / ligand IC50 (^M)^ SD (^M) Complex / ligand IC5«((iM)t SD 
[Tb.L'l 3 9 3 4 2 [Eu .L ' jCl , > 2 4 0 -
[Tb.L^jCl, 131 2 7 173 15 
[Eu.L-]Cl3 109 2 0 [Tb.L'']Cl3 40 .9 8.9 
[Eu.L'"]Cl3 144 1 2 [Eu.L' jCl j 72.9 4.1 
[Eu.L''']Cl3 121 1 7 [Eu.L"]Cl3 120 10 
[ E u . L ' ° ] > 2 4 0 - [ E U . L " ] ( O T 0 3 79 .0 9.4 
[Eu.L""] > 2 4 0 - [Eu.L'^](0Tf)3 > I 0 0 -
[ E U . L ' I C I , 173 3 4 > 1 5 0 -
180 1 5 [ E U . L " ] 55.9 19.1 
[Eu.L''']Cl3 5.6 0.3 [Tb.L"'°]Cl3 > 2 4 0 -
L ' " 4 .9 1.3 [Tb.L""']Cl3 77 33 
[Eu .L ' - jCI , 164 3 1 [Tb.L"'lCl3 131 33 
L*° 99.3 11.8 [Eu.L'*^]Cl3 57 .4 1.5 
[Eu.L*'']CI, > 2 7 0 - [Eu.L"]Cl3 7.2 0.5 
L ' " > 3 5 0 - [Eu.L'^jCl , 13 5 
[Eu.L"^]Cl2 109 13 
• Values are mean for data from three independent experiments with quadruplicate readings in 
each experiment. 
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6.2.2 General comments about cytotoxicity 
The results show that most complexes have IC50 values of greater than 100 pM; many 
greater than 200 | i M . Since cellular studies are generally performed in this work at 
50 | i M , the complexes can be considered to be non-toxic for the purposes of these 
investigations. However, there are isolated examples of complexes which exhibit much 
higher cytotoxicity. In order to understand the mechanisms by which they kill cells, 
these cases were investigated further and are discussed in Section 6.2.4. 
These cytotoxicity measurements demonstrate the importance of carefully considering 
dosages. A number of studies in the past used concentrations as high as 1 mM,*''' '^ ^ 
which for most complexes are toxic. For [Eu.L^]^"^, for example, dosing cells at 1 mM, 
nine times above the IC50 value, resulted in permeabilisation of the cell membrane. 
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Other general comments can be made from the cytotoxicities observed. The replacement 
of Eu for Tb does not appear to greatly alter the cellular toxicity; [Eu.L^]''"^ and 
[Tb.L^]^"*", for example, exhibit similar IC50 values, within the range of error. It appears 
that neutral complexes are generally less cytotoxic than cationic complexes; [ T b . L ' ] is 
three times less toxic than [Tb.L^]"''^, while the hydrolysed complexes [Eu.L'*] were not 
toxic over the range tested, in contrast to their ester forms, [Eu.L'']^'^. This could be due 
to the decreased interaction of neutral complexes with the mitochondria, important 
players in apoptosis, or due to the lower protein association observed for these neutral 
complexes. 
It can be noted that changing the groups appended to the chromophore has some effect 
on the IC50 of the complex. For the series [Eu.L^]^"^ and [Tb.L^]^"^, in which the moiety 
at the 7-position of the chromophore is changed, there is significant variation in the 
cytotoxicity. This could indicate that the appended group is interacting with cellular 
species and inducing toxic effects in some cases. Notably, complexes containing an 
appended 'Bu group appear to exhibit higher cytotoxicity: [Tb.L^JCb, [Eu.L^JCIs and 
[Tb.L^'*''] have IC50 values of 41, 73 and 57 \iM respectively. It was hypothesised that 
this was due to interaction with the mitochondrial membrane, and was further 
investigated, as discussed in Section 6.3 below. 
All ligands studied follow similar toxicity trends to their complexes: non-toxic ligands 
appear to give rise to non-toxic complexes, while the toxic ligand L^"* forms the toxic 
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complex [Eu.L^'*]Cl3. This suggests that the metal ion itself is either not exerting any 
additional toxic effects, or that in this case, the complex is prone to dissociation 
Most complexes were tested with chloride as the counterion, as this was the form 
commonly synthesised and studied. Investigation of the chloride and triflate salts of 
[ E U . L " ] ^ " ^ gave IC50 values of 120 and 79 | J M respectively. This suggests that the 
counterion may have an effect on the toxicity of a complex. In addition to the 
considerably lower solubility of triflate complexes, this provides further evidence that 
triflate salts are not the most ideal form for administration of complexes. 
6.2.3 An alternative method for assessing cytotoxicity 
In order to confirm the cytotoxicity data derived from the MTT assay, a different method 
was investigated. This assay utilised WST-I ((4-[3-(4-iodophenyI)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-l,3-benzene disulfonate) which, like MTT, is a tetrazolium ion that is 
cleaved by mitochondrial reductase (Scheme 6.2). The principal difference between 
MTT and WST-1 is that the reduced product of WST-1 is water soluble, and the DMSO 
solubilisation step is therefore no longer required."^ 
02N 
mitochondrial M NaOaS 
•N / = \ reductase HN-N > = \ 
i j - S O , N a ^ _ > — ^ > - S 0 3 N a 
N = N 
WST-1 I 
Scheme 6.2 
NIH 3T3 cells were prepared in an identical manner to that described for the MTT assay. 
WST-1 was added to the wells for the final 30 min, 1 h, 2 h or 4 h of incubation in order 
to determine the minimum time required for good readings. After incubation, the trays 
were immediately processed in the plate reader. It was found that cells incubated with 
WST-1 for 30 min gave very similar readings to cells treated for longer times. A 30 min 
incubation with this reagent was therefore adopted for subsequent studies. It was also 
necessary to select the appropriate blank to use for the photometric measurements. For 
MTT assays, DMSO was used as a blank. Initial WST-1 assays were performed using 
growth medium as a blank, but a number of wells gave negative readings. It was 
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therefore necessary to add WST-1 to the medium (in the absence of cells) for the blank. 
This is likely to be due to the fact that the tetrazolium form of WST-1 absorbs weakly in 
the spectral region of interest, and this must be taken into account. 
In order to study the WST-1 assay in comparison to the MTT assay, IC50 values of four 
complexes were assessed using each method in parallel (Table 6.2). The results for the 
two assays were very similar. This confirms the validity of the results presented in Table 
6.1. The advantages of WST-1 over MTT are its solubility, and the short time for which 
the cells must be incubated with the dye. Both properties are particularly advantageous 
for the measurement of I C 5 0 values at shorter time points. WST-1 would therefore be the 
reagent of choice for future studies, particularly those which monitor changes in toxicity 
over time. 
Table 6.2: Comparison of IC50 values derived from parallel measurements using the WST-1 and MTT 
assays following 24 h incubation 
Complex / ligand IC50 (HM) 
M T T 
ICso (.\1M) 
WST-1 
[ E U . L ' ° ] C I , >200 nM >200 nM 
[Eu.L"']Cl3 9 nM 1 1 nM 
[Tb.L']Cl3 45 \iM 40 nM 
[ E U . L " ] ( O T 0 3 70 nM 59 nM 
6.2.4 Understanding cytotoxicity of selected lanthanide complexes 
While most complexes have IC50 values of greater than 100 \iM, there are isolated 
examples which are more cytotoxic (Table 6.1). Notably, complexes [Eu.L^'']'''^, 
[Eu.L*^]^^ and [Eu.L**]^* had IC50 values of 5.6, 7.2 and 13 respectively. It is 
important to understand how these complexes are causing cell death, in order to avoid 
such features in future probe design. 
Complexes [EU.L'^]^"^ and [Eu.L^Y"^ were synthesised amongst a series of different 
conjugates linked to emissive terbium complexes in an investigation of the 
compartmentalisation of such complexes.'^*' [EU.L'^]-'"^ incorporates a C12 chain, 
while [EU.L'*]"^^ was synthesised by conjugation to an oligoguanidinium moiety which 
itself was designed to localise in the mitochondria. '"'^  Attempts to observe the cellular 
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behaviour of these two complexes, however, were marred by their high cytotoxicities, as 
evidenced by their low IC50 values (Table 6.1). These cytotoxicities can be compared to 
relatively lower toxicities of other complexes bearing the same chromophore and 
pendant arms, [Tb.L''*]^'^. In order to understand the mechanisms by which these 
complexes ki l l cells, an apoptosis-necrosis flow cytometry assay was performed. 
= 0 
N ! N 
Ph 0 - r - -Ln - -_3 - -N 
NH 
[Ln.L'S]3* 
HN^  
Ph 0 - | ^ - - L n - - J - - N 
NH 
[Ln.L'*]3-
The apoptosis-necrosis assay utilises the different properties of cells which are 
undergoing apoptosis and necrosis."^^ Propidium iodide (PI) is a cell impermeable salt 
whose fluorescence is enhanced 30-fold on binding to DNA. As it can only enter 
necrotic cells, which have compromised membrane integrity, the presence of propidium 
iodide fluorescence indicates necrosis. Annexin V is a phospholipid-binding protein 
which has a high affinity for the phospholipid phosphatidyl serine (PS), which is 
presented on the membrane of cells in early apoptosis.'^ ^^ This binding event is signalled 
by induced fluorescence of the fluorescein which is conjugated to the Annexin V in the 
form of fluorescein isothiocyanate (FITC)."^^ As well as presenting PS, late apoptotic 
cells experience some loss of membrane integrity, and can therefore be distinguished 
from early apoptotic cells which show no PI fluorescence. 
Both CHO and NIH 3T3 cells were treated with complexes [EU.L '^ ]^^ and [Eu.L**]^^ 
and stained with PI and the annexin V-FITC conjugate. As controls, cells were treated 
with ethanol to induce necrosis, and staurosporine, which induces apoptosis."** Example 
flow cytometry dot plots for complex-treated cells are shown in Figure 6.2. 
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Figure 6 .2: Flow cytometry plots following staining with propidium iodide and Annexin V - n X C of 
(a) CHO cells after 24 h incubation with [ E U . L " ] ' * and (b) N I H 3T3 cells after 4 h incubation with 
[ E u . L " ] ' ^ 
Cells treated with [Eu.L*^]'''^ do not exhibit significant annexin-FITC fluorescence, but a 
population are stained by PI, suggesting that they are undergoing necrosis. This is 
consistent with the expectation that the long hydrophobic chain lodges in the lipid 
bilayer, disrupting the cell membrane. This indicates that future probe design should 
avoid such hydrophobic moieties. Cells treated with [Eu.L**]^"^, on the other hand, do 
show FITC fluorescence, and a path can be seen from viable cells through early 
apoptotis, with the largest population lying in the quadrant corresponding to late 
apoptosis. An explanation for this observation is that the polyguanidinium vector 
transports the conjugate to the mitochondria, which are heavily involved in the induction 
of apoptos i s .Whi le it is desirable to design complexes which are trafficked to the 
mitochondria, it is important to ensure that they do not adversely affect mitochondrial 
function. This wil l be considered further in Section 6.3. 
The other cytotoxic complex identified from the M T T assays is [Eu.L^'']^^, which 
exhibited an IC50 value of 5.6 pM.'^^ Interestingly, the oxygen analogue, [Eu.L^*]^^ is 
30-fold less cytotoxic. As demetallation of the complexes had been observed in 
carbonate-binding studies, as described in Chapter Five (page 134), the in cellulo 
speciation is likely to be that of the dissociated complex. The cytotoxicities of the 
ligands alone are very similar to those of the complexes (Table 6.1). In order to 
166 
C H A P T E R SIX: EFFECTS O F C O M P L E X E S O N C E L L U L A R H O M E O S T A S I S 
understand better the difference in toxicity between the oxygen- and sulfur-containing 
compounds, IC50 values of the chromophores alone were evaluated (Table 6 .3) . Again, it 
can be noted that the azaxanthone ( 2 4 ) is less cytotoxic than the azathiaxanthone (25) . 
The azathiaxanthone is, however, ten times less toxic than the related ligand and 
complex. Further studies were performed of the sulfoxide ( 2 6 ) and sulfone (27) 
derivatives of this azathiaxanthone, as they are likely to be the products of in cellulo 
oxidative metabolism. The sulfone derivative has an IC50 value of 21 | i M , and is 
therefore likely to contribute to the toxicity of the complex and its ligand. It is not the 
presence of this sensitiser alone which causes this cytotoxicity, as other azathiaxanthone-
containing complexes such as [Eu.L***]^"^ and [ E U . L " ] ^ ^ are considerably less toxic. 
Instead, the ready dissociation of [Eu-L^**]^* may contribute to increased metabolism of 
the chromophore, releasing the toxic sulfone. 
IN n 
H j O - r - - E u - - -
- N / : N 
P h -
X=0 
x=s 
[EU.L5»]3* 
Table 6.3: Cytotoxicity data for [ E U . L ' ] ' * and related compounds in NIH 3T3 cells following 24 h 
incubation, showing standard deviations (SD) 
Compound IC50 (jiM) SD 
[Eu .L"]Cl3 >200 nM -
180 ixM 15 nM 
24 >240 nM -
[Eu.L''']Cl3 5.6 0.3 \M 
4.9 nM 1.3 nM 
25 72.5 nM 6.3 nM 
26 >240 nM -
27 21.2 nM 0.2 nM 
2-methylazaxanthone 2-methylazaxathionthone 
24 25 
s 
o 
26 
" N ' .S, 
0' O 
27 
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6.3 Mitochondrial membrane potential 
In addition to being non-toxic towards cells, cellular probes must also be designed to 
have minimal interaction with normal cellular process, and to have as little effect as 
possible on cellular homeostasis. For mitochondrial probes, this requires a minimal 
effect on the mitochondrial membrane potential (MMP), which allows for the normal 
function of the electron transport chain. One means by which the MMP can be 
monitored is through the use of fluorescent dyes in flow cytometry. One such assay, 
described by Pendergrass et (3/.,"™ measures the green fluorescence of Mitotracker Green 
FM (MTG), which stains all mitochondria, independent of their MMP,'^' against the red 
fluorescence of chloromethyl-X-rosamine (CMXRos), for which mitochondrial uptake 
increases with MMP. 272 
This method was utilised to study the effects of five complexes which demonstrated 
some mitochondrial localisation: [Eu.L*^]-''^ and [Eu.L**"]^"^, which appeared to localise 
solely in the mitochondria at times up to 12 h, and [Tb.L*]^^, [ E U . L ' ] ^ * and [Tb.L"'"']^^ 
which exhibited a lysosomal / mitochondrial distribution pattern. 
V 
H.o-r-^,H:J R = OMe, X = O 
R = OH, X = 0 
N ', N ~-~ 
[EU.l6»]3-
[ T b . L V 
• -N 
N •, N- - - . ^ 
[ E U . l V " 
HN 
H 0 = < 
NH 
Ph 
'Bu 
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CHO cells were treated with 50 complex for one or four hours for [Eu.L*]^* and for 
four or twenty-four hours for the remaining three complexes. 200 nM MTG and 
CMXRos were added for the final thirty minutes. Cells were then harvested and 
analysed by flow cytometry, measuring the green (FLl ; MTG) fluorescence against the 
red (FL4; CMXRos). 
Carbonyl cyanide p-trifluoromethoxylphenyl-hydrazone (FCCP; 28) was employed to 
provide a control for cells with disrupted MMP. FCCP is an uncoupling agent which 
readily crosses the mitochondrial membrane, disrupting the proton gradient and hence 
destroying the M M P . " " Cells were treated with either 20 ^ M or 100 ^ M FCCP, 
concentrations which have previously been reported to elicit approximately half-
maximal and maximal changes (respectively) in the fluorescence of CMXRos.^™ 
\\ 
N 
28 
The ratio of red to green fluorescence (FL4/FL1) was calculated for each treatment 
(Figure 6.3). As previously observed, treatment with increasing concentrations of FCCP 
led to disruption of the MMP and decreased labelling by CMXRos, and hence a lower 
FL4/FL1 ratio."° This decreased red fluorescence was not observed for [Eu.L*"]'''^ and 
[Eu.L*'^]"'^; instead, the red fluorescence appeared to increase with respect to the green. 
This suggests that these complexes do not disrupt the MMP. Importantly, there is no 
significant effect of time on the MMP, nor of a change in the complex charge (of 3+ to 
2+). This suggests that these complexes localise in the mitochondria without disrupting 
its membrane potential, confirming the potential for their use as probes of normal 
mitochondrial conditions. 
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Figure 6.3: FL4/FL1 mean intensity from flow cytometric analysis of CHO cells with various treatments. 
FCCP treatments are 20 \M (blue) and 100 ^iM (red) for 3 h; [Eu.L*°]'* and [Eu.L*'f'^ treatments are 
50 for 1 h (blue) and 4 h (red); [Tb.L*]'"", [Eu.L*]'* and [ T b . L " " ] ' * treatments are 50 for 4 h (blue) 
and 24 h (red). 
The remaining three complexes, on the other hand, demonstrate more noticeable changes 
in MMP. For all three complexes, the FL4/FL1 intensity is less than for untreated cells at 
all timepoints. For [Tb.L*]^"^ and [Tb.L^"**]^^, this ratio decreases with time, while for 
[ E U . L ' ] ^ ^ the FL4/FL1 ratio indicates a greater uncoupling at 4h, with partial restoration 
of the MMP after 24 h. In order to better understand this behaviour, an apoptosis-
necrosis assay was performed (Figure 6.4). Higher complex concentrations (200 | J M ) , 
above the measured I C 5 0 values (Table 6.1), were employed in order to maximise the 
number of dead cells that could be observed. 
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Figure 6.4: Flow cytometry plots following staining with propidium iodide and Annexin V-FITC of CHO 
14<li34 cells treated for 24 h with (a) 200 |xM [Tb.L*]"'", (b) 200 n M [Eu.L'] ' ' " and (c) 200 p M [Tb.L ] 
The flow cytometry plots indicate that a population of cells treated with [Tb.L*]^"^ are 
stained with PI, and are therefore undergoing necrosis. In contrast, cells treated with 
[ E U . L ' ] ' ' ' ^ are stained with Annexin-FITC as well as PI, indicative of apoptosis. The flow 
cytometry plot for [Tb.L^**^]^"^ is harder to interpret, with cells lying in both apoptotic 
and necrotic regions. 
These modes of cell death observed for [Tb.L^]''"^ and [Eu.L*]^"*^ are consistent with the 
observed mitochondrial membrane potentials. Necrosis is a traumatic event which 
affects all aspects of cellular function. It is likely that a perturbed MMP is an effect of 
disrupted mitochondrial membranes rather than a cause of necrosis. Over time, therefore. 
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the damage to the mitochondria should increase, as is observed with the decreasing 
MMP of cells treated with [Tb.L*]^"^. In contrast, apoptosis occurs via a cascade of 
controlled events which are often mediated by the mitochondria."*^ Cells undergoing 
apoptosis, such as those treated with [EU.L' ] ' "^ , are therefore expected to exhibit a rapid 
change in MMP, as evidenced by the low FL4/FL1 ratio after 4 h (Figure 6.3). After 
24 h, however, a large proportion of the cells which initially showed a reduced MMP 
would have completed apoptosis and would be too fragmented to be measured by flow 
cytometry. The assay will therefore measure a larger proportion of viable cells at this 
time point, with a higher average MMP. 
Each of the three complexes under study contained a 'Bu group appended to the 
sensitiser. It was initially thought that this group was responsible for the increased 
toxicity for complexes such as these. I f this were the case, it would be expected that all 
three complexes should effect cell death by a similar mechanism. This was not found to 
be the case, so it appears that it is not simply the 'Bu group itself which is causing the 
observed cytotoxicity. 
6.4 Conclusions 
In designing probes to report on sub-cellular conditions, it is essential that the probes 
themselves do not interfere with cellular functions. Principally, it is important to design 
probes that are non-toxic at the concentrations at which they wil l be used. Studies of the 
cytotoxicity of a range of luminescent lanthanide complexes indicate that induction of 
cell death is the exception, rather than the rule. Studies of these isolated toxic complexes 
have highlighted some design features which should be avoided. The measurement of 
cytotoxicity remains of great importance in the assessment of a potential cellular probe. 
Another important indicator of cellular homeostasis is the mitochondrial membrane 
potential, which affects both the energy production of the cell and the induction of 
apoptosis. The complexes which were noted in Chapter Three (page 76) to localise to the 
mitochondria alone at early time-points did not appear to perturb the MMP, in agreement 
with their low toxicity. In contrast, complexes which localised quickly to both the 
lysosomes and the mitochondria were more toxic, and did result in an altered MMP with 
concomitant induction of cell death. This provides further confirmation that such a class 
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of complexes, which does not show one clear localisation pattern, should be avoided in 
future probe design. 
The results reported in this chapter indicate that luminescent lanthanide complexes do 
not, in general, dramatically perturb cellular homeostasis. They therefore have great 
promise for application as sub-cellular probes. 
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CONCLUSIONS 
C H A P T E R S E V E N : C O N C L U S I O N S 
7.1 General conclusions 
The design of luminescent lanthanide complexes as luminescent probes has received 
widespread attention and interest. Reviews of the subject highlight the bias of research 
towards the design of systems which can respond to their environment, but not to 
considerations of the cellular behaviour of such systems.^'' "^ ^ Studies of novel 
complexes generally report only in vitro properties and assume that the complex will 
behave in a similar manner in cellulo. The interaction of complexes with cells is, 
however, an essential design consideration, and warrants greater attention. 
This study of luminescent lanthanide complexes has been significantly aided by work in 
Durham over the past eight years, which has produced a range of complexes which vary 
in structure and behaviour. The synthesis of one set of complexes, bearing a 
tetraazatriphenylene chromophore and amino acid-based pendant arms, is described in 
Chapter Two. Characterisation of these complexes by various spectrometric methods 
revealed that substitution of alanine- for phenylalanine-based pendant arms results in 
adoption of a distinctly different geometry, in which the atom occupying the capping 
apical site of the polyhedron has changed, and a A- rather than A-configuration is 
observed. Despite these marked structural changes, it appears to be overall complex 
hydrophobicity rather than geometry that dictates aspects of complex behaviour such as 
protein association. Each complex within this class exhibits a similar cellular uptake, 
localisation and toxicity profile. The information derived from these complexes 
contributed to the study of a broader range of complexes described throughout the rest of 
this thesis. 
The selection of a suitable luminescent lanthanide complex for use as a cellular probe 
requires the simultaneous fulfilment of a number of properties. A complex which 
exhibits high luminescence in cellular medium but is cytotoxic, for example, would not 
be a suitable candidate. Nor would a complex which is sensitive to the concentration of 
citrate, but which localises in an organelle in which this anion is not of interest. The 
chapters of this thesis have addressed these issues. 
An essential aspect of the design of cellular probes involves directing the complex to an 
appropriate sub-cellular locality. This work has demonstrated that complexes generally 
localise in the lysosomes or mitochondria. In addition, nucleolar localisation can be 
promoted and this tendency has been linked to cases of enhanced membrane 
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permeability. While these membrane effects perturb the homeostasis of the cell, this 
technique may prove to be a valuable method by which to probe this protein-rich region 
of the cell. 
In addition to identification of localisation behaviour, structural aspects which promote 
distribution in each organelle have been defined. While the nature of the pendant arms 
does not appear to have any effect on the sub-cellular distribution, complexes bearing 
three identical pendant arms appear to exhibit less well-defined localisation profiles than 
those possessing a free cyclen NH. A number of modifications to the chromophore 
structure have been investigated, revealing that it is the nature of the linkage between the 
chromophore and the cyclen ring which most dramatically influences localisation. In 
contrast, variation of the substituents on the chromophore does not appear to 
significantly affect localisation, but can influence other aspects of cellular behaviour, 
such as sensitivity to quenching, protein affinity and cytotoxicity. 
Another essential requirement for a sub-cellular probe is its ability to cross the cell 
membrane. Some complexes which were poorly visible by microscopy were previously 
believed to be excluded from the cell. Investigations of uptake and quenching behaviour 
indicated that these complexes did enter the cell, where their luminescence was strongly 
quenched. Indeed, all complexes were observed to be transported into the cell at similar 
rates. Mechanistic studies revealed a common active mode of uptake involving 
macropinocytosis. This allows for the uptake of structurally diverse complexes, and 
subsequent release of these complexes into the cytoplasm for trafficking to various 
organelles. 
The sub-cellular speciation of a complex is very important in determining its efficacy. 
Emission spectroscopy of whole cells which had been treated with complex proved to be 
an effective method of probing the form adopted by the complex in cells. In this way, it 
was observed that complexes generally exist in protein-bound form. One interesting case 
was ('555j-[Ln.L^]•'^ which binds enantioselectively to drug site I I of serum albumin 
with a concomitant change in helicity. This change was signalled by inversion of the 
circularly polarised luminescence. 
Finally, it is important that probes cause minimal perturbation to cellular structure and 
function. Evaluation of cytotoxicity revealed that luminescent lanthanide complexes are 
generally non-toxic at working concentrations. Isolated complexes which did cause 
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death did so by readily explained mechanisms, which can be avoided in future probe 
design. The effect of mitochondrially-locaiising complexes on mitochondrial membrane 
potential (MMP) was also investigated. Those complexes which did perturb MMP also 
exhibited modest cytotoxicity, and should therefore be avoided in future probe design. 
While the primary aim of this work was to investigate the cellular behaviour of 
luminescent lanthanide complexes to aid future probe design, this work has highlighted 
existing complexes which show particular promise. For example, complexes based on 
the ligands L* exhibit low toxicity and good anion selectivity. In addition, they show 
clear mitochondrial localisation at time points up to 12 h, without perturbation of the 
mitochondrial membrane potential. 
7.2 Implications for probe design 
The objective of the work described in this thesis was to gain a greater understanding of 
the cellular behaviour of luminescent lanthanide complexes to aid in the design of 
cellular probes. The conclusions which have been reached concerning the interaction of 
complexes with cells have highlighted a number of important factors for consideration. 
Each chapter of this thesis has addressed a separate aspect of cellular behaviour. In 
probe design, however, it is essential to consider all facets together. This section 
attempts to draw together the various conclusions reached to highlight future directions 
for the study of luminescent lanthanide complexes. 
The design of compounds for use as sub-cellular probes or drugs often employs 
strategies to induce certain cellular behaviour. For example, compounds might be 
encapsulated in liposomes to enhance cellular uptake, or conjugated to peptides to 
improve uptake and localisation. However, these strategies may also alter properties 
such as selectivity, toxicity or efficacy. It is therefore important to assess whether such 
modifications are required, or whether cellular behaviour of the native compound is 
sufficient to achieve its purpose. 
For the luminescent lanthanide complexes, it is evident that no such strategy need be 
employed to induce cellular uptake. A l l complexes were observed to be transported 
readily across the cell membrane. The wide range of complexes studied indicates that is 
likely that any lanthanide complex of a similar structure (bearing a cyclen macrocycle 
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and heterocyclic sensitiser) will undergo macropinocytosis. Future probe design 
therefore need not concentrate on inducing cellular uptake. 
In a similar manner, i f lysosomal or mitochondrial localisation is required, it is not 
necessary to tag complexes to direct their delivery. Clear structural requirements for 
mitochondrial localisation have been defined, while a lysosomal localisation appears to 
be the default distribution. I f other localisations are desired, however, it might be 
necessary to investigate more drastic structural modifications, or to conjugate the 
complex to a moiety with well-defined cellular behaviour. The studies reported here 
have indicated that sub-cellular localisation and other aspects of cellular behaviour, such 
as susceptibility to quenching and protein binding, are regulated by different structural 
factors. This allows the fine-tuning of probe behaviour by making small structural 
modifications, without affecting the sub-cellular localisation. 
This work has highlighted a number of aspects of cellular behaviour which must be 
screened at an early stage in the design process to assess for potential use as a cellular 
probe. This should minimise the time spent in fully optimising and characterising a 
complex which may exhibit ideal in vitro behaviour, but does not function in the cellular 
environment. Among factors which must be assessed are cytotoxicity and susceptibility 
to quenching. It is also important to study the effect of protein binding or association on 
the selectivity and responsiveness of a potential probe. 
7.3 Future work 
This work has elucidated a number of significant biological properties of luminescent 
lanthanide complexes. However, there remain unanswered questions about the cellular 
behaviour of these complexes, particularly with respect to their sub-cellular localisation. 
While the mechanism of cell uptake has been studied and defined, the pathways by 
which complexes are trafficked between organelles is less clear. The preliminary results 
from the FRET experiments with RFP-tagged actin and tubulin could be investigated 
further. For example, it would be valuable to assess in vitro association or binding of 
complexes with either protein. Intracellular trafficking could also be studied by selecting 
inhibitors of organellar functions, such as polyvinylpyrrolidone, which disrupts 
lysosomes,^''^ or antimycin, which inhibits mitochondrial function. . 277 
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The sub-cellular distribution of a complex which has been observed here by fluorescence 
microscopy could be further confirmed by use of a complementary technique, such as 
electron microscopy or X-ray fluorescence spectroscopy, as discussed in Section 3.6.3 
(page 96). It might also be valuable to repeat the preliminary sub-cellular fractionation 
experiments, and collect a lysosomal fraction in addition to the nuclear and 
mitochondrial. This could allow for quantification of the relative distribution of complex 
throughout the cell. By collecting the emission spectra from these separated organelles, a 
more sophisticated understanding of sub-cellular speciation could be gained. Another 
aspect of sub-cellular localisation, which has not been explored here, is how localisation 
behaviour might be controlled by the cell cycle. Future work might involve 
synchronisation of the cell cycle and subsequent microscopic examination of 
intracellular localisation during mitosis and interphase. 
In addition to these studies, which attempt to better understand cellular behaviour, 
further work is also required in the assessment of existing complexes for use as cellular 
probes. Studies thus far have concentrated on only a few indicators of in cellulo efficacy, 
such as susceptibility to quenching and serum albumin binding. Valuable work might 
involve the identification of other factors which are also important in determining probe 
efficacy, such as the binding of other common proteins. 
The luminescent lanthanide complexes studied in this work have been designed to 
provide in cellulo information by their emission profiles. This is most likely to be 
manifested in a probe for use in a spectral imaging microscope. Future work in assessing 
the suitability of complexes for this purpose would require testing in such a set-up, to 
confirm that the information gained thus far from fluorescence microscopy and emission 
spectroscopy experiments can be combined to give information with high spatial and 
temporal resolution. 
7.4 Final remarks 
This work has demonstrated that the luminescent lanthanide complexes are very well 
suited to the purpose of probing cellular conditions. In addition to desirable chemical 
properties, such as long luminescence lifetimes and information-rich emission spectra, 
these complexes have been shown to be readily transported across the cell membrane 
and into cellular compartments, and to minimally perturb normal cellular function. 
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Luminescent lanthanide complexes therefore fu l f i l the requirements of an effective 
cellular probe set out in Section 1.2.3 (page 6), and certainly merit further attention and 
research in the future. 
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8.1. General experimental 
All solvents used were laboratory grade and were dried over an appropriate drying 
agents when required. All reagents were used as supplied by commercial sources unless 
otherwise stated. Water and H2O refer to high purity water obtained from the 
"PuriteSTILL Plus" purification system, with conductivity of 0.04 |i,S cm" '. Reactions 
requiring anhydrous conditions were carried out using Schienk-Iine techniques under an 
atmosphere of dry argon. 
Thin layer chromatography was performed using silica plates (Merck Art 5554) or 
neutral aluminium oxide plates (Merck Art 5550), both of which are fluorescent under 
UV irradiation (254 nm). Preparative column chromatography was performed using 
silica (Merck Silica Gel 60, 230-400 mesh) or neutral aluminium oxide (Merck 
Aluminium Oxide 90, activity I I - I I I , 70-230 mesh) which had been pre-washed in ethyl 
acetate. 
Al l pH measurements were performed using a Jenway 3320 pH meter attached to an 
Aldrich Chemical Company micro-pH combination electrode, calibrated using pH 4, 7 
and 10 buffer solutions. 
Melting points were recorded using a Reichart-Kofler block and are uncorrected. 
8.1.1. Spectroscopy 
' H N M R spectra were recorded at 199.99 MHz on a Varian Mercury-200, 299.91 MHz 
on a Varian Unity-300, 400.13 MHz on a Bruker Avance spectrometer, 499.78 MHz on 
a Varian Inova-500 or at 699.73 MHz on a Varian V N M R S - 7 0 0 . '^C N M R spectra were 
recorded at 100.57 MHz on a Bruker Avance spectrometer, 125.67 MHz on a Varian 
Inova-500 or at 175.95 MHz on a Varian V N M R S - 7 0 0 . A l l spectra were recorded in 
commercially-available deuterated solvents, and were referenced to solvent residual 
proton signals. 
Electrospray mass spectra were recorded on a Thermo Finnigan LTQ with methanol as 
the carrier solvent. High resolution mass spectrometry was performed on a Thermo 
Finnigan LTQ-FT. 
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Infrared spectra were obtained using 
attachment. 
Perkin Elmer Spectrum R X l with an ATR 
UVA'is absorbance spectra were recorded on a Perkin Elmer Lambda 900 UV/Vis/NIR 
spectrometer. Emission spectra and lifetimes were measured on a Fluorolog-3 and a Perkin 
Elmer L S 5 5 luminescence spectrometer using FL Winlab software. All samples were 
contained in quartz cuvettes with a path length of 1 cm and measurements obtained relative 
to a reference of pure solvent contained in a matched cell. Luminescence spectra of the 
lanthanide(III) complexes were recorded following indirect excitation of the 
lanthanide(III) ion via the chromophore, at the stated maximal excitation wavelength. 
Lifetime measurements were obtained by excitation of the sample by a short pulse of 
light (at Jtmax) followed by monitoring the integrated intensity of light (546 nm for 
terbium, 612 nm for europium) emitted during a fixed gate time, after a delay of td 
(Figure 8.1). Measurements were made for at least 20 delay times over a period of three 
or more lifetimes. A gate time of 0.1 ms was used, and the excitation and emission slits 
were set to 10 and 5 nm respectively. The obtained decay curves were plotted in 
Microsoft Excel and fitted to equation 8.1: 
I^A. + A.e-" [8.1] 
where / is the intensity at time t after the flash 
Ao is the intensity after decay is completed 
A J is the pre-exponential factor 
k is the rate constant for decay of the excited state. 
The excited state lifetime, r, is the inverse of the rate constant, it. 
Time 
Figure 8.1: Measured parameters for lifetime measurements 
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Absorbance of biological samples in 96-well plates was measured on an Analytik Jena 
FLASHScan 530 using WinFLASH version 1.5 software. 
CPL spectra were measured at the University of Glasgow, with the assistance of Dr R. 
D. Peacock. 
Relaxivity measurements were made at 37 °C and 60 MHz on a Bruker Minispec mq60 
instrument. The mean value of three separate measurements was recorded, and values 
stated were corrected for the diamagnetic contribution (Rid=0.27 at 60 MHz, 310 K). 
HPLC analysis was performed using a Perkin Elmer series 200 system. The stationary 
phase was a Phenomenex Synergy 4 | i Fusion-RP 80 (150 x 4.6 mm). The solvent 
system was H 2 O + 0.1% HCOOH / CH3CN + 0.1% HCOOH (gradient elution) with a 
run time of 20 min, according to the gradient outlined in Table 8.1. 
Table 8.1: H P L C conditions employed for analysis of ligands and complexes. Flow rate: 1 mL/min; 
solvent A: HiO + 0.1% formic acid; solvent B: acetonitrole + 0.1% formic acid 
Time / min Solvent A / % Solvent B / % Curvature 
0 100 0 0 
15 0 100 1 
20 0 100 0 
25 100 0 -3 
27 100 0 0 
8.1.2. Cellular studies 
Three cell lines were selected for cellular studies: CHO (Chinese Hamster Ovary), 
NIH 3T3 (mouse skin fibroblast) and HeLa (human endothelial carcinoma cells). Cells 
were maintained in exponential growth as monolayers in F-12 (Ham) medium, DMEM 
(Dulbecco's Modified Eagle Medium) and RPMI 1640 medium respectively. For each 
cell line, the medium was supplemented with 10% foetal bovine serum (FBS) and 1% 
(v/v) penicillin and streptomycin. Cells were grown in plastic culture flasks, with no 
prior surface treatment. Cultures were incubated at 37 °C, 20% average humidity and 
5% (v/v) C O 2 . Cells were harvested by treatment with 0.25% (v/v) trypsin solution for 
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5 min at 37 °C. Cell suspensions were pelleted by centrifugation at 1000 rpm for 3 min, 
and were resuspended by repeated aspiration with a glass pipette. 
In order to determine cell number, cells were detached from the flask by trypsinisation. 
Cells were then pelleted and resuspended in 4 mL medium, and an aliquot of the cell 
suspension injected into a haemocytometer (Fisher). The number of cells in a grid of 
volume 100 nL was counted using a light microscope, and the values for four separate 
grids measured to give an average cell count. 
8.1.2.1. Microscopy 
Cells were seeded in 12-well plates on glass coverslips and allowed to grow to 40% -
60% confluence, at 37 °C in 5% C O 2 . At this stage, the medium was replaced and cells 
were treated with drugs and complexes as appropriate. For NIH 3T3 and HeLa cells, 
DMEM lacking phenol red was used from this point onwards. Following incubation, the 
coverslips were washed with phosphate-buffered saline (PBS; pH 7.5), mounted on 
slides and the edges sealed with colouriess, quick-dry nail varnish to prevent drying out 
of the sample. 
Epifluorescence images were taken on a Zeiss Axiovert 200M epifluorescence 
microscope with a digital camera, G365 filters (Zeiss) were employed for excitation of 
the complexes, 546+12 and 575-625 filters (Comar) used for emission of Tb and Eu 
respectively and the FITC emission and excitation filter sets were selected for 
visualisation of LysoTracker and MitoTracker Green. Images were processed, given 
false colour and overiaid using Zeiss Axiovision and ImageJ software. 
8.1.2.2. Uptake studies 
Cells were seeded in 6-well plates and allowed to grow to 80% - 100% confluence, at 
37 °C in 5% C O 2 . At this stage, the medium was replaced and cells treated with drugs at 
concentrations shown in Table 8.1. Complexes (50 nM) were added 30 min later and the 
cells incubated for a further 4 h. Following incubation, the medium was removed and the 
cells washed three times with PBS. 500 nL of lysis buffer (10 mM Tris, pH 7.5, 100 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% protease inhibitor cocktail) was then added 
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to each well, and the cells incubated at 5 °C for fifteen minutes. 3 x 25 ^.L aliquots of the 
supernatant were taken from each well for the BCA assay, as described below, and 
400 | i L was submitted for ICP-MS analysis. 
Table 8.1: Inhibitors / activators of uptake pathways and the dosage concentrations utilised 
Treatment Dosage 
Sucrose 50 mM 
Chlorpromazine 50 nM 
Filipin 1 mg/mL 
Wortmannin 300 nM 
Amiloride 3 mM 
Phorbol 12-myristate-13-acetate 50 ng/mL 
l,2-Dipalmitoyl-ra6--diacylglycerol 500 ng/mL 
Monensin 2 nM 
Chloroquine 10 nM 
Poly-L-iysine" 0.01% 
' Prepared from a 10% solution as commercially available 
Total protein content was determined in lysed cells using the bicinchoninic acid protein 
assay (BCA™ Protein Assay Kit).'^^ A BSA standard curve was constructed in the range 
0.2 to 1 mg/mL. 25 pL of standards and samples were aliquoted into triplicate wells of a 
96-well plate and 200 )iL of BCA reagent mix was added to each well. Absorbance at 
540 nm was measured after 10 h incubation at room temperature using a microplate 
reader. Protein concentration for each sample was determined against the standard curve. 
Example results for a set of cells treated with [Eu.L^JCb are shown in Figure 8.2. 
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a 1.6 
E 
c 
Csl 
U> 
(b) 
y = 0.0018x+0.1684 
R2 = 0.9976 
0 
0 200 400 600 800 
[BSA]/Jig mL"' 
sample 
replicate 
average 
[protein] 
Hg/mL 
1 2 3 
1 0.291 0.307 0.418 0.339 96.0 
2 0.351 0.373 0.320 0.348 101.2 
3 0.869 0.984 1.042 0.965 449.5 
4 0714 0.784 0.667 0.722 312.3 
5 0.459 0.442 0.402 0.434 150.0 
6 0.576 0.643 0.622 0.614 251.3 
7 0.533 0.549 0.495 0.526 201.5 
8 0.636 0.629 0.618 0.628 259.2 
9 0.513 0.567 0.592 0.557 219.4 
10 0.316 0.278 0.317 0.304 76.4 
11 0.464 0.502 0.491 0.486 179.0 
Figure 8.2: Example data set for the determination of protein concenu-ation using the BCA assay for cells 
treated v i^th [ E U . L ' ] ' " showing (a) BSA standard curve and (b) protein concentrations calculated from 
u-iplicate readings of each sample from calibration curve 
Inductively coupled plasma mass spectrometry determinations of europium, terbium or 
gadolinium concentrations were made by Dr. C. Ottley in the Department of Earth 
Sciences at Durham University. Experimental data for the uptake of [Eu.L^JCb in the 
presence of various drugs are shown in Table 8.2. 
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Table 8.2: Example data for uptake studies of [ E U . L ' I C I , showing (a) calculation of intracellular 
lanthanide concentration from [protein] (from BCA assay) and ['^'Eu] (from I C P - M S ) , and (b) the average 
and relative uptake calculated from triplicate measurements 
(a) 
Treatment 
[protein] ['^'Eu] [Eu] [Eu] / protein 
\ig/ mL ng / mL nmol / m L pjnol / g 
Blank 249.7 0.087 0.0006 0.0022 
Control 292.1 101.9 0.670 2.30 
Chloroquine 255.6 84.41 0.554 2.17 
Chlorpromazine 197.6 76.8 0.504 2.55 
Filipin 274.0 115.8 0.762 2.78 
Monensin 256.6 74.5 0.489 1.91 
Poly-L-lysine 264.6 108.3 0.715 270 
Sucrose 207.3 70.2 0.465 2.24 
Wortmannin 241.4 66.7 0.440 1.82 
Amiloride 278.4 72.5 0.478 1.72 
Phorbol acetate 183.4 76.0 0.503 2.74 
Diacylglycerol 155.9 90.6 0.599 3.84 
5 ° C 265.8 37.1 0.245 0.92 
(b) Uptake 
fimo\ E u / g protein 
replicate 1 replicate 2 replicate 3 average % uptake 
Control 2.30 3.25 3.59 3.05 100.0 
Chloroquine 2.17 3.30 3.4 2.96 97.0 
Chlorpromazine 2.55 2.33 4.01 2.96 97.2 
Filipin 2.78 2.30 4.35 3.14 103.2 
Monensin 1.91 1.92 2.98 2.27 74.5 
Poly-L-lysine 2.70 3.53 4.23 3.49 114.4 
Sucrose 2.24 2.48 3.51 2.74 90.0 
Wortmannin 1.82 1.81 1.85 1.83 60.0 
Amiloride 1.72 1.45 1.69 1.62 53.2 
Phorbol 12-myristate-13-acetate 2.74 6.15 4.80 4.56 149.8 
1,2-dipalmytoylglycerol 3.84 7.84 6.01 5.90 193.5 
5 ° C 0.92 1.35 0.84 1,04 34.0 
8.1.2.3. Cytotoxicity 
Approximately 1 x 10"* NIH-3T3 cells in 100 ^ L DMEM were seeded into each well of 
flat-bottomed 96-well plates and allowed to attach overnight. Complex solutions were 
added to triplicate wells to give final concentrations over a 2-log range. After 24 h 
incubation, IC50 values were measured by one of two methods: MTT or WST-1. Both 
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methods utilise the cleavage of the tetrazolium ion by mitochondrial reductase in viable 
cells.-"' 
For the MTT method, 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide 
(MTT; 1.0 m M ) ' " was added to each well and the plates incubated for a further 4 h. The 
culture medium was removed, and DMSO (150 ^L) was added. The plate was shaken 
for 20 sec and the absorbance measured immediately at 540 nm in a microplate reader 
against a blank plate containing DMSO. 
MTT 
For the WST-1 assay, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-l,3-
benzene disulfonate (WST-1, 10 loL)* '^* was added to each well and the plates incubated 
for a further 30 min. The plate was shaken for 20 sec and the absorbance measured 
immediately at 450 nm in a microplate reader against a blank of DMEM containing 
10 WST-1 per well. 
02N 
0 , . , . r v 
SOaNa 
WST-1 
For both methods, IC50 values were determined as the drug concentration required to 
reduce the absorbance to 50% of that in the untreated, control wells, and represent the 
mean value for data from at least three independent experiments. Example 
measurements and calculations for [Eu.L'jCh are shown in Figure 8.3. 
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(a) [ E U . L ' ] 
mM 
log[Eu.L'] 
A540 nm average 
% 
viability 
replicate 1 replicate 2 replicate 3 
0.0 2,45 2.56 2.36 2,46 100 
7.1 0,85 2.3 2.52 2.40 2.41 98.1 
13.6 1.13 1.8 2,03 2.29 2.04 82.7 
25.0 1.40 1.88 1.4 1.73 1.67 68.2 
47.6 1.68 1.4 1.15 0.77 1.11 44.9 
90.9 1.96 0.55 0.49 0.58 0.54 
22 
166.7 2,22 0,05 0.25 0.068 0.12 4,8 
285.7 2.46 -0,03 0.04 0.064 0.025 1.1 
(b) 100 
80 
60 
2 
.2 40 
20 
y=-69,978x + 161,32 
R? = 0,9936 
100 200 
[Eu.L']/^M 
300 
logEEu.Ll 
Figure 8.3: Example data from IC50 determination for [ E U , L ' ] C 1 , by the MTT assay ( N I H 3T3 cells, 24 h 
incubation), showing (a) data from absorbance measurements and calculation of % viability, (b) variation 
of cell viability with concentration on a linear scale and (c) a logarithmic scale, allowing calculation of an 
IC50 value of 41.4 |iM. 
8.1.2.4. Flow cytometric assays 
Flow cytometric analysis and sorting was conducted using a Dakocytomation Inc. 
MoFlo multi-laser flow cytometer (Fort Collins, CO, USA) operating at 60 psi with a 
70 f iM nozzle. Samples were interrogated with a lOOmW 488 nm solid state laser. 
Fluorescence signals were detected through interference filters (FLl 530/40, FL2 
670/30 nm) and were collected in the logarithmic mode. Data were analysed using 
Summit v4.3 software (Dakocytomation). 
For flow cytometry, cells were grown to confluence in 6-well plates. Medium was 
replaced and cells were treated with complex. Cells were detached from the plastic 
surface with 0.25% (v/v) trypsin solution for five minutes at 37 °C. The resulting cell 
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suspension was pelleted by centrifugation. Immediately prior to flow cytometric 
analysis, cell suspensions were filtered through a 40 ^ml filter. 
The apoptosis-necrosis assay distinguishes cells which are undergoing different forms of 
cell death."*' Propidium iodide (PI) is a marker for necrotic cells as it is excluded from 
viable cells, but can enter necrotic cells, for which the membrane is compromised. Upon 
DNA binding, the fluorescence of PI increases 30-fold. The annexin V-FITC conjugate 
is a marker for apoptotic cells, as it binds to the phosphatidyl serine (PS) which is 
presented on the membrane of cells in eariy apoptosis.^** This binding event is signalled 
by induced fluorescence of the conjugated fluorescein moiety. In this assay, the cell 
pellet was resuspended in 500 [iL binding buffer (10 mM HEPES at pH 7.5, 0.14 M 
NaCl and 2.5 mM CaCb). This suspension was incubated with 0.5 \ig/mL annexin-FITC 
and 2 p.g/mL propidium iodide for ten minutes in the dark. Four controls were used, as 
illustrated in Table 8.3. 
Table 8.3: Set-up of control wells used for apoptosis-necrosis assay 
Control Stains Treatment 
Blank - -
Apoptosis annexin-FITC staurosporine (1 \iM, 3h) 
Necrosis propidium iodide ethanol (70%, 5 °C, 3h) 
Untreated 
cells 
annexin-FITC, 
propidium iodide 
[Eu.L**^]'* (50 ^iM, 4h) 
The mitochondrial membrane potential assay ™^ measures the green fluorescence of 
Mitotracker Green FM (MTG), which stains all mitochondria, independent of their 
MMP,~^' against the red fluorescence of chloromethyl-X-rosamine (CMXRos), for 
which mitochondrial uptake increases with MMP.'' '" Cells were incubated with 200 nM 
MTG and CMXRos for thirty minutes prior to harvesting. Following centrifugation, the 
cell pellet was resuspended in 500 |xL PBS. Relative mitochondrial membrane potential 
was calculated by measuring the mean intensity of F L l (green) and FL4 (red) channels. 
Example data for the measurement of the MMP of [Eu.L*^]^"" and [Eu.L*']^^ with respect 
to controls are shown in Table 8.4. 
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Table 8.4: Data from flow cytometric analysis of CHO cells with various treatments. FL4/FL1 gives an 
indication of relative mitochondrial membrane potential 
Sample Stains Treatment 
F L l 
mean 
F L 4 
mean 
F L 4 / F L 1 
1 _ - 34.0 8.7 0.257 
2 MTG - 480.7 8.5 0.018 
3 CMXRos - 34.8 63.0 1.810 
4 MTG, CMXRos - 518.2 94.4 0.182 
5 MTG, CMXRos FCCP" (20 nM, 3h) 476.2 52.8 0.111 
6 MTG, CMXRos FCCP(100nM, 3h) 884.7 62.2 0.070 
7 MTG, CMXRos [ E U . L ' " ] ' * (50 | IM, Ih) 719.8 181.5 0.252 
8 MTG, CMXRos [Eu.L*"]'* (50 pM, 4h) 686.9 228.7 0.333 
9 MTG, CMXRos [EU.L' '^ ] '^ (50 nM, Ih) 552.7 143.4 0.259 
10 MTG, CMXRos [Eu.L*']'-' (50 nM, 4h) 560.1 149.8 0.267 
' FCCP = Carbonyl cyanide p-trifluoromethoxylphenyl-hydrazone 
8.1.2.5 Expression of RFP-tagged proteins 
Cells containing RFP-tagged tubulin or actin were cultured using Cellular Lights™ 
Actin-RFP and Tubulin-RFP kits following the prescribed protocol (Invitrogen)."*" 
RFP-tagged proteins were expressed in CHO cells which had been grown to confluence 
on glass coverslips in 6-well plates. Following expression, cells were treated with Tb 
complex (100 |xM) for 4 hours. The coverslips were then mounted on microscope slides, 
as described in Section 8.1.2.1, and visualised using a Zeiss LSM510 Meta confocal 
microscope using 405 nm and 543 nm lasers, and Zeiss imaging software. 
8.1.2.6 Sub-celluJar fractionation 
CHO and NIH 3T3 cells were grown in 75 cm" culture dishes and harvested by 
treatment with trypsin (0.1%) followed by centrifugation (1000 rpm, 3 min, 25 °C). 
Nuclei were extracted from the cell suspension using the Nuclei EZ Prep Kit (Sigma)*'' 
and Mitochondria were extracted from CHO cell using the Mitochondria Isolation Kit 
(Pierce Biotechnology)'^^^ according to the provided instructions. 
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8.1.3. Lipophilicity 
Lipophilicity was measured as the relative partitioning of the complex between water 
and 1-octanol. Water was saturated with 1-octanol, and 1-octanol was saturated with 
water. Complexes were prepared as 100 nM solutions in water and mixed with 1-octanol 
in 1:2, 1:1 and 2:1 water:octanol ratios. Mixtures were agitated for twelve hours, after 
which time emission spectra of the water and 1-octanol layers were collected. The 
complex concentration was calculated at the emission maximum with reference to 
calibration curves constructed for at least five concentrations between 0 and 100 |aM for 
water and 0 and 40 | i M for 1-octanol. For each mixture, the logP value was calculated 
according to equation 8.2: 
[XI 
-ocianol logP = \og^ [8.2] 
Final logP values were calculated as the average of at least two replicates of the three 
solvent mixtures. Example data for [ E U . L " ' ' ] are shown in Figure 8.4. 
(a) 25 T 
20 
i- 15 
s 
c 10 
5 
0 
0 
y = 210521X + 3 4 8 0 3 6 
R2 = 0.9988 
20 40 60 80 
Concentration / \iM 
( b ) 12 
10 
>• ^ 
S 6 
y = 112513X + 11393 
F? = 0.9993 
20 40 60 80 
Concentration / 
100 
H 2 O 1 - o c t a n o l 
S a m p l e I6I6 [Eu]h20 I6I6 [Eu],.oct P l o g P 
A 14.4 67.0 5.0 67.0 0.67 -0.18 
B 15.0 69.7 5.0 69.7 0.63 -0.2 
C 14.4 66.7 5.4 66.7 0.71 -0.15 
D 14,5 67.2 5.6 67.2 0.74 -0.13 
E 15.8 73.2 5.6 73.2 0.67 -0.17 
F 16.2 75.2 6.3 75.2 0.74 -0.13 
a v e r a g e 
S . D . 
-0.16 
0.03 
F i g u r e 8 . 4 : Calibration curves for [ E u . L " " ] in (a) H . O and (b) 1-octanol, and log? calculations for six 
replicates 
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8.2. Syntheses 
[ E U . L ' ] was synthesised by Robert Poole." [Eu.L^'']^^ [Eu.L^'']^^ [Eu.L'*'']^^ 
[Eu.L'*'']^^ [Eu.L*^']-^ and [ E U . L ' ' ] ^ ^ were synthesised by Benjamin Murray,'"^' while 
[Tb .L*]^^ [ E U . L " ] ^ ^ and [ E U . L ' " ] ^ ^ were prepared by Craig Montgomery. 
[ E U . L " ] ^ ^ was synthesised by Junhua Yu, and [Eu.L*^]^^ and [Eu.L*^]"' by Robert Pal. 
[Tb.L''*^]'' ' and [Tb.L'"' ']^' ' were synthesised by Siobhan Richardson and Philip Stenson 
respectively." [Tb.V*^f*, [Tb.V*'f\ [Tb.L^^]^^ and [Tb.L^]^^ were prepared by Filip 
Kielar.'^^-'" 
AZ-Bromoacetyl-fSj-alanine and A'-bromoacetyl-fSj-phenylalanine ethyl esters were 
prepared by Junhua Yu. Ethyl esters of f/fj-alanine and (/Jj-phenylalanine were prepared 
by esterification in ethanol, catalysed by HCl, using standard procedures. 
A^-BromoacetyI-fi?>alanine ethyl ester 
o 
f/?j-Alanine ethyl ester (5.5 g, 33 mmol) was suspended in dry chloroform (50 mL) and 
cooled to 0 °C in a salt-ice water bath. Following the addition of triethylamine (7 mL, 
5.1 g, 51 mmol), bromoacetyl bromide (4.4 mL, 10.1 g, 50 mmol) was added dropwise 
to the suspension. The mixture was allowed to warm to room temperature and was 
stirred under argon overnight. The suspension was washed with an aqueous saturated 
sodium bicarbonate solution, and the chloroform removed to yield a brown oil. The 
product was purified by column chromatography (silica, eluted with dichloromethane) to 
yield A'-bromoacetyl-f/?)-alanine ethyl ester as an off-white solid (4.3 g, 18 mmol, 55%). 
RF (silica; 5% CH3OH in CH2CI2): 0.46, mp 65 - 66 °C. ' H N M R (500 MHz, CDCI3): 5 
1.31 (3H, t,J = 7.0, CH2CH3), 1.46 (3H, d,J = 7.0, Ala CH3), 3.89 (2H, s, Br-CH.), 4.24 
(2H, q, y = 7.0, CH2CH3), 4.56 ( I H , q, 7 = 7.0, Ala CH), 7.06 ( I H , broad, NH). '^C 
N M R (500 MHz, CDCI3): 5 14.36 (CH2CH3), 18.50 (Ala CH3), 29.01 (CHzBr), 49.04 
(Ala CH), 62.03 (CH2CH3), 165.31 (Ala C=0), 172.63 (amide C = 0 ) . H R M S (+ m/z): 
[ M + H ] ^ calculated for C7H,303N^^Br, 238.0073; found, 238.0069. 
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yV-Bromoacetyl-W-phenylalanine ethyl ester 
H CHj o 
Phenylalanine ethyl ester (1.0 g, 4.1 mmol) was suspended in dry chloroform (30 mL) 
and cooled to 0 °C in a salt-ice water bath. Following the addition of triethylamine 
(1.5 mL, 1.1 g, 11 mmol), bromoacetyl bromide (1.0 mL, 2.3 g, 11 mmol) was added 
dropwise to the suspension. The mixture was allowed to warm to room temperature and 
was stirred under argon overnight. The suspension was washed with an aqueous 
saturated sodium bicarbonate solution, and the chloroform removed to yield a brown oil. 
The product was purified by column chromatography (silica, eluted with 1% 
MeOHiDCM) to yield A'-bromoacetyl-f/Jj-phenylalanine ethyl ester as an off-white solid 
(0.85 g, 2.7 mmol, 66%). 
RF (silica; 5% C H 3 O H in C H 2 C I 2 ) : 0.51, mp 71 - 72 °C (lit. value ^^ '71-72 °C for 5 
enantiomer) ' H N M R (200 MHz, MeOD): 5 1.27 (3H, t, 7 = 7.2, C H 2 C H 3 ) , 3.17 (2H, d, 
7 = 6.2, Phe CH2), 3.86 (2H, s, Br-CH2), 4.21 (2H, q, J = 7.2, CH2CH3), 4.78 ( I H , q, 
y = 6.2, Phe CH), 7.15 (2H, d, J = 6.5, ArH ortho), 7.30 (3H, m, ArH para and meia). 
'^C NMR (500 MHz, CDCI3): 5 14.36 (CH2CH3), 28.94 (CH?Br). 38.01 (Phe CH2), 
54.00 (Phe CH), 62.01 (CH2CH3), 127.55 (ArH para), 128.88 (ArH meta), 129.61 (ArH 
ortho), 165.36 (Phe C=0), 171.09 (amide C=0). HRMS (+ m/z): [M+HY calculated for 
C,3Hi703N''^Br, 314.0386; found, 314.0382 
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A^-Dansyl sarcosine 
Sarcosine (32 mg, 0.36 mmol) was dissolved in an aqueous saturated NaHCOs solution 
(10 mL). A solution of dansyl chloride (121 mg, 0.45 mmol) in acetone (2 mL) was 
added, and the resulting mixture was stirred at room temperature overnight. The mixture 
was subsequently evaporated to dryness, and the solid residue resuspended in water. The 
insoluble solids were removed by filtration. The supernatant was acidified to pH 4 by the 
addition of dilute HCl, at which point a pale green precipitate of dansyl sarcosine was 
formed. This product was isolated by filtration and was recrystallised from acetone 
(95 mg, 82%). 
mp 198-199 °C. ' H N M R (400 MHz, CD3OD): 5 2.19 (3H, s, sarcosine C H 3 ) 2.85 (6H, 
s, dansyl C H 3 ) , 4.00 (2H, s, sarcosine C H 2 ) , 7.24 ( I H , m, ArH), 7.56 (2H, d, 7 = 8.2, 
ArH), 8.19 ( I H , d, 7 = 8.2, ArH), 8.31 ( I H , d, 7 = 8.7, ArH), 8.55 ( I H , d, 7 = 8.7, ArH). 
'^C N M R (400 MHz, C D 3 O D ) : 6 34.8 (dansyl C H 3 ) , 47.7 (sarcosine C H 3 ) , 50.9 
(sarcosine C H 2 ) , 115.3 (C Ar), 119.7 (C Ar), 123.2 (C Ar), 125.5 (C Ar), 126.4 (C Ar), 
127.2 (C Ar), 127.9 (C Ar), 127.9 (C Ar), 129.2 (C Ar), 130.2 (C Ar), 134.9 (C Ar), 
151.9 (sarcosine COOH). HRMS (+ m/z): [M+Na]^ calculated for Ci5Hi8N204SNa, 
345.0885; found, 345.0883. 
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l,4,7-Tris-tert-butoxylcarbonyl-l,4,7,10-tetraazacyclododecane" 
o 
. 0 ^ / \ I 
A solution of di-tert-butyl dicarbonate (7.6 g, 35 mmol) in dichloromethane (70 mL) was 
added dropwise to a stirred solution of 1,4,7,10-tetraazacyclododecane (2.5 g, 15 mmol) 
in dichloromethane (250 mL). The mixture was stirred at room temperature for 2 h. 
Evaporation of the solvent afforded a transparent oil, which was purified by column 
chromatography (silica; gradient elution C H 2 C I 2 to 5 % C H 3 O H / C H 2 C I 2 ) to give the title 
compound as a colourless solid (5.0 g, 11 mmol, 73 % ) . 
RF (silica; 10% C H 3 O H in C H 2 C I 2 ) : 0.29. mp 61-62 °C. ' H NMR (400 MHz, C D C I 3 ) : 8 
1.28 (27H, br s, C H 3 ) , 2.67 (4H, br m, C H 2 ) , 3.0-3.3 (8H, br m, CH.), 3.47 (4H, m, 
C H 2 ) . 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris(fert-butoxycarbonyl)-l,4,7,10-tetraazacyclododecane 73 
Potassium carbonate (810 mg, 4.7 mmol) and a catalytic amount of potassium iodide 
were added to a solution of 1,4,7-tris-rerf-butoxycarbonyl-1,4,7,10-
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tetraazacyclododecane (500 mg, 1.2 mmol) in acetonitrile (20 mL). The mixture was 
heated to 60°C and a solution of 6-chloromethyl-l0,11,12,13-tetrahydro-4,5,9,14-
tetraazabenzo[b]triphenylene (390 mg, 1.2 mmol) in dichloromethane (3 mL) was added. 
The reaction mixture was boiled under reflux under argon overnight, after which time 
the solution was filtered and the salts washed with dichloromethane. Evaporation of the 
solvent afforded an orange residue, which was purified by column chromatography 
(silica gel; gradient elution CH2CI2 to 2.5 % CH3OH/ CH2CI2) to yield the title 
compound as a pale yellow solid (424 mg, 0.60 mmol, 52%), identical to an authentic 
sample. 
RF (silica; 5% CH3OH in CH2CI2): 0.29. ' H NMR (300 MHz, CDCI3): 5 0.92-0.71 (27H, 
br m, CH3), 2.04 (4H, m, HIO, H13), 2,42-2.99 (4H, m, CH2ring), 3.07-3.87 (16H, br m, 
CH2 ring, H I 1, HI2) , 4.24 (2H, s, CH2-dpqC), 7.67 ( I H , m, H2), 7.72-7.97 ( I H , br s, 
H7), 9.71 ( I H , br s, H3), 9.26-9.44 (2H, br m, H8, HI ) . 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenyIene)-
1,4,7,10-tetraazacycIododecane^'' 
Trifluoroacetic acid (9 mL) was added to a solution of l-(6-methyl-10,l l,12,13-
tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-tris(^^r^-butoxycarbonyl)-
1,4,7,10-tetraazacyclododecane (590 mg, 0.77 mmol) in dichloromethane (9 mL). The 
mixture was stirred at room temperature overnight. The solvent was evaporated and the 
residue washed with dichloromethane (3 x 10 mL). The residue was resuspended in an 
aqueous solution of potassium hydroxide ( I M ; 10 mL) and the product extracted into 
dichloromethane ( 3 x 1 0 mL). The organic layer was dried over K2CO3, and the solvent 
removed under reduced pressure to yield the title compound as a pale orange solid 
(270.3 mg, 0.577 mmol, 75%). 
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'H NMR (400 MHz, CDCI3): 6 2.06 (4H, m, HIO, HI3) , 2.60-3.00 ( I6H, m, CHjring), 
3.21 (4H, m, H I 1, H12), 4.22 (2H, s, CH2-dpqC), 7.25 ( I H , d, J = 8.0, H7), 7.63 ( IH, 
dd, J = 8.2, 4.4, H2), 8.03 ( I H , dd, 7 = 4.4, 1.4, H3), 9.23 ( I H , d, 7 = 8.0, H8), 9.44 ( IH, 
dd,y = 8.2, 1.4, H I ) . 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris[rs>l-(l-phenyl)ethylcarbamoylmethyl]-l,4,7,10-tetraazacyclododecane" 
N N 
N N 
Potassium carbonate (120 mg, 0.85 mmol) and a catalytic amount of potassium iodide 
were added to a solution of l-(6-methyl-10,l l,12,13-tetrahydro-4,5,9,14-
tetraazabenzo[b]t^iphenylene)-l,4,7,10-tet^aazacyclododecane (80 mg, 0.17 mmol) in 
acetonitrile (5 mL). The reaction mixture was heated to 60 °C and a solution of (S)-N-{]-
phenyleth-l-yl)chloroacetamide (99 mg, 0.50 mmol) in dichloromethane (5 mL) was 
added. The reaction mixture was heated to reflux overnight under argon. The solution 
was filtered and the salts washed with dichloromethane. Evaporation of the solvent 
resulted in an orange solid which was purified by column chromatography (neutral 
alumina; gradient elution CH2Cl2to 1% CH3OH/CH2CI2) to give the title compound as a 
yellow solid (87 mg, 0.091 mmol, 54%). 
RF (neutral alumina; 7.5% CH3OH in CH2CI2): 0.55. mp 148-149 °C (lit. value 148 -
150 °C). HRMS (-1- mJzy[M+H]* calculated for CjvHegNnOB, 954.5506; found, 954.5505 
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1 -(6-Methy I-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b] triphenylene)-4,7,10-
tris[('/fj-l-(l-phenyl)ethylcarbanioylmethyl]-l,4,7,10-tetraazacyclododecane 
An analogous procedure to that described for synthesis of the (SSS) isomer was 
followed, using f/?)-N-(l-phenyleth-l-yl)chloroacetamide. A l l spectroscopic 
characteristics were identical to those observed for the (SSS) isomer. 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris(ethyi-N-acetyI-S-alanine)-l,4,7,10-tetraazacyclododecane 
CO,Et 
EtOjC 
Potassium carbonate (80 mg, 0.58 mmol) and a catalytic amount of potassium iodide 
were added to a solution of l-(3-methyl-10,l l,12,13-tetrahydrodipyrido[3,2-a:2',3'-c] 
phenazine)-l,4,7,10-tetraazacyclododecane (55 mg, 0.12 mmol) in acetonitrile (5 mL). 
The reaction mixture was heated to 60°C and a solution of N-bromoacetyl-fSj-alanine 
ethyl ester (77 mg, 0.34 mmol) in dichloromethane (5 mL) was added. The reaction 
mixture was heated to reflux overnight, under argon. The solution was filtered and the 
salts washed with dichloromethane. After evaporation of the solvent, the residue was 
washed with ether to give the title compound as a yellow-brown solid (30 mg, 
0.10 mmol, 29%). 
mp 129-130 °C. ' H NMR (200 MHz, CDCI3): 5 1.16 (3H, t, J = 6.4, arm CH2CH3), 1.37 
(3H, d, / = 7.2, arm Ala CH3), 2.09 (4H, m, HIO, H13), 2.83 (16H, m, CH2ring), 3.24 
(4H, m, H I 1, HI2) , 4.00-4.15 (4H, m, arm CH2CH3, CH2-dpqC), 4.60 ( IH , q, 7 = 7.2, 
arm Ala CH), 7.27 ( I H , d, J = 8.0, H7), 7.65 ( I H , dd, J = 8.2, 4.4, H2), 8.06 ( I H , dd, 
7 = 4.4, 1.4, H3), 9.20 ( I H , d, 7 = 8.0, H8), 9.42 ( I H , dd, 7 = 8.2, 1.4, HI) . 
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HRMS(+m/z): [M+H]^ calculated for C48H68N,,09, 943.1266; found, 943.1259. 
H P L C : t R = 10.9 min. 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris(ethyI-N-acetyl-i?-aIanine)-l,4,7,10-tetraazacycIododecane 
An analogous procedure to that described for synthesis of the (555) isomer was 
followed, using A'-bromoacetyl-f/?j-alanine ethyl ester. Al l spectroscopic characteristics 
were identical to those observed for the (SSS) isomer. 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenyIene)-4,7,10-
tris(ethyl-N-acetyI-S-phenylalaiiine)-l,4,7,10-tetraazacyclododecane 
I N 
0 1 O 
EtOjC 
N CO,Et 
Potassium carbonate (88 mg, 0.63 mmol) and a catalytic amount of potassium iodide 
were added to a solution of l-(6-methyl-10,ll,12,13-tetrahydro-4,5,9,14-
tetraazabenzo[b]triphenylene)-l,4,7,10-tetraazacyclododecane (60 mg, 0.13 mmol) in 
acetonitrile (5 mL). The reaction mixture was heated to 60 °C and a solution of 
/V-bromoacetyl-5-phenylalanine ethyl ester (120 mg, 0.38 mmol) in dichloromethane 
(5 mL) was added. The reaction mixture was heated to reflux overnight, under argon. 
The solution was filtered and the salts washed with C H 2 C I 2 . Evaporation of the solvent 
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gave rise to an orange residue, which was purified by column chromatography (neutral 
alumina; gradient elution CH2Cl2to 1% CH3OH/CH2CI2) to give the title compound as a 
yellow solid (74 mg, 0.079 mmol, 51%). 
mp 119-120 °C. RF (neutral alumina; 5% CH3OH in CH.Cb): 0.33. ' H NMR (300 MHz, 
CDCb): 0.95-1.40 (18H, m, CH2CH3, CHCH3), 2.06 (4H, m, HIO, HI3), 2.40-3.00 
(16H, br m, CH.ring), 3.43 (4H, m, H I 1, H12), 3.80-4.80 (17H, m, CH2CO, CH.-dpqC, 
CH), 6.95-7.35 (15H, m, phenyl CH), 7.58 ( I H , m, H7), 7.70 ( I H , br m, H2), 7.98 ( IH , 
br m, H3), 9.38 ( I H , m, H8), 9.49 ( I H , m, H I ) . HRMS {+ m/z): [M-i-H]^ calculated for 
C66H8oN|,09, 1171.4160; found, 1171.4165. HPLC: t R = 14.1 min 
l-(6-Methyl-10,ll,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris(ethyl-N-acetyI-/f-phenylaIanine)-l,4,7,10-tetraazacyclododecane 
An analogous procedure to that described for synthesis of the (555) isomer was 
followed, using N-bromoacetyl-f^j-phenylalanine ethyl ester. A l l spectroscopic 
characteristics were identical to those observed for the (555) isomer. 
(SSSj-IEu.L^]Cl3^^ 
1 -(6-Methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris[f5j-1 -(1 -phenyOethylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane (16 mg, 
0.017 mmol) and europium(III) trifluoromethanesulfonate (10 mg, 0.017 mmol) were 
dissolved in dry acetonitrile (5 mL) and the resulting solution was heated to reflux under 
argon overnight. The solution was then added dropwise to ether (20 mL), the precipitate 
centrifuged and the solvent decanted. The solid was redissolved in acetonitrile and the 
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process repeated to yield a pale yellow solid. This solid was then converted to the 
chloride salt by stirring with Dowex 1x8 200-400 mesh CI which had previously been 
washed with 1 M hydrochloric acid and neutralised with water. The solid Dowex was 
removed by filtration and the solvent removed by freeze drying to yield the title 
compound as an off-white solid (15 mg, 0.013 mmol, 73%). 
Spectroscopic characteristics were identical to those reported previously.HRMS 
{+ mJz): [M]^^ calculated for CsyHeyOaNnEu, 368.1537; found, 368.1541 
2ir .^ 73 (SSS>[Tb.LlCl3 
3+ 
An analogous procedure to that described for synthesis of the Eu complex was followed 
using 1 -(6-methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]tripheny lene)-
4,7,10-tris[(S)-1 -(1 -phenyl)ethy Icarbamoylmethyl]-1,4,7,10-tetraazacyclododecane (16 
mg, 0.017 mmol) and terbium(III) trifluoromethanesulfonate (10 mg, 0.017 mmol) in dry 
acetonitrile (5 mL), giving the product as a yellow sohd (14 mg, 0.012 mmol, 66%). 
Spectroscopic characteristics were identical to those reported p rev ious ly .HRMS 
(-1- m/z): [M]^* calculated for C 5 7 H 6 7 0 3 N , , T b , 370.8222; found, 370.8226 
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(SSS)-[GdL^]Cl3" 
An analogous procedure to that described for synthesis of the Eu complex was followed 
using 1 -(6-methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-
4,7,10-tris[(5'j-1 -(1 -phenyl)ethylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane (16 
mg, 0.017 mmol) and gadolinium(III) acetate (5.7 mg, 0.017 mmol) in methanol:water 
(1:1,5 mL), giving the product as a yellow solid (13.5 mg, 0.011 mmol, 65%). 
Spectroscopic characteristics were identical to those reported previously.^^ HRMS 
(+ m/z): [M+2H]^ calculated for CsTHesNuOjGd, 1109.4513; found 1109.4517. 
18. (S5S>[YL^]Cl3 
17' 18; 19' 3+ 
10 11 
16" N 
NH 15 
19' 18-
An analogous procedure to that described for synthesis of the Eu complex was followed 
using 1 -(6-methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-
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4,7,10-tris[(5j-1 -(1 -phenyl)ethylcarbamoylmethyl]-1,4,7,10-tetraazacyclododecane (26 
mg, 0.027 mmol) and yttrium(III) acetate (6.7 mg, 0.025 mmol) in methanol:water (1:1, 
5 mL), giving the product as a yellow solid (23 mg, 0.019 mmol, 75%). 
' H NMR (700 MHz, D 2 O ) : 0.79 (3H, m, H16'), L l l (3H, m, H17'), 1.25 ( I H , m, cyclen 
C H 2 ) , 1.39 ( I H , m, cyclen C H . ) , 1.61 (3H, m, H17"), 1.84 (2H, m, amide C H 2 ) , 2.01 
(5H, m, H l l , H12, cyclen C H 2 ) , 2.17 (3H, m, cyclen C H 2 ) , 2.26 ( I H , m, cyclen C H 2 ) , 
2.34 ( I H , m, amide C H 2 ) , 2.52 (2H, m, amide C H 2 ) , 2.67 ( I H , m, HI6'), 2.75 (2H, m, 
cyclen C H 2 ) , 2.97 ( I H , m, cyclen C H 2 ) , 3.20 (3H, m, cyclen C H 2 ) , 3.22 (4H, m, HIO, 
H13), 3.33 ( I H , m, amide C H 2 ) , 3.68 ( I H , m, cyclen C H 2 ) , 4.01 ( I H , m, H16'), 5.04 
( I H , m, H16"), 6.37 (2H, m, H19"), 6.47 (3H, m, H18", H20"), 6.76 ( I H , m, H15"), 6.87 
(2H, m, H15'), 7.33 (4h, m, H17'), 7.38 (4H, m, H19'), 7.40 (2H, m, H20'), 7.75 ( I H , m, 
H7), 8.35 ( I H , m, H2), 9.30 ( I H m, H3), 9.53 ( I H , m, H8), 9.59 ( I H , m, H I ) . HRMS (+ 
m/z): [M]^^ calculated for C57H65N,,03Y, 347.4824; found 347.4816. 
(RRR)-[La.L^]Ch 
(RRR)-[Eu.L-]Ch, f/?/?/?;-[Tb.L^]Cl3, f/?/?/?)-[GdL^]Cl3 and (RRR)-rn}]Ch were 
synthesised by analogous procedures to ('S55)-[Eu.L^]Cl3, ('555)-[Tb.L"]Cl3, f55S)-
[GdL-]Cl3 and ('S55>[YL-]Cl3 respectively, using (RRR)-L-. Spectroscopic 
characterisation was identical to that observed for f555)-[Ln.L"]Cl3. Opposite chirality 
for the Eu and Tb complexes was confirmed by CPL (see main text). 
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(SSSj-LEu.L^lCb 
3+ 
CO,E. 0 - | J ^ - - : E u _ ^ 
An analogous procedure to that described for (55Sj-[Eu.L']Cl3 was followed, using l-(6-
methy 1-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-tris(ethy 1-
N-acetyl-^-alanine)-1,4,7,10-tetraazacyclododecane (15 mg, 0.015 mmol) and 
europium(III) trifluoromethanesulfonate (9 mg, 0.015 mmol) in dry acetonitrile (5 mL). 
The title compound was obtained as an off-white solid (12 mg, 0.010 mmol, 68%). 
' H NMR (500 MHz, 283K, D 2 O ) Peaks range from 44.0 to -19.5 ppm. Selected peaks at: 
44.00, 40.71, 29.93, 25.41, 20.87 ppm; -9.36, -10.37, 13.40, 13.63, 19.54 ppm. HRMS 
(H-m/z): [M]^^ calculated for C48H67N,,09Eu, 359.1435; found, 359.1439. HPLC: 
tR = 10.9 min. 
(SSS)-[Tb.L^'']Cl3 
3+ 
An analagous procedure to that described for fSSSj-LEu.L^^JCb was followed, using 
1 -(6-methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
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tris(ethyl-N-acetyl-f5)-alanine)-1,4,7,10-tetraazacyclododecane (21 mg, 0.022 mmol) 
and terbium(III) trifluoromethanesulfonate (13mg, 0.022 mmol) in dry CH3CN (5 mL), 
giving the product as an off-white solid (10 mg, 0.0088 mmol, 40%). 
HRMS {+ m/z):[M]^^ calculated for C48H67Nii09Tb, 366.8120; found, 366.8118. HPLC: 
tR = 8.8 min. 
(RRRHLn.L^'jCh 
('/?/?/?>[Eu.L^'']Cl3 and C/?/?/?j-[Tb.L^^]Cl3 were synthesised by analogous procedures to 
(SSS)-[E\i.L^']Ch and f555J-[Tb.L^']Cl3 respectively, using (RRR)-L^\ Spectroscopic 
characterisation was identical to that observed for f555j-[Ln.L-^^]Cl3. Opposite chirality 
was confirmed by CPL (see main text). 
fSSS>[Eu.L^^]Cl3 
H 
EtOjC. . N 
3+ 
om. E u — — - o 
EtOjC 
N COjEt 
H 
An analogous procedure to that described for (555)-[Eu.L^]Cl3 was followed, using l-(6-
methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-tris(ethyl-
N-phenylalanine)-l,4,7,10-tetraazacyclododecane (30 mg, 0.026 mmol) and 
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europium(III) trifluoromethanesulfonate (15 mg, 0.026 mmol) in dry acetonitrile (6 mL). 
The title compound was obtained as an off-white solid (20 mg, 0.015 mmol, 58%). 
' H NMR (500 MHz, 283K, D 2 O ) Peaks range from 12.2 to -20.2 ppm. Selected peaks at: 
12.21, 12.05, 11.39, 11.04, 10.79 ppm; -8.61, -8.92, -10.64, -12.59, -15.92, -20.24 ppm. 
HRMS (+ m/z): [M]^* calculated for C66H79O9N11EU, 440.1748; found, 440.1752. 
HPLC: t R = 11.8 min 
(5SS>[Tb.L^'']Cl3 
H 
ElOjC N \ \ I .' \ 
CO.E, 
An analagous procedure to that described for ('555)-[Eu.L^'']Cl3 was followed, using 1-
(6-methyl-10,11,12,13-tetrahydro-4,5,9,14-tetraazabenzo[b]triphenylene)-4,7,10-
tris(ethyl-N-acetylphenylalanine)-1,4,7,10-tetraazacyclododecane (30 mg, 0.026 mmol) 
and Tb(III) trifluoromethanesulfonate (15 mg, 0.026 mmol) in dry acetonitrile (6 mL). 
The product was obtained as an off-white solid (26 mg, 0.020 mmol, 77%). 
HRMS (-1- m/z):[M]^^ calculated for CeeHTgNnOgTb, 422.8433; found, 422.8332. HPLC: 
tR = 11.0 min 
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(RRR)-[hn.V'']Ch 
(RRR)-[E\i.L^^]Ch and (RRR)-[Th.L^^]Ch were synthesised by analogous procedures to 
fSSSj-LEu-L^'lCh and r555>[Tb.L''']Cl3 respectively, using (RRR)-L'\ Spectroscopic 
characterisation was identical to that observed for r555j-[Ln.L''']Cl3. Opposite chirality 
was confirmed by CPL (see main text). 
rsssj-LEux*"] 
To a solution of (SSS)-[Eu.L^^]Ch (1 mg, 0.0095 mmol) was added an aqueous solution 
of potassium hydroxide (286 | iL ; 0.02 M) and the mixture stirred at 40 °C for 12 h. The 
solution was neutralised using dilute HCl, and the product retained in solution for 
subsequent studies. 
' H N M R (500 MHz, 283K, D 2 O ) Peaks range from 36.8 to -20.9 ppm. Selected peaks at: 
36.82, 29.06, 25.66, 24.29, 14.25, 13.53 ppm; -14.42, -15.30, -16.73, -18.64, -20.27, -
20.86 ppm. HPLC: IR = 9.9 min. 
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rSSSj-LTb.L""] 
NH 
An analogous procedure to that described for (SSS)-[Eu.L'^^] was followed, using 
(SSS)-[Th.V^]Ch (1 mg, 0.0095 mmol). The neutral complex was retained in solution 
for subsequent testing. 
HPLC: tR = 8.7 min 
(RRRHEu.L^Vi 
f^/?/?j-[Eu.L'*'']Cl3 was prepared by an analogous procedures to (SSS)-[Eu.L*^]Ch, by 
hydrolysis of (RRR)-[Eu.L^^]C\i. Spectroscopic characterisation was identical to that 
observed for fS55J-[Eu.L'*'']Cl3. Opposite chirality was confirmed by CPL (see main 
text). 
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(SS5>[Eu.L'''] 
An analogous procedure to that described for f555j-[Eu.L'^^] was followed, using 
r555j-[Eu.L^'']Cl3 (1 mg, 0.0095 mmol). The compound was retained in solution for 
subsequent testing. 
'H NMR (500 MHz, 283K, D 2 O ) Peaks range from 14.1 to -20.6 ppm. Selected peaks at: 
14.12, 13.27, 12.67, 10.63, 10.27 ppm; -14.81, -15.26, -16.97, -17.90, -20.55 ppm. 
HPLC: t R = 10.88 min. 
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•0,c 
•o,c 
An analogous procedure to that described for (SSS)-[Eu.L'^^] was followed, using 
(55S>[Tb.L^'']Cl3 (15 mg, 0.0096 mmol). The product was isolated by freeze drying, 
giving the neutral complex as an off-white solid (6 mg, 0.0055 mmol, 73%). 
HPLC: t R = 10.17 min 
(RRR)-[Eu.L^'']Ch 
f/?/?/?j-[Eu.L'^'']Cl3 was prepared by an analogous procedure to f555j-[Eu.L'"']Cl3, by 
hydrolysis of f^/?/?j-[Eu.L^'']Cl3. Spectroscopic characterisation was identical to that 
observed for (SSS)-[Eu.L'^^]Ch. Opposite chirality was confirmed by CPL (see main 
text). 
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APPENDIX ONE - S E L E C T E D COMPLEXES 
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